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ABSTRACT 
 Lung cancer (LC) is the leading cause of cancer death in the US, claiming over 
160,000 lives annually. Although CT screening has been shown to be efficacious in 
reducing mortality, the limited access to screening programs among high-risk individuals 
and the high number of false positives contribute to low survival rates and increased 
healthcare costs.  As a result, there is an urgent need for preventative therapeutics and 
novel interception biomarkers that would enhance current methods for detection of early-
stage LC.  
 This thesis addresses this challenge by examining the hypothesis that 
transcriptomic changes preceding the onset of LC can be identified by studying bronchial 
premalignant lesions (PMLs) and the normal-appearing airway epithelial cells altered in 
their presence (i.e., the PML-associated airway field of injury). PMLs are the presumed 
precursors of lung squamous cell carcinoma (SCC) whose presence indicates an 
increased risk of developing SCC and other subtypes of LC. Here, I leverage high-
  
vii 
throughput mRNA and miRNA sequencing data from bronchial brushings and lesion 
biopsies to develop biomarkers of PML presence and progression, and to understand 
regulatory mechanisms driving early carcinogenesis.  
 First, I utilized mRNA sequencing data from normal-appearing airway brushings 
to build a biomarker predictive of PML presence. After verifying the power of the 200-
gene biomarker to detect the presence of PMLs, I evaluated its capacity to predict PML 
progression and detect presence of LC (Aim 1). Next, I identified likely regulatory 
mechanisms associated with PML severity and progression, by evaluating miRNA 
expression and gene coexpression modules containing their targets in bronchial lesion 
biopsies (Aim2). Lastly, I investigated the preservation of the PML-associated miRNAs 
and gene modules in the airway field of injury, highlighting an emergent link between the 
airway field and the PMLs (Aim 3).  
 Overall, this thesis suggests a multi-faceted utility of PML-associated genomic 
signatures as markers for stratification of high-risk smokers in chemoprevention trials, 
markers for early detection of lung cancer, and novel chemopreventive targets, and yields 
valuable insights into early lung carcinogenesis by characterizing mRNA and miRNA 
expression alterations that contribute to premalignant disease progression towards LC. 
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CHAPTER ONE: Introduction 
1.1.  Tobacco-Induced Lung Cancer As The Leading Cause Of Cancer Death 
 Every 200 seconds someone in the U.S. loses their battle with lung cancer 51. 
While the great majority of these deaths could be prevented by eliminating their main 
cause - the active exposure to tobacco smoke, lung cancer could be cured even in long-
time heavy smokers if it was detected early, i.e. before it has spread to lymph nodes or 
metastasized. In fact, only about 18% of patients live with the diagnosis more than 5 
years - a number shockingly low in comparison to breast cancer’s (90%), prostate 
cancer’s (99%), and colorectal cancer’s (65%) 5-year survival rates 51. Yet, there exists a 
significant disparity among these cancers in research funding. In 2014, the National 
Cancer Institute awarded an estimated $254mln (https://fundedresearch.cancer.gov) to 
lung cancer research, paying more than twice as much to breast cancer which accounts 
for only a quarter as many annual deaths 51. Counterintuitively, lung cancer’s societal 
burden, which can be quantified as years of life lost (YLL) or disability-adjusted life-
years (DALY) significantly surpasses that of other leading cancers, contributing to 
increased health-care and economic costs 27. Motivated by the low survivability and high 
societal costs, many researchers have focused their efforts on developing much needed 
early lung cancer screening methods, that would allow detection in subjects presenting 
without evident symptoms. 
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  In 2002-2004 the National Lung Screening Trial (NLST) recruited over 50,000 
participants with smoking history to compare the efficacies of low-dose computed-
tomography (CT) and chest radiography (X-ray) in reducing mortality from lung cancer 
by detecting tumors at an early stage 109. Participants were randomized into two groups, 
screened annually for 3 years with the group-assigned method and followed. The NLST 
Research Team found that low-dose CT performed better at detecting clinically 
significant abnormalities and ultimately led to a reduction in deaths 15-20% larger as 
compared to X-ray. However, the rate of overdiagnosis by CT (percentage of suspected 
lung tumors ending up being slow-growing and non-life threatening or completely 
benign) of non-small cell lung cancer (NSCLC) was high, at 22.5% 32,91. These results 
suggest that benefits from early lung cancer detection with CT should be weighed against 
the potentially incurred extra healthcare cost as well as health risks including unnecessary 
surgery or harmful chemotherapy in overdiagnosed cases, and that refocusing efforts on 
the precancerous stages of disease where intervention benefits outweigh the risks may 
improve lung cancer mortality rates just as well. 
1.2. Bronchial Premalignant Lesions (PMLs) And Their Role In Lung 
Carcinogenesis 
 Bronchial premalignant lesions (PMLs) are histological abnormalities in the 
central airways, characterized by variably thickened basement membrane separating the 
epithelium from the underlying connective tissue 1. They can be observed and sampled 
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via autofluorescence bronchoscopy, and reproducibly graded by a pathologist 86. The 
natural history of PMLs, which follows a step-wise progression model whereby normal 
cells proceed through pathological stages from basal-cell hyperplasia and squamous 
metaplasia, to mild, moderate and severe dysplasia, to carcinoma in-situ, has been well 
documented 63,748,103. 
 Collectively referred to as dysplasia, PMLs are the presumed precursors of lung 
squamous cell carcinoma (SCC) 55. Several premalignant lesion prevalence studies 
showed that high-grade dysplasia has a higher prevalence in patients with invasive 
carcinoma and that the lesion number and severity correlate with increased risk for 
developing lung cancer 8,10,48,90,127. What is more, subjects with lesions that progress or 
persist over time, have been shown to have increased risk of progressing to invasive SCC 
83, and more often than not, the invasive SCC was observed to develop at a location that 
was different from the location of the monitored lesion 136. In addition, there exists 
limited evidence that mortality from lung cancer could improve by 90% if the 
premalignant lesions were detected and treated early 31. However, because of the fact that 
PMLs are dynamic and do not strictly follow the linear progression model (their 
histology might worsen and improve multiple times within a patient 22) there is a lack of a 
well-established causal link between the lesions and the disease, which may explain why 
the current standard of care excludes monitoring PMLs in the context of prevention or 
early detection of lung cancer. Thus, pursuing PML detection and monitoring in the 
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context of early stage diagnostics may help refine the link between premalignant disease 
and lung tumorigenesis.  
1.3. Role of Biomarkers in Disease Management 
 Biomarker discovery is a promising area of research focusing on deciphering 
predictive signatures responsible for disease onset, development, or prognosis, and 
applying these signatures to improve disease diagnosis, management, and treatment. The 
National Institutes of Health Biomarkers Definitions Working Group defines a biomarker 
as “a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention.” 124 Depending on their intended clinical purpose, biomarkers can aid in 
disease-risk assessment (e.g. serum-based biomarker for Alzheimer’s disease 76 or blood 
gene expression-based biomarker for sarcoidosis 150), detection of preexisting conditions 
(e.g. lipid-based biomarker for Acute kidney injury 29,108), determination of disease 
progression rate (e.g. imaging-based biomarkers for Parkinson’s disease 81 and 
Alzheimer’s disease 82), and patient stratification for improved targeted therapy (e.g. 
EGFR mutations in non-small cell lung cancer 129). In addition, many biomarker-based 
diagnostics use non-invasive procedures making them more accessible, easier to 
administer, and posing lesser patient burden.  
 Of great interest to this work are lung cancer biomarkers. A wide range of sample 
types, platforms and molecules have been used over the past several decades to develop 
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biological markers that would aid in the identification of subjects at high risk for 
developing lung cancer or those with a potentially curable early-stage disease (as 
reviewed in Brothers et al. 23). Among epigenetic biomarkers, many focus on processes 
involved in DNA methylation, which can affect downstream phenotypes without the 
modification of the DNA itself. For example, Belinsky et al. have used genome-wide 
methylation profiling of sputum and lung biopsy samples to identify P16-INK4A 
(CDKN21) as hypermethylated in lung tumors and sputum samples of smokers17. This 
result was recapitulated one year later in another study that used paired serum and lung 
tissues 35. In addition, high methylation of SHOX2 was determined to be indicative of the 
presence of malignant disease in subjects with suspect lung cancer using bronchial fluid 
aspirated during bronchoscopy 106 and plasma 65. More recently, a risk classification 
model was used to identify a panel of three genes whose methylation status was capable 
of identifying subjects at varied lung cancer risk levels (i.e., RASSF1A was found to be 
hypermethylated in the high-risk group with at least 60% chance of developing lung 
cancer, while 3OST2 and PRDM14 were hypermethylated in the low-risk groups) 52. 
Among gene expression-based biomarkers, some utilize easily accessible bronchial 
brushings of normal-appearing epithelium and the notion of field cancerization, which 
characterizes the transcriptomic changes in the normal airway as reflective of smoking 
status and lung cancer. For example, Spira et al. have developed an 80-gene biomarker 
that distinguished between samples from subjects with and without lung cancer with 83% 
accuracy 120. A follow-up study has demonstrated the biomarker’s independence from 
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clinical covariates and its increased value as a component of a combined clinicogenomic 
model 14. The biomarker has since been refined 141 and validated 114. Another study 
identified a panel of 14 antioxidant and DNA repair-associated genes whose extreme 
expression (either low or high) was prevalent in brushes from subjects with and without 
lung cancer 19. In addition, several blood-based gene-expression diagnostic biomarkers 
have been attempted. Although white blood cells have been shown to share alternations 
characteristic of lung tumors 113,146, a limited number of transcriptomic studies 
demonstrates high performance in plasma and serum, mostly due to the instability of 
circulating mRNA 23. However, several studies have now turned to liquid biopsy as a 
means to identify blood-based biomarkers using circulating tumor DNA (ctDNA) and 
cell-free DNA (cfDNA), which are believed to be released into the bloodstream via 
processes such as apoptosis and necrosis, and whose levels can be easily monitored in 
patients over time. Although still in nascent stages of development and validation, these 
proof-of-concept biomarkers show great promise in monitoring tumor burden 33,37,128, 
identification of mechanisms of resistance in EGFR-mutated NSCLC 89,117, prediction of 
response to chemotherapy with carboplatin in KRAS-mutated NSCLC 87, or prediction of 
response to tyrosine kinase inhibitor in EGFR-mutated NSCLC 77. Finally, miRNA-based 
biomarkers have played a significant role in lung cancer diagnosis and assessment of 
premalignant disease. In a 2009 study, Mascaux et al. have identified a panel of miRNAs 
dysregulated in premalignant lesion biopsies of varied severity 79. In another study, a 
small set of miRNAs were shown to discriminate between subjects with stage I SCC and 
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controls 143. Interestingly, several miRNA-based biomarkers have also leveraged liquid 
biopsy in plasma samples. Boeri and Sozzi et al. have identified 21 and validated in large 
Italian cohort, a plasma-based miRNA panel, which when coupled with low-dose CT 
(LDCT), reduced the LDCT rate of overdiagnosis five-fold 118. Furthermore, the 24-
miRNA biomarker was also evaluated from a perspective of disease prognosis. At 
baseline, biomarker scores from 84 subjects with LC detected by LDCT were binned 
according to the estimated level of risk, and checked again at follow-up five years later. 
Survival rates were found to be strongly correlated with assigned risk groups 110. Also 
utilizing plasma samples, Shen et al. found miR-21, miR-210 and miR-486-5p to be 
capable of distinguishing plasma samples from subjects with malignant vs. benign 
solitary pulmonary nodules (SPNs) detected previously by CT (or controls) with 75% 
sensitivity and 85% specificity 112. Similarly, a panel of 13 miRNAs discovered using 
sputum samples, was shown to differentiate between malignant and benign SPNs and 
offer potential reduction in CT-related overdiagnosis rates 142.  
1.4. Concepts and Methodologies 
1.4.1. RNA and miRNA 
 Phenotypic diversity is believed to be vastly influenced by variation in gene 
expression patterns. An intermediary between DNA and protein, mRNA molecules 
(messenger RNAs) carry genetic information from the cell’s nucleus to the cytoplasm, 
and the control of their transcription from DNA and translation into protein plays a 
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crucial role in the regulation of gene expression and thus cell function. Molecular events 
impacting the behavior of oncogenes and tumor-suppressor genes, such as mutations, 
gene amplifications, and chromosomal rearrangements are well described in 
carcinogenesis (as reviewed in Brothers et al.96).  Recently, post-transcriptional 
regulation mediated by microRNAs (miRNAs) has been observed to play an important 
role in lung carcinogenesis 93. miRNAs are short (~22 nt) non-protein-coding single-
stranded RNAs (ssRNAs) which regulate gene transcription by binding via imprecise 
sequence-specific base-pairing to their mRNA target’s 3’ end. One miRNA can regulate 
tens to hundreds of genes at once, and it is said that 30% of protein-coding genes are 
affected by miRNAs 75,93. In cancer, dysregulation of oncogenic miRNAs can promote 
excessive cell proliferation and impairment of apoptosis by targeting tumor suppressors 
for degradation, expression reduction, or both 57. Recently, Perdomo et al demonstrated 
the importance of miR-4423 in primate-specific repression of lung carcinogenesis and 
regulation of airway epithelial cell differentiation 94. miRNAs promise clinical utility as 
disease biomarkers and potential therapeutic targets due to their increased stability and 
tissue-specific expression compared to mRNAs. 
1.4.2. High-Throughput Sequencing and Microarrays 
 The detection and quantification of gene expression is possible thanks to DNA 
microarrays. A microarray is a microscope slide with thousands of tiny holes containing 
probes of genes or other known DNA sequences organized in a grid. mRNA samples 
  
 
9 
collected from studied individuals are first converted into cDNA (complementary DNA), 
labeled with distinct color dyes and allowed to hybridize (bind) to the chip. The 
expression of each gene in a sample is treated as proportional to the observed intensity of 
color in a location on the chip with a given gene. Although newer technologies have 
started to replace microarrays in many research labs, historically these arrays have 
facilitated the creation of an extensive collection of differential expression studies that 
should not be overlooked. 
 More recently, next generation sequencing (NGS) has taken transcriptomics by 
the storm by offering a wider dynamic range of detection, the ability to identify novel 
transcripts, reduced background noise, and increased cost-effectiveness due to 
multiplexing capabilities. RNA-Seq protocol typically involves isolating total RNA from 
samples under investigation. For mRNA-specific sequencing, the naturally 
polyadenylated (poly-A) mRNA molecules are first purified using oligo-dT magnetic 
beads and fragmented. Then, the RNA fragments are reverse transcribed into the first 
strand complementary DNA (cDNA), after which the second cDNA strand is also 
synthesized. Fragment ends are repaired (overhangs are converted into blunt ends), and a 
single A nucleotide is added to the 3’ end. Indexing adapters containing a complimentary 
T nucleotide are then ligated to the cDNA fragments. Using PCR, DNA libraries carrying 
adapters are amplified and then summarized to reflect overall transcript abundance 
(Illumina®). Because miRNAs lack the poly-A tail, additional steps have to be taken to 
select for these small molecules prior to reverse transcriptase. Specifically, total RNA can 
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be size-fractionated by gel electrophoresis, which involves cutting and purifying a gel 
fragment containing only sequences of desired length (~22 nucleotides) 66.  
 Most analyses in this thesis rely on RNA and miRNA-Seq transcriptomics 
experiments, but microarrays play an important role in validating of some of the findings. 
1.4.3. Genomic Biomarker Development 
 A typical biomarker development process involves multiple stages designed to 
ensure proper formulation of the biomarker, its adequate validation (both from a 
computational as well as a clinical utility point of view), and finally translation into the 
clinic 41. The general idea behind the various steps is to provide a robust and useful tool 
that will fulfill an unmet need, be easy to administer, and pose great benefit and minimal 
risk to the patient.  
 Briefly, at the discovery stage markers are first identified using methodologies 
aimed at answering a predefined question. This may include genes or miRNAs whose 
expression correlates with treatment response, disease prognosis, or subject risk-
stratification. Ideally, the biomarker can then be internally validated on a random subset 
of samples left out of the biomarker discovery process to prevent bias. Alternatively, 
cross-validation approaches can also be employed in cases where samples size is small. 
In addition, at this stage, biomarker’s independence from clinical and demographic 
covariates (e.g. sex, age, smoking status, prior cancer history) is also established. Then, 
external validation in additional independent datasets takes place, as well as experimental 
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validation of biomarker candidates. Clinical utility is then assessed by evaluating 
performance metrics such as sensitivity (percentage of subjects with a condition who are 
identified as such), specificity (percentage of subjects without a condition who are 
identified as such), positive predictive value (probability of a positive test correctly 
identifying subjects with a condition) and negative predictive value (probability of a 
negative test correctly identifying subjects without a condition). 
1.4.4. Network Analyses in Transcriptomics 
 Unlike monogenic diseases (e.g. sickle-cell anemia or Huntington’s), lung cancer 
is a complex disease, in which atypical phenotype is manifested through an abnormality 
not in a single gene but the entire complex molecular machinery. To understand how 
these anomalies cause disease phenotypes, it is essential to study the entire system, as the 
organization within biological networks is not random 11.  
 Typically, biological networks can be visually represented by graphs – 
mathematically derived net-like structures containing nodes connected to each other with 
edges. While nodes often correspond to molecular components of the cell, edges can 
represent a wide array of biological interactions between them. For example, metabolic 
networks represent the biochemical and molecular processes that take place in a cell in 
order to maintain life, with many subnetworks corresponding to metabolic pathways 20. 
Cell signaling networks showcase how individual signaling pathways affect each other, 
elucidating the manner in which a biological system may respond to a signal. In protein-
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protein interaction networks 56. In epistasis interaction networks, genes are connected if 
there exists an interaction between them when one is knocked out or down-regulated 107. 
Edges in disease-gene interaction networks represent mutational events that cause or 
contribute to the disease and typically connect a phenotype to a genotype underscoring 
the complexity of disease. In drug interaction networks, therapeutics are linked to their 
targets, highlighting the many-to-many relationships 88. Finally, gene regulatory networks 
display cellular mechanisms governing cell function by regulation of mRNA transcription 
and translation into protein 60. 
 Of great interest to this work are gene coexpression networks, which use 
expression-profile correlation as a measure of gene similarity and are becoming popular 
tools in biomedical research 116. Weighted Gene Coexpression Network Analysis 
(WGCNA) 147 described in detail in Chapter 3 has been successfully applied in late onset 
Alzheimer’s disease (LOAD) to identify an immune and microglia module strongly 
associated with pathophysiology of LOAD, and TYROBP as a master regulator 
implicated in neuronal damage 18. Another study used WGCNA to develop a small-cell 
lung cancer specific classifier with capacity to stratify patients for therapy. Spleen 
tyrosine kinase (SYK) was identified as a potential oncogene which could be targeted in 
SYK-positive patients 135. In general, network-based approaches offer advantages in 
biological and clinical settings, as they provide system-wide context for single genes 
implicated in a disease and elucidate the influence of interconnectedness of cellular 
components on phenotype. What is more, they may aid in disease classification and drug 
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target identification (reviewed in Barabasi et al. 11). Finally, we can use them to 
understand the molecular modifications that take place in a diseased or otherwise 
perturbed system, by exploring the topological alterations we observe in a network. 
1.5. Dissertation Aims  
This thesis examines the hypothesis that transcriptomic changes preceding the 
onset of lung cancer can be identified by studying bronchial premalignant lesions (PMLs) 
and the normal-appearing airway epithelial cells altered in their presence (i.e., the PML-
associated airway field of injury). In the following aims, I leverage high-throughput 
mRNA and miRNA sequencing data from bronchial brushings and lesion biopsies to 
develop biomarkers of PML presence and progression, and to understand regulatory 
mechanisms driving early carcinogenesis.  
 
Aim1: Develop and validate a gene expression-based biomarker for lung cancer 
premalignancy in the airway field of injury 
 Since PMLs are the presumed precursors of squamous cell carcinoma and tend to 
occur more frequently in patients with invasive carcinoma, they constitute risk factors for 
developing lung cancer. Currently detectable only via autofluorescence bronchoscopy, 
PMLs are not monitored as part of standard of care partially due to limited access to and 
relative invasiveness of the technology, as well as lack of reliable surrogate endpoints 
(i.e. intermediate markers such as PML regression that (a) may strongly correlate with 
and (b) be more easily measured in lieu of true endpoints such as a decrease in lung 
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cancer-related mortality). In addition, PML histology within a patient can vary greatly 
and more peripheral lesions may be missed by bronchoscopy. Thus, to address these 
challenges, in this aim I utilized mRNA sequencing data from normal-appearing airway 
brushings obtained from the main stem bronchus using widely-available white-light 
bronchoscopy, to build a biomarker predictive of PML presence, with a capacity to 
identify PMLs likely to progress. Given the field’s potential to reflect the overall health 
of the airway, the biomarker could help identify high-risk smokers in need of a more 
aggressive follow-up. 
 
Aim2: Identify miRNA/mRNA regulatory interactions associated with severity and 
progression of lung cancer premalignant lesions 
 Although the natural history of PMLs is thought to follow a step-wise process in 
which histologically normal cells gradually acquire the characteristics of cytological 
atypia, the PMLs are dynamic and can worsen and improve multiple times within a 
patient. In addition, little is known about the effects of mRNA/miRNA interactions on 
lesion progression. In this aim, I sought to find out if gene and miRNA expression 
extracted from lesion biopsies harbored information about PMLs’ potential to change 
over time. I identified likely regulatory mechanisms associated with PML severity and 
progression, by evaluating miRNA expression and gene coexpression modules containing 
their targets in bronchial lesion biopsies. 
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Aim3: Identify shared genomic and regulatory alterations associated with lung 
carcinogenesis in the field, the lesion and the tumor. 
 Gene expression extracted from bronchial brushings proved to have great utility 
in detecting the presence of PMLs in Aim1. Additionally, in Aim 2 gene expression 
extracted from lesion biopsies was demonstrated to be reflective of PML severity and 
progression. In this aim, I examined the preservation of the PML-associated miRNAs and 
gene modules in the airway field of injury, highlighting an emergent link between the 
airway field and the PML and thus a potential for leveraging bronchial brushes to monitor 
PMLs over time. In addition, I evaluated the preservation of PML-associated regulatory 
mechanisms in tumors. 
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CHAPTER TWO: Developing and Validating a Gene Expression-Based Biomarker 
for Lung Cancer Premalignancy in the Airway Field of Injury 
2.1. Background 
 Bronchial premalignant lesions (PMLs) are histological abnormalities in the 
airway characterized by the presence of dysplastic tissue 8. Although typically presumed 
to be precursors for lung squamous cell carcinoma (SCC), PML presence anywhere in the 
airway can be a risk marker for the development of any subtype of lung cancer 54. Several 
premalignant lesion prevalence studies showed that high-grade dysplasia was often 
present in patients with invasive carcinoma 127 and that the lesion number and severity 
correlate with increased risk for developing lung cancer [reviewed in Banerjee et al.10]. In 
addition, mortality from lung cancer is estimated to improve by 90% if the premalignant 
lesions were detected and treated early 10. In light of this evidence, pursuing PML 
detection in the context of chemoprevention looks promising, and could help identify 
high-risk patients in need of such an intervention.  
 Although CT screening has been successful at detecting early stage lung cancers, 
it is not sensitive enough to detect central lesions. As an alternative, airway monitoring 
can be performed with the use of flexible bronchoscopy. In order to visualize the lesions, 
the procedure requires the use of an autofluorescent light that makes the affected 
bronchial mucosa appear brown in comparison to the surrounding unaffected tissue which 
appears green. While fairly effective, with 89% sensitivity (as opposed to 67% of white 
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light bronchoscopy) 36, autofluorescence bronchoscopy is not commonly available and 
many major health centers across the country lack the access to this equipment. A much 
more conventional and accessible technology is white-light bronchoscopy, which, while 
widely used as a follow-up diagnostic in patients with suspect lung cancer nodules 
detected by CT, lacks the sensitivity to detect PMLs and central cancers such as SCC . In 
addition, due to the lack of successful chemopreventive agents and effective risk 
assessment methods, the need for intermediate end-point biomarkers that would account 
for more than just demographic and clinical characteristics is clear 63. 
 Cigarette smoke is a known carcinogen 50 which induces smoking-related airway 
damage.  Upon exposure, the genomic response of cytologically normal epithelial cells 
that line the respiratory tract becomes altered, reflecting the existence of an airway “field 
of injury”. In the past couple of decades, several studies have demonstrated the validity of 
this hypothesis 111,119. In 2007, Beane et al. have used bronchial brushings to identify 
subsets of gene expression changes that were slowly reversible or irreversible upon 
smoking cessation 15. In the context of chemoprevention, whereby “pharmaceutical 
interventions slow or reverse the progression of pre-malignancy to invasive cancer” 121, 
in a study by Gustafson et al. the PI3K pathway, which plays a crucial role in cell growth 
and survival, was shown to be upregulated in the normal airway of subjects with 
dysplasia and respond to chemoprevention treatment with myo-inositol 44. Similarly, in a 
placebo-controlled trial conducted by Keith et al. 62, treatment with iloprost (a 
prostacyclin found to be downregulated in lung cancer) caused an overall decrease in 
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average dysplasia grade across all observed lesions among former smokers. In the context 
of chronic obstructive pulmonary disease (COPD), Steiling et al. have identified 
transcription factor ATF4 as a transcriptional regulator of the airway gene expression 
response 122, while Androutsopoulos et al. found that genes implicated in the metabolism 
of xenobiotics, including the cytochrome P450 enzyme CYP1A1, were upregulated in the 
normal airway of smokers with COPD 6. Similarly, miRNA expression modifications 
have been demonstrated in the normal airway exposed to tobacco smoke 105and linked to 
smoking-related medical conditions: A set of antioxidant genes was found to be 
upregulated in smokers with chronic bronchitis 46. Multiple miRNAs have been identified 
as slowly-reversing their expression upon smoking cessation and linked to lung cancer 
due to their association with cell differentiation and inflammatory disease pathways 138. 
Finally, miR-218 was identified as a tumor suppressor regulating inhibition of cancer cell 
proliferation and EGFR-mediated migration in NSCLC 151. Given the strong genomic 
signal resulting from cigarette-smoke exposure, the airway may be a marker for not only 
smoking status, but also the underlying disease state that is caused by the smoking-related 
gene and miRNA modifications.  
 Spira et al have previously developed a gene-expression biomarker for lung 
cancer 120utilizing the airway field of injury hypothesis. The biomarker was built using 
airway brushings from 77 patients undergoing bronchoscopy, and achieved accuracy, 
sensitivity and specificity of 83%, 80%, and 84%, respectively, on an independent test 
set. When coupled with cytopathology as compared to bronchoscopy alone, the 
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biomarker showed a two-fold increase in diagnostic sensitivity. The 80-gene signature 
predicted cancer in patients with negative cytopathology with 95% certainty; similarly, 
both negative tests predicted the patient to be cancer-free with 70% certainty. In addition, 
a follow-up study has demonstrated the biomarker’s independence from clinical 
covariates and its increased value as a component of a combined clinicogenomic model 
14. More recently, the gene-expression based biomarker was refined and validated in a 
large clinical trial 114,141. The 17-gene biomarker provides an intermediate step between a 
non-diagnostic bronchoscopy and invasive nodule biopsy, in patients with intermediate 
pulmonary nodules detected by CT. These promising results suggest that the large-scale 
adoption of such lung cancer diagnostic biomarkers in the clinic could reduce patient care 
costs and shorten the wait time before a final diagnosis is made improving outcome and 
patient’s quality of life.  
 In this chapter, we are extending this paradigm by developing a gene-expression 
based biomarker using cytologically normal airway epithelial cells that reflect the 
presence of premalignant lesions in high-risk smokers. This valuable tool developed to 
detect and assess bronchial premalignant lesions could aid in stratification of high-risk 
patients into chemoprevention trials, identification of the most effective chemopreventive 
agent, and detection of lesions warranting aggressive follow-up. 
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2.1. Methods 
2.1.1. Sample Collection 
Bronchial brushings of normal-appearing airway collected cross-sectionally from high-
risk subjects with and without PMLs profiled by RNA-Seq 
 Autofluorescence bronchoscopy was performed to obtain bronchial airway 
brushings from subjects enrolled in the British Columbia Lung Health Study (BC-LHS) 
at the British Columbia Cancer Agency (BCCA) (Vancouver, BC) between June 2000 and 
March 2011130. In addition, during the procedure PMLs were sampled (if present) and 
evaluated by a team of pathologists. Histological lesion grade was assigned to each 
sampled PML and the worst histology observed was recorded and assigned to the 
corresponding, normal-appearing brushing. The study participants with normal or 
hyperplasia histology enrolled in the BC-LHS were current or recent former smokers 
between 50 and 75 years old with no prior history of lung cancer, who smoked for at least 
20 years and whose estimated 3-year lung cancer risk was at least 2%. Baseline bronchial 
brushes were collected from subjects with evidence of PMLs enrolled in multiple 
chemoprevention studies, were current or recent former smokers between 40 and 79 years 
old with no prior history of lung cancer and at least 30 pack years (i.e. having smoked 1 
pack a day for 30 years).  
 Bronchial brushes of normal-appearing epithelium from 84 BCCA subjects (1 
brush from each subject) with and without PMLs were selected to undergo mRNA-Seq 
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while ensuring balanced clinical covariates, such as age, pack years, race, sex, and COPD 
status. 
 The data is available from NCBI’s Gene Expression Omnibus (GEO) using the 
accession ID GSE79315. 
Bronchial brushings of normal-appearing airway collected longitudinally from high-risk 
subjects with history of PMLs profiled by RNA-Seq 
 Additional bronchial airway brushings were obtained from subjects participating 
in the High-Risk Lung Cancer-Screening Program at Roswell Park Cancer Institute 
(RPCI) (Buffalo, NY) between December 2009 and March 2013. These subjects were at 
high risk for developing lung cancer by either having a prior history of lung or 
aerodigestive cancers or by being a current or recent former smoker at least 50 years of 
age, with at least 20 smoked pack years. Fifty-one bronchial brushes of normal-appearing 
epithelium from 23 RPCI subjects with and without PMLs were profiled by mRNA-Seq 
(18 subjects had 2 procedures and 5 subjects had 3 procedures). Samples were classified 
as stable/progressive if the worst histological grade at the second time point for a given 
patient remained the same or worsened, and regressive if the worst histological grade at 
the second time point improved. The RPCI samples were utilized in biomarker validation 
to evaluate its power to identify subjects with progressing lesions by calculating 
differences in the biomarker score between sequential procedures. The data is available as 
part of GSE79315. 
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Bronchial brushings of normal-appearing airway collected cross-sectionally from 
subjects with and without COPD and PMLs profiled by microarrays 
 A total of 238 bronchial airway brishings from current and former smokers with 
and without COPD and PMLs were profiled on Affymetrix Human Gene 1.0 ST Array as 
described in Steiling et al 122 and used as an external source of validation samples to 
further evaluate the biomarker’s ability to detect PMLs. CEL files with mRNA expression 
were downloaded from GEO (GSE37147) and processed by Dr. Jennifer Beane using 
Robust Multi-array Average (RMA) 53 and the Ensembl Gene CDF v16.0.0 file 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/16.0.0/ensg.asp
) to standardize gene annotation. Fourty four samples were filtered out based on sex 
mismatches and quality. A subset of 36 samples profiled on microarrays as part of the 
study originated from BCCA subjects and was used as an overlapping validation set. The 
remaining 158 bronchial airway brushings obtained and profiled in the same manner from 
additional subjects at high risk of developing lung cancer, were used as an independent 
validation set. 
Bronchial brushings of normal-appearing airway collected cross-sectionally from 
subjects with and without lung cancer and profiled by microarrays.  
 Current and former smokers with suspect lung cancer underwent flexible 
bronchoscopy as part of two additional microarray studies. A total of 164 samples 
described by Spira et al. 120 were profiled on Affymetrix HG-U133A Array and deposited 
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in GEO as GSE4115. A total of 299 samples described by Silvestri et al 114 were profiled 
on Affymetrix Human Gene 1.0 ST Array and deposited in GEO as GSE66499. These 
extra bronchial brushing datasets were downloaded from GEO in CEL format and 
processed using Robust Multi-array Average (RMA) 53 and the Ensembl Gene CDF 
v16.0.0 file 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/16.0.0/ensg.asp
) to standardize gene annotation. Both studies were used to validate the biomarker’s 
ability to distinguish brushings from subjects with and without lung cancer. 
Tumor and adjacent normal biopsies collected cross-sectionally from subjects with lung 
squamous cell carcinoma and profiled by RNA-Seq.  
 Tumor (n=502) and matched adjacent normal (n=51) samples collected from 
subjects with squamous cell lung cancer were profiled by mRNA-Seq by The Cancer 
Genome Atlas (TCGA) Research Network Team 137. RSEM-normalized log2-transformed 
counts along with the corresponding clinical data were downloaded from the UCSC 
Xenabrowser, which provides access to TCGA’s Genomic Data Commons (GDC) Data 
Portal, and used to evaluate the biomarker’s ability to distinguish normal from tumor 
samples originating from subjects diagnosed with lung cancer. 
  
 The Institutional Review Boards (IRBs) of all participating institutions approved 
the studies and all subjects provided written informed consent. 
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2.1.2. RNA Library Preparation and RNA Sequencing 
 Total RNA was extracted from bronchial brushings using miRNeasy Mini Kit 
(Qiagen). Sequencing libraries were prepared from total RNA samples using Illumina® 
TruSeq® RNA Kit v2 and multiplexed in groups of four using Illumina® TruSeq® 
Paired-End Cluster Kit. Each sample was sequenced on the Illumina® HiSeq® 2500 to 
generate 100-nucleotide paired-end reads. Demultiplexing and generation of FASTQ files 
were performed using Illumina® CASAVA v1.8.2.  
2.1.3. Data Generation, Summarization and Quality Control  
 For the BCCA samples, sequencing reads in FASTQ format were aligned to the 
reference human genome (hg19) using TopHat (v2.0.4) 132 with default parameters. The 
insert size mean and standard deviation were determined empirically based on alignment 
results using MISO 61. Reads were realigned using TopHat and the insert size parameters. 
Alignment and quality metrics were calculated using RSeQC v2.3.3 140. To assess 3’ bias 
per sample, the gene-body ratio metric was derived as the ratio between the average read 
coverage at 80% of the gene length and the average coverage at 20% of the gene length. 
Gene count estimates were derived using Python-based HTSeq-count 4 and the Ensembl 
v64 annotation in the General Transfer Format (GTF). Gene filtering was first conducted 
on normalized counts per million (CPM) calculated using edgeR and a modified version 
of the mixture model employed in the SCAN.UPC 95 Bioconductor package. A gene was 
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included in downstream analyses if the mixture model classified it as “on” (i.e. “signal”) 
in at least 15% of the samples. 
 In addition, to provide cross-platform compatibility, biomarker discovery and 
validations were performed on common 11,926 genes present on the RNA-Seq platform 
(Illumina HiSeq 2500 used with Ensembl v64 GTF) and two microarray platforms 
(Affymetrix GeneChip Human Gene 1.0 ST Array used with custom ENSG Homo 
sapiens CDF from Brainarray v11 and Affymetrix Human Genome U133A Array used 
with custom ENSG Homo sapiens CDF from Brainarray v16). 
 For the RPCI samples, gene counts were computed using RSEM 72 and Bowtie 69 
with Ensembl v74 GTF annotation. 
 The sample and gene filtering methods for the (a) overlapping and independent 
bronchial brushing samples from subjects with and without COPD and PMLs profiled by 
microarray 122, (b) the bronchial brushing samples from subjects with and without lung 
cancer profiled by microarray 114,120, and (c) the TCGA LUSC tumor and adjacent normal 
biopsies from subjects with lung cancer profiled by RNA-Seq 137, are described in the 
corresponding publications. 
2.1.4. Gene expression-based prediction of smoking status 
 Microarray data from Beane et al. 16 (Gene Expression Omnibus [GEO] accession 
ID GSE7895) was re-analyzed by Dr. Jennifer Beane using Robust Multi-array Average 
(RMA) 53 and the Ensembl Chip Definition File (CDF v16.0.0) 
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(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/16.0.0/ensg.asp
). The limma R package 99 was used to identify genes differentially expressed between 
current (n=52) and never (n=21) smokers as previously described 15. Ninety-four genes 
(FDR<0.001) were differentially expressed between current and never smokers. The 
weighted voting algorithm 134 was trained on z-score normalized microarray data (n=73) 
across the 94 genes and used to predict smoking status in the 75 mRNA-Seq samples 
summarized with z-scored log2-transformed counts per million (log2 CPM). 
2.1.5. Biomarker Discovery Pipeline 
 A gene expression biomarker discovery pipeline was developed to test thousands 
of parameter combinations to identify a biomarker capable of distinguishing between 
samples from subjects with and without PMLs. Samples were first assigned by batch 
(corresponding to sequencing lane) to either a discovery set (n=58) or a validation set 
(n=17), and the validation set was excluded from biomarker development.  The 
biomarker was developed using subsets of the discovery set established by randomly 
splitting the samples into training (80%, n=46) and test (20%, n=12) sets 500 times, 
setting a common random seed of 150112. In each iteration, training set samples were 
passed through a series of six biomarker discovery steps, and the last step involving class 
prediction was in addition applied to the test set samples. The flowchart in Figure 2.1 and 
the following sections describe the pipeline steps in detail: 
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1. Balancing Signature 
 We tested gene signatures consisting either of an equal or unequal number of 
genes up- and down-regulated in subjects with dysplastic lesions. 
2. Input Data Preprocessing 
 We tested three input data types. HTSeq-count (v0.5.4) 3 was used to derive gene 
count estimates (raw counts). In addition, Cufflinks (v2.0.2) 133 was used to derive reads 
per kilobase per million mapped reads (RPKM) using BAM files containing only 
properly paired reads. We also calculated log2-transformed counts per million (CPM) by 
applying edgeR (v3.8.6) 101 to raw counts using the “TMM” method (weighted trimmed 
mean of M-values 102).  
3. Gene Filtering 
 Signal-based gene filtering was conducted as described in detail in the Methods. 
In short, a gene was included in downstream analyses if the mixture model classified it as 
“on” in at least 1%, 5%, 10% or 15% of the samples. For CPM input data type, we 
recalculated CPM values using raw counts after filtering out genes. 
4.  Feature Selection 
 To identify genes differentially expressed (DE) between samples with and without 
premalignant lesions (PMLs), we applied several algorithms to our filtered dataset. The 
algorithms used were as follows:  
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1. edgeR: We applied the edgeR package (v3.8.6) 101 to raw counts only. After 
calculating normalization factors (calcNormFactors) and estimating common 
(estimateGLMCommonDisp) and tagwise (estimateGLMTagwiseDisp) dispersion 
factors, we identified DE genes associated with the presence of PMLs using a 
generalized linear model, correcting for sex, COPD status, and smoking status 
covariates. For balanced signatures, the sign of the log2-fold change of expression 
between conditions determined gene directionality. For all models regardless of 
balancing, gene importance was defined by FDR-adjusted p-value from likelihood 
ratio tests (glmLRT). 
2. edgeRgb: We used the edgeR package as described in #1, additionally correcting 
for gb-ratio (described in section 2.1.3).  
3. lm: We applied the limma package (v3.22.7) 134 to CPMs, RPKMs, or voom-
transformed raw counts 70. Voom transformation was applied using a linear model, 
adjusting for sex, COPD status, and smoking status covariates, after calculating 
normalization factors. We used the same model to identify DE genes associated 
with the presence of PMLs. For balanced signatures, the sign of the moderated t-
statistic obtained via eBayes and topTable determined gene directionality. For all 
models regardless of balancing, gene importance was defined by the magnitude of 
the t-statistic. 
4. lmgb: We used the limma package as described in #3, additionally correcting for 
gb-ratio (described in section 2.1.3). 
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5. glmnet: We applied the glmnet package (v1.9-8) 38 to CPMs, RPKMs, or voom-
transformed raw counts (as in #3) to identify DE genes associated with the 
presence of PMLs. For balanced signatures, gene directionality was determined 
by the sign of the t-statistic obtained via limma by running a linear model 
described in #3. We carried out the following series of steps using all genes for 
unbalanced signatures and separately using up- and down-regulated genes for 
balanced signatures: First, RPKMs and CPMs were z-score normalized, while raw 
counts were voom-transformed. Then, due to the binary character of our response 
variable (dysplasia status), a logistic regression model was fit using the binomial 
distribution family and elastic net mixing parameter α = 0.5 (indicating a tradeoff 
between ridge and lasso regressions). The standardize option was set to FALSE, 
causing the coefficients to be returned on the original scale, thus allowing their 
magnitude to be interpreted as gene importance. Next, a range of regularization 
parameters λ was generated via leave-one-out cross-validation (nfolds = 46), and 
the λ giving the minimum mean cross-validated error (lambda.min) was chosen to 
estimate the coefficients. Finally, DE genes were defined as having non-zero 
coefficients and then sorted by importance based on the coefficients’ magnitude. 
6. randomForest: We applied the randomForest package (v4.6-12) 73 to CPMs, 
RPKMs, and voom-transformed raw counts (as in #3), setting the number of trees 
(ntree) to 100 and importance to TRUE. For balanced signatures, the sign of the t-
statistic as described in #5 determined gene directionality. For all models 
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regardless of balancing, gene importance was determined by the magnitude of the 
importance variable, defined as the mean decrease in accuracy over both 
conditions. 
7. DESeq: We applied the DESeq package (v1.18.0) 2 to unmodified raw counts 
only. DE analysis to find genes associated with the presence of PMLs included 
data normalization (estimation of the effective library size), variance estimation, 
and inference for two experimental conditions, as outlined in the DESeq package 
vignette 
(https://www.bioconductor.org/packages/3.3/bioc/vignettes/DESeq/inst/doc/DESe
q.pdf). For balanced signatures, the sign of the log2-fold change of expression 
between the two conditions determined gene directionality. For all models 
regardless of balancing, gene importance was defined by FDR. 
8. SVA: We applied the sva package (v3.12.0) 71 to CPMs, RPKMs, or voom-
transformed raw counts. Raw counts were voom-transformed using a linear model 
including only dysplasia status as the predictor variable. The number of surrogate 
variables (SVs) not associated with dysplasia status was estimated using the 
default approach of Buja and Eyuboglu 24 (“be” method). SVs were then 
identified using the empirical estimation of control probes (“irw” method), and up 
to 5 were added as covariates in the linear model (limma package). The adjusted 
model was then used to once again voom-transform raw counts, and subsequently 
fitted to identify DE genes associated with the presence of PMLs. For balanced 
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signatures, the sign of the moderated t-statistic obtained via topTable determined 
gene directionality. For all models regardless of balancing, gene importance was 
defined by the magnitude of the t-statistic. 
9. pAUC (partial AUC) 80: We applied the rowpAUCs function in the genefilter 
package (v1.48.1) 39 to CPMs, RPKMs, or voom-transformed raw counts (as in 
#3). We used 10 class label permutations and a sensitivity cutoff of 0.1 for a 
specificity range of 0.9-1. For balanced signatures, the sign of the moderated t-
statistic obtained via limma’s topTable determined gene directionality. For all 
models regardless of balancing, gene importance was defined by the magnitude of 
the t-statistic. 
5. Gene Signature Size 
 After the feature selection step, we selected the top scoring 10, 20, 40, 60, 80, 
100, or 200 genes, making sure that for balanced signatures, half originated from an 
ordered list of up-regulated genes, and half from an ordered list of down-regulated genes. 
6. Prediction Method 
 For each set of genes, we applied multiple prediction methods to predict dysplasia 
status (presence of PMLs) in a training set of 46 samples and a test set of 12 samples. 
These training and test set samples differed in each iteration, which resulted from 
randomly splitting the 58 discovery set samples. The following prediction methods were 
used: 
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1. glmnet: We used glmnet (v1.9-8) 38 to first estimate a range of penalty parameters 
λ in 10-fold cross validation using the binomial distribution family parameter and 
α = 0 to ensure all feature-selected genes were included in predictions. Dysplasia 
status was then predicted as a binary class, using lambda.min penalty.  
2. wv (weighted voting) 40: We used the weighted voting algorithm to predict 
dysplasia status. 
3. svm (Support Vector Machine) 30: We used the svm function in the e1071 package 
(v1.6-7) 84 with linear kernel and 5-fold cross validation for class prediction. 
4. rf (random forest): We used the randomForest package (v4.6-12) 73  with 1000 
trees, requesting a matrix of class probabilities as output. 
5. nb (Naïve Bayes): We used the naiveBayes function in the e1071 package (v1.6-
7) with default parameters. 
 Each of the prediction algorithms generated a vector of predicted scores and a 
vector of predicted labels for all samples in the training and test sets.  
Evaluating Performance 
 We considered all statistically and computationally viable combinations of the 
above six parameters. The predicted class labels calculated for each model (i.e., a 
combination of parameters), coupled with true class labels were then used to calculate 
performance metrics for the biomarker. 
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 For each model, we calculated these metrics for each of the 500 iterations 
(different training and test sets assembled from the discovery set samples) and then 
averaged over all iterations. In addition to the standard performance metrics, we 
calculated model overfitting and gene selection consistency. The overfitting metric was 
calculated as the difference between the train set AUC and the test set AUC. Specifically, 
a model performing well on the training set but poorly on the test set would suggest a 
high degree of overfitting and thus achieve a high overfitting score. For each model, the 
gene selection consistency metric was calculated as the average (“normalized” to 
biomarker size in a given model) percentage of genes passing the gene filter, that were 
selected into the final gene committee in all 500 iterations:  
 
For example, a model resulting in a 10-gene biomarker would have the highest 
consistency (1) if it selected the same 10 genes in all 500 iterations (10 unique genes 
selected altogether). The same model would have the lowest consistency (0) if it selected 
a different set of 10 genes in all iterations (10 genes x 500 iterations = 5000 unique genes 
altogether). 
Selecting Best Performing Model 
 In selecting the best model, we considered the degree of model overfitting, model 
gene selection consistency and test set AUC. First, we identified top 10% least overfitting 
models. Simultaneously, we identified top 10% most consistent models. Finally, the 
!"#$%$&'#!( = 1 − #	.#%/.'	0'#'$	%#	122	%&'31&%"#$ − 4%"5136'3	$%7'4%"5136'3	$%7'	×	#	%&'31&%"#$ − 4%"5136'3	$%7' 
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model with the highest test set AUC among models fulfilling both criteria was chosen as 
the final model.  
Selecting Final Gene Signature 
 Due to the nature of internal cross-validation, the biomarker genes selected by the 
best model may differ (only slightly, assuming the model is highly consistent) between 
iterations due to differences in the sample composition of the training set in each cross-
validation. Therefore, we generated the final gene signature by training the best 
biomarker model using all 58 discovery set samples and best model parameters, allowing 
the pipeline to discover a new “consensus” signature. 
Positivie and Negative Controls 
 The biomarker discovery pipeline was also used to develop control biomarkers. 
As positive controls, we used smoking status and sex phenotypes to identify biomarkers 
that could successfully distinguish former from current smokers, and females from males, 
respectively. As negative controls, we used randomly shuffled labels for dysplasia status, 
smoking status, and sex. Label shuffling was conducted preserving the association 
between gene expression profiles and remaining phenotypes; i.e., in the case of shuffled 
dysplasia status, only dysplasia status was shuffled while other phenotypes and the 
corresponding gene expression profile remained unchanged and linked to the same 
sample ID. 
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2.1.6. Biomarker Validation Pipeline 
 We tested the performance of the final biomarker using the biomarker discovery 
pipeline in validation mode. In this mode, the pipeline takes in the entire discovery set (n 
= 58) as the training set, and an external validation set as the test set. The test set is first 
corrected for gb-ratio (RNA-Seq quality metric) using limma, and the residual data is 
used as input. Both training and test sets are then z-score normalized. The pipeline is run 
using only the final model to generate prediction labels and prediction scores for the test 
set samples. Finally, pROC package (v1.8) 100 is used to visualize and quantify biomarker 
performance by plotting a ROC curve using prediction scores as the response and the 
dichotomous phenotype as the predictor, and extracting the AUC value from the resulting 
ROC object. 
Detecting PML Presence Using Bronchial Brushings from Subjects With and Without 
PMLs Profiled by RNA-Seq  
 To validate the biomarker’s ability to detect the presence of PMLs, we tested the 
performance of the biomarker in smokers with and without PMLs (n=17 samples) left out 
of the biomarker discovery process. To assess the robustness of the results, we randomly 
permuted dysplasia status labels 100 times, obtaining biomarker scores for all 17 samples 
in each of the iterations. We then concatenated the 100 newly generated biomarker score 
sets for randomized labels, creating a predictor vector consisting of 1700 scores. 
Similarly, we concatenated 100 identical copies of biomarker score sets for true labels, 
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creating a response vector of the same length. This allowed us to visualize the 
performance of the biomarker on true and randomized labels in a single ROC curve. 
Moreover, we evaluated the biomarker’s platform dependence by testing its ability to 
detect PMLs in an overlapping and an independent set of microarray samples. 
Detecting PML Progression Using Longitudinally-Collected Bronchial Brushings from 
Subjects With History of PMLs Profiled by RNA-Seq 
 To validate the biomarker’s ability to predict sample progression/regression, we 
first used the biomarker to score the longitudinally collected RPCI samples (n=51). Next, 
we calculated the difference in scores between two consecutive time points for each 
patient (later time point biomarker score - earlier time point biomarker score). For 
example, a subject with 3 samples from 3 different time points would have 3 scores, and 
thus two score differences could be calculated; a subject with 2 samples from 2 time 
points would have 2 scores, and thus 1 score difference.  Each pair of samples was 
assigned a “progressing/stable” or “regressing” phenotype. A “progressing/stable” 
phenotype indicated that the worst histological grade of PMLs sampled during the 
baseline procedure increased in severity or remained unchanged at follow-up; while a 
“regressing” phenotype indicated that the worst histological grade of PMLs sampled at 
baseline decreased in severity at follow-up. We quantified the ability of the score 
difference to predict the “progression/regression” phenotype by plotting a ROC curve, 
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using the vector of score differences as the predictor variable, and the 
progression/regression phenotype as the response variable.  
Detecting Lung Cancer Presence Using Bronchial Brushings from Subjects With and 
Without Lung Cancer Profiled by Microarray 
 To validate the biomarker’s ability to detect the presence of lung cancer, we tested 
the model in microarray and RNA-Seq samples from subjects with and without lung 
cancer.  
Functional Enrichment 
 The final biomarker genes’ role in relevant biological pathways and processes was 
evaluated using Enrichr 28. Enrichment was tested using Fisher’s Exact Test in gene 
enrichment categories such as BioCarta, Reactome, GO, KEGG, etc, calculated for the 
gene overlap between the biomarker genes and genes implicated in each considered 
pathway.  
2.2. Results 
2.2.1. Sample Population 
 Cytologically normal epithelial cells were collected via bronchial airway 
brushings using autofluorescence bronchoscopy from current and former smokers at the 
BCCA. Sample and gene filtering yielded 13,870 out of 51,979 genes and 82 samples 
(n=2 excluded due to quality or sex annotation mismatches) for analysis.  Data from 
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Beane et al. 16 was used to predict the smoking status of the 82 samples. Airway 
brushings with an assigned histological grade of metaplasia (n=7), were removed from 
further analysis due to classification uncertainties. The remaining 75 samples were 
dichotomized into two groups: samples with no evidence of PMLs (brushes from subjects 
with no abnormal fluorescing areas or those corresponding to biopsies having normal or 
hyperplasia histology, n=25); and samples with evidence of PMLs (brushes 
corresponding to biopsies having mild, moderate, or severe dysplasia, n=50).  
 Important clinical covariates including COPD status, self-reported smoking 
history and genomically-derived smoking status were not significantly different between 
the two groups (Table 2.2). For biomarker development, the 75 BCCA samples were split 
by batch (sequencing lane) and used separately in biomarker discovery (n=58) and 
validation (n=17) (Table 2.2) 
 The change in biomarker score as a predictor of PML progression was tested in 51 
RPCI RNA-Seq samples (Table 2.3 and Table 2.4).  
 The biomarker’s ability to detect PMLs was further validated in 36 overlapping 
and 158 independent samples from current and former smokers enrolled in 
chemoprevention studies 122,123 (Table 2.5 and Table 2.6), in addition enabling the 
concurrent evaluation of the biomarker’s performance on a microarray platform. 
 Moreover, the biomarker’s ability to distinguish bronchial brushing samples from 
subjects with and without lung cancer was tested in two microarray datasets (n=164 and 
n=299) 114,120(Table 2.7 and Table 2.8). 
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 Finally, the biomarker’s ability to distinguish tumor samples from adjacent normal 
samples originating from subjects with squamous cell lung cancer, was evaluated using 
223 TCGA RNA-Seq LUSC samples  137 (Table 2.9). 
2.2.2. Performance Metrics 
 A total of 7,700 parameter combinations (models) were tested using the biomarker 
discovery pipeline. The validity of the pipeline was evaluated by examining performance 
metrics across all models and all 500 iterations for dysplasia status as well as positive and 
negative controls.  
 Overall, the performance of the biomarker on dysplasia status as summarized by 
the average test set AUC across 500 iterations ranged between 40% and 80%, with a 
median of 69% and standard deviation of 5%. The train set AUC average ranged between 
53% and 100%, with a median of 97% and standard deviation of 6%. The overall 
performance of the biomarker on positive and negative control has been summarized in 
(Figure 2.3).  
 The performance of the biomarker was also summarized by the individual 
parameters of each model. The test and train set AUCs were evaluated separately by 
balancing, data type, gene filter, etc. These metrics reflect the performance of one 
parameter summarized over there remaining parameters, e.g. Figure 2.2 illustrates that 
200-gene biomarkers performed better than smaller size ones, regardless of balancing, 
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data type, gene filter, etc., and that RPKMs gave slightly better results that CPM or raw 
counts regardless of other parameters.  
 Model overfitting defined as the difference between test and train set AUCs was 
summarized for dysplasia status and positive and negative controls along with model 
consistency in  Figure 2.4. 
 All performance metrics including average sensitivity, specificity, PPV and NPV 
were summarized in Table 2.10. 
2.2.3. Selection of Best Model and Final Gene Signature 
 In selecting the final model, we first considered choosing the model with the 
highest test set AUC. However, among the 7,700 models we tested, 27 had an AUC > 
0.79 and 147 had an AUC > 0.78, which is within 0.02 of the maximum AUC observed 
for all models (max AUC = 0.80). Thus, the decision to simply pick the top scoring 
model would be arbitrary, as almost all representatives of parameters considered were 
among the top 147 scoring models. To circumvent this limitation, in deciding about the 
final model we took into consideration the degree of model overfitting and consistency. 
We picked the model with the highest test set AUC from a subset of models that ranked 
among the top 10% (770 models) of least overfitting models and the top 10% (770 
models) of most consistent models.  
 The final model had test set AUC of 0.78 (ranking 216th among best test set AUC 
models), an 11% overfitting score (ranking 57th among least overfitting models), and a 
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98% consistency score (ranking 446th among most consistent models) in cross-validation 
(Table 2.11). The selected model produced an imbalanced signature of 200 features, after 
filtering out genes expressed in less than 15% of samples and applying a quality-
corrected linear model to CPM for feature selection and weighted voting algorithm for 
classification. 
 Although the final chosen model did not achieve the highest test set AUC, 
incorporating other performance metrics allowed us to select a model that better captures 
the signal without overfitting, producing more robust results. 
2.2.4. Positive and Negative Controls 
 The biomarker’s ability to distinguish samples from subjects with and without 
PMLs was evaluated against its power to tell current smokers from former, and males 
from females. Many tested models performed very well on the positive controls, which 
confirms the ability of the pipeline to find relevant biomarkers for traits with especially 
strong signal, such as smoking status and sex. As expected, the biomarker performed 
poorly on all three negative controls defined by shuffling the phenotype labels for 
dysplasia, smoking and sex, resulting in random class assignments and AUCs of around 
0.5 (Figure 2.3). 
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2.2.5. Validations 
Detecting Presence of PMLs 
 Validation set (n=17). The biomarker’s ability to distinguish samples from 
subjects with and without PMLs was first evaluated in the validation set (n=17) of 
samples left out of the biomarker discovery process. The model achieved AUC of 0.75, 
and correctly predicted 5/5 of dysplasias (sens = 100%) and 9/12 of normals (spec = 
75%). To assess the biomarker’s robustness, the dysplasia status variable was shuffled 
100 times. The model achieved AUC of 51% in predicting shuffled dysplasia status 
(negative control for dysplasia status), confirming the biomarker’s expected poor 
performance predicting random signal (Figure 2.5). 
 Overlapping microarray PML set (n=36). A total of 238 samples collected from 
subjects with and without COPD were profiled on Affymetrix Human Genome U133A 
Array 122. A subset of the original BCCI samples (n=36) originated from patients enrolled 
in this study and were subjected to profiling by both microarray and RNA-Seq. These 
additional microarray samples were used as an overlapping validation set (Table 2.5). The 
model achieved AUC of 73%, and correctly predicted 10/11 of dysplasias (sens = 91%) 
and 13/25 of normals (spec = 52%) (Figure 2.6) 
 Independent microarray PML set (n=158). A remainder of 158 samples analyzed 
in the same paper 122 and not profiled by RNA-Seq, were used as an independent 
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validation set (Table 2.6). The model achieved AUC of 64%, and correctly predicted 
24/35 of dysplasias (sens = 68%) and 51/123 of normals (spec = 42%) (Figure 2.7) 
Detecting Progression of PMLs 
 RNA-Seq longitudinal PML set (n=51). To validate the biomarker’s ability to 
predict sample progression/regression, we used longitudinally collected RPCI samples. 
Among the 26 subjects, 18 had brushings performed at two time points, and five at three 
time points (Table 2.3). Subjects with a single time point (n=3) were removed from 
further analysis. First, we examined the performance of the biomarker scores in 
identifying samples from subjects with and without PMLs. When Metaplasias were 
classified as Normals, the model achieved an AUC of 62.3%, correctly predicting 21/31 
samples from subjects with PMLs (sens =68%) and 11/20 samples from subjects with no 
evidence of PMLs (spec = 55%) (Figure 2.8). 
 We sought to find out if the differences in biomarker scores between consecutive 
time points would improve the performance. To test this hypothesis, we analyzed 28 
score differences, and samples with a negative score difference were designated as 
regressing, and those with a positive score as progressing or stable. We quantified the 
ability of the score difference to predict the progression/regression phenotype by plotting 
a ROC curve and extracting the AUC as described in Methods. The model achieved an 
AUC of 74.9% (Figure 2.9). 
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Detecting Presence of Lung Cancer 
 Lung cancer bronchial brushes microarray set 1 (n=164). The biomarker’s ability 
to distinguish samples from subjects with and without lung cancer was evaluated in 
additional bronchial brushings profiled on microarray 120. Cancer samples were assigned 
the dysplasia phenotype. The model achieved 69.3% AUC , and correctly predicted 57/78 
cancer samples (sens = 73%) and 48/86 normals (spec =56%). (Figure 2.10). 
 Lung cancer bronchial brushes microarray set 2 (n=299). Additional bronchial 
samples profiled on microarray as part of the AEGIS trial 114,141were used as a validation 
set, and similarly, cancers were treated as dysplasias. The model achieved AUC of 
52.3%, and correctly predicted 137/223 cancer samples (sens = 61%) and 32/76 normals 
(spec = 42%) (Figure 2.11). 
 TCGA Lung SCC tumor RNA-Seq set (n=553). Finally, 553 tumor and adjacent 
normal samples from subjects with lung squamous cell carcinoma catalogued in the 
LUSC dataset by the Cancer Genome Atlas Data Portal 137, were assessed within the 
biomarker framework. Tumor samples were assigned the status of dysplasia. The model 
achieved AUC of 81.8%, correctly predicting 315/502 (sens=63%) tumor samples and 
43/51 adjacent normal (spec=84%) (Figure 2.12). 
2.2.6. Biological Enrichment and Pathway Analysis 
 The 200 final biomarker genes were evaluated for their potential role in biological 
pathways using Enrichr. Pathways involved in respiratory electron transfer chain, 
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formation of ATP, oxidative phosphorylation and metabolism were strongly enriched 
among genes up-regulated in the airways of subjects with PMLs. Other up-regulated 
pathways included p53 signaling, and mitochondrial biogenesis. Among upregulated 
transcription factors, we observed the activating transcription factor 2 (ATF2) and the 
estrogen receptor 1 (ESR1). Down-regulated pathways included the Pelp1 and CARM1 
modulation of estrogen receptor.   
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Figure 2.1 Biomarker discovery and validation pipelines.  
(LEFT) Samples (n=75) were split into a discovery set (n=58) and a validation set (n=17). The 
pipeline was run 500 times, and each time the discovery set was randomly split into training (80% 
of samples, n=46) and test (20% of samples, n=12) sets. The training set samples were used to 
train the biomarker using all statistically and computationally feasible combinations of pipeline 
parameters, including: 1. Up- / down-regulation ratio: TRUE or FALSE (see Balancing 
signature). 2. Data type: raw counts, RPKM or CPM (see Input data preprocessing). 3. Gene 
filter: genes with signal in at least 1%, 5%, 10%, or 15% of samples (see Gene filter). 4. Feature 
selection: edgeR, edgeR correcting for gb-ratio, limma, limma correcting for gb-ratio, glmnet, 
random forest, DESeq, SVA, or partial AUC (see Feature selection). 5. Gene number: 10, 20, 40, 
60, 80, 100, or 200 genes (see Biomarker size). 6. Prediction method: weighted voting, random 
forest, SVM, naïve bayes, or glmnet (see Prediction method). (RIGHT) In validation mode, the 
pipeline is run only once. The entire discovery set (n=58) is used to train the biomarker with 
parameters selected for the final model. The selected prediction algorithm is then applied to the 
validation set and performance metrics are calculated as before.  
  
  
 
47 
Table 2.1 Performance measures used to evaluate performance of the biomarker. 
TP = true positives; FP = false positives; TN = true negatives; FN = false negatives; MCC = 
Matthews’s Correlation Coefficient; and AUC = Area Under the Curve. 
AUC for ROC (Receiver Operating Characteristic) 
Accuracy 
 
 
Sensitivity 
 
 
Specificity 
 
 
Positive Predictive Value 
(PPV) 
 
Negative Predictive Value 
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Table 2.2 Demographic characteristics of the discovery and validation sets stratified by dysplasia status. 
Data are means (SD) for continuous variables and proportions with percentages for dichotomous variables. P-values are for the 
comparison of all-Caucasian subjects with and without premalignant lesions (dysplasia), using two sample t-tests for continuous variables 
or Fisher’s exact test for categorical variables.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Factor Overall Normal Dysplasia p-value Overall Normal Dysplasia p-value
No. Samples 58 20 38 17 5 12
Age 62.7 (7.1) 64.1 (5.8) 61.9 (7.6) 0.24 63.9 (8.6) 66 (5.8) 63 (9.7) 0.45
Male 37/58 (63.8) 12/20 (60) 25/38 (65.8) 0.78 14/17 (82.4) 4/5 (80) 10/12 (83.3) 1
Current smoker 28/58 (48.3) 9/20 (45) 19/38 (50) 0.79 8/17 (47.1) 2/5 (40) 6/12 (50) 1
Pack years 48.2 (16.9) 49.4 (18.9) 47.5 (15.9) 0.71 44.6 (12.9) 40.5 (11.6) 46.3 (13.5) 0.39
FEV1% Predicted 86.5 (17.7) 87.8 (16.7) 85.7 (18.5) 0.66 69.5 (16.2) 71 (17.7) 68.9 (16.3) 0.83
FEV1/FVC Ratio 72.1 (7.7) 75.1 (6.3) 70.4 (8) 0.02 67 (8.1) 66.8 (8.5) 67.1 (8.3) 0.95
COPD (FEV1%<80 & FEV1/FVC<70) 11/58 (19) 2/20 (10) 9/38 (23.7) 0.3 11/17 (64.7) 3/5 (60) 8/12 (66.7) 1
Histology <0.001 <0.001
Normal 11/58 (19) 11/20 (55) 1/17 (5.9) 1/5 (20)
Hyperplasia 9/58 (15.5) 9/20 (45) 4/17 (23.5) 4/5 (80)
Metaplasia 0/58 (0) 0/17 (0)
Mild Dysplasia 29/58 (50) 29/38 (76.3) 6/17 (35.3) 6/12 (50)
Moderate Dysplasia 6/58 (10.3) 6/38 (15.8) 6/17 (35.3) 6/12 (50)
Severe Dysplasia 3/58 (5.2) 3/38 (7.9) 0/17 (0) 0/12 (0)
Discovery Set Validation Set
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Table 2.3 Demographic characteristics of the RNA-Seq cross-sectional bronchial brushing 
dataset stratified by dysplasia status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. Top table 
summarizes data by samples, and bottom table summarizes data by subjects. P-values are for the 
comparison between the Dysplasia and Normal groups, using two sample t-tests for continuous 
variables or Fisher’s exact test for categorical variables. 
 
 
  
Factor Overall
No. of subjects 23
No. of procedures per subject (mean [range]) 2.2 (2-3 visits)
Days between visits (mean [range]) 344 (98-721 days)
Age 58.26 (6.83)
Sex
female 12
male 11
Race
Caucasian 22
African American 1
Lung Cancer 0
Smoking
current 10
former 10
former 3
Pack Years 49.22 (23.74)
Factor Overall Dysplasia Normal p-value
No. Samples 51 31 20
Age 58.2 (6.6) 58.52 (6.93) 57.62 (6.15) 0.637
Sex 0.567
female 27 15 12
male 24 16 8
Race < 0.001
Caucasian 49 29 20
Other 2 2 0
Lung Cancer 0 0 0
Smoking
current 25 18 7
former 25 12 13
never 1 1 0
Pack Years 48.6 (22.58) 46.58 (21.42) 51.7 (24.5) 0.435
Worst Histological Lesion Observed < 0.001
Normal 5/51 (9.8) 5/51 (9.8)
Hyperplasia 6/51 (11.8) 6/51 (11.8)
Metaplasia 9/51 (17.6) 9/51 (17.6)
Mild Dysplasia 3/51 (5.9) 3/51 (5.9)
Moderate Dysplasia 20/51 (39.2) 20/51 (39.2)
Severe Dysplasia 8/51 (15.7) 8/51 (15.7)
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Table 2.4 Demographic characteristics of the RNA-Seq paired PML dataset stratified by 
PML progression/regression. 
Data are means (SD) for continuous variables and counts for dichotomous variables. P-values are 
for the comparison of sample pairs from subjects with regressing and progressing/stable 
premalignant lesions, using two sample t-tests for continuous variables or Fisher’s exact test for 
categorical variables 
  
Progressing
Stable
No. Samples 51 34 22
No. Sample Pairs 28 17 11
No. Patients** 23 16* 10*
Age 58.1 (6.5) 58.4 (6.9) 57.6 (6.1) 1
Sex 0.7
female 15 10 5
male 13 7 6
Race
Caucasian 28 17 11
Lung Cancer 0 0 0
Smoking 0.148
ever 27 17 10
never 1 0 1
Pack Years 48.1 (22) 49.8 (24.8) 45.4 (17.6) 1
Histological Grade Change -0.9 (1.7) -1.9 (1.0) 0.7 (1.3) <0.001
Time between Procedures (Days) 343.8 (171.9) 350.9 (199.6) 332.8 (125.9) 0.77
Factor Overall Regressing p-value
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Table 2.5 Demographic characteristics of the microarray overlapping PML dataset 
stratified by dysplasia status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. P-values are 
for the comparison of subjects with and without premalignant lesions (dysplasia), using two 
sample t-tests for continuous variables or Fisher’s exact test for categorical variables. 
 
  
Overall Dysplasia Normal p-value
No. Samples 36 11 25
Sex 0.159
female 16 7 9
male 20 4 16
Age 65.63 (5.86) 68.16 (5.44) 64.52 (5.8) 0.086
COPD 0.224
no 26 6 20
yes 10 5 5
Smoking 1
current 17 5 12
former 19 6 13
Pack Years 46.05 (15.15) 47.59 (5.005) 45.41 (17.84) 0.708
Histology < 0.001
Normal 12 0 12
Hyperplasia 13 0 13
Metaplasia 0 0 0
MildD 9 9 0
ModD 2 2 0
SevD 0 0 0
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Table 2.6 Demographic characteristics of the microarray independent PML dataset 
stratified by dysplasia status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. P-values are 
for the comparison of subjects with and without premalignant lesions (dysplasia), using two 
sample t-tests for continuous variables or Fisher’s exact test for categorical variables. 
 
  
Overall Dysplasia Normal p-value
No. Samples 158 35 123
Sex 0.052
female 64 9 55
male 94 26 68
Age 64.44 (5.44) 65.05 (5.11) 64.26 (5.54) 0.454
COPD 0.048
no 97 16 81
yes 61 19 42
Smoking 1
current 59 13 46
former 99 22 77
Pack Years 48.05 (20.99) 48.63 (16.6) 47.9 (22.07) 0.863
Histology < 0.001
Normal 55 0 55
Hyperplasia 68 0 68
Metaplasia 0 0 0
MildD 23 23 0
ModD 9 9 0
SevD 3 3 0
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Table 2.7 Demographic characteristics of the microarray lung cancer bronchial brushing 
dataset 1 stratified by cancer status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. P-values are 
for the comparison of subjects with and without lung cancer, using two sample t-tests for 
continuous variables or Fisher’s exact test for categorical variables. 
 
  
Overall Cancer Normal p-value
No. Samples 164 78 86
Sex 0.592
female 41 18 23
male 122 60 62
NA 1 0 1
Age 58.15 (14.32) 64.54 (9.63) 52.28 (15.42) < 0.001
NA 1 0 1
Smoking 0.654
current 130 60 70
former 33 18 15
NA 1 0 1
Race < 0.001
Caucasian 110 67 43
Other 53 11 42
NA 1 0 1
Pack Years 44.92 (31.95) 54.92 (26.77) 35.73 (33.67) < 0.001
NA 1
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Table 2.8 Demographic characteristics of the microarray lung cancer bronchial brushing 
dataset 2 stratified by cancer status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. P-values are 
for the comparison of subjects with and without lung cancer, using two sample t-tests for 
continuous variables or Fisher’s exact test for categorical variables. 
 
 
 
 
Table 2.9 Demographic characteristics of the RNA-Seq lung tumor biopsy dataset 1 
stratified by cancer status. 
Normal refers to biopsy taken from area adjacent to the tumor. Data are means (SD) for 
continuous variables and counts for dichotomous variables. P-values are for the comparison of 
subjects with and without lung cancer, using two sample t-tests for continuous variables or 
Fisher’s exact test for categorical variables. 
 
 
  
Overall Cancer Normal p-value
No. Samples 299 223 76
Sex 0.178
female 123 97 26
male 176 126 50
Age 62.27 (12.1) 64.48 (10.55) 55.8 (13.98) < 0.001
COPD 0.0315
no 191 139 52
unknown 4 1 3
yes 104 83 21
Smoking 0.107
current 127 101 26
former 172 122 50
Pack Years 43.79 (30.54) 47.84 (31.3) 31.64 (24.57) < 0.001
Overall Cancer Normal p-value
No. Samples 553 502 51
Sex 0.879
female 144 130 14
male 408 371 37
Age 67.3 (8.59) 67.2 (8.58) 68.24 (8.65) 0.414
Smoking 0.654
current 213 195 18
former 340 307 33
Pack Years 52.68 (31.01) 52.69 (31.03) 52.57 (31.21) 0.98
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Table 2.10 Biomarker performance in cross-validation. 
Summary of performance metrics for 7700 considered models. Each performance measure 
represents summaries over 500 iterations per model. The first row summarizes parameters used 
by the 7700 models. The second and third rows summarize performance for train and test set, 
respectively. ACC=accuracy, SENS=sensitivity, SPEC=specificity, PPV=positive predictive 
value, NPV=negative predictive value, MCC=Mathew’s Correlation Coefficient, AUC=Area 
Under the (ROC) Curve, MAQC2=performance metric derived in MicroArray Quality Control 
Study (Table 2.1).The fourth row summarizes model overfitting and consistency. 
 
 
 
  
transformation sample_filter  data_type gene_filter feature_selection number_features prediction_mode  balanced
raw:7700  bal  :3850  counts:3500  0.01       :1540  glmnet :1050  Min.   : 10.0  glmnet:1540  Mode :logical  
imbal:3850  cpm   :2100  0.05       :1540  lm     :1050  1st Qu.: 20.0  nb    :1540  FALSE:3850     
rpkm  :2100  0.1        :1540  lmgb   :1050  Median : 60.0  rf    :1540  TRUE :3850     
0.15       :1540  pauc   :1050  Mean   : 72.9  svm   :1540  
lam.grt.cor:1540  rf     :1050  3rd Qu.:100.0  wv    :1540  
Max.   :200.0  
 ACC.tr.dysp  SENS.tr.dysp  SPEC.tr.dysp  PPV.tr.dysp  NPV.tr.dysp  MCC.tr.dysp  AUC.tr.dysp MAQC2.tr.dysp
Min.   :0.621  Min.   :0.117  Min.   :0.579  Min.   :0.325  Min.   :0.688  Min.   :0.087  Min.   :0.525  Min.   :0.539  
1st Qu.:0.817  1st Qu.:0.820  1st Qu.:0.816  1st Qu.:0.715  1st Qu.:0.903  1st Qu.:0.629  1st Qu.:0.911  1st Qu.:0.860  
Median :0.909  Median :0.895  Median :0.965  Median :0.921  Median :0.944  Median :0.797  Median :0.969  Median :0.933  
Mean   :0.892  Mean   :0.864  Mean   :0.907  Mean   :0.854  Mean   :0.934  Mean   :0.772  Mean   :0.947  Mean   :0.917  
3rd Qu.:0.987  3rd Qu.:0.985  3rd Qu.:0.996  3rd Qu.:0.991  3rd Qu.:0.992  3rd Qu.:0.971  3rd Qu.:0.999  3rd Qu.:0.992  
Max.   :1.000  Max.   :1.000  Max.   :1.000  Max.   :1.000  Max.   :1.000  Max.   :1.000  Max.   :1.000  Max.   :1.000  
 ACC.ts.dysp  SENS.ts.dysp  SPEC.ts.dysp  PPV.ts.dysp  NPV.ts.dysp  MCC.ts.dysp  AUC.ts.dysp MAQC2.ts.dysp
Min.   :0.481  Min.   :0.041  Min.   :0.527  Min.   :0.167  Min.   :0.596  Min.   :-0.105  Min.   :0.403  Min.   :0.429  
1st Qu.:0.629  1st Qu.:0.395  1st Qu.:0.685  1st Qu.:0.502  1st Qu.:0.702  1st Qu.: 0.194  1st Qu.:0.660  1st Qu.:0.627  
Median :0.655  Median :0.468  Median :0.785  Median :0.549  Median :0.727  Median : 0.255  Median :0.692  Median :0.659  
Mean   :0.654  Mean   :0.476  Mean   :0.756  Mean   :0.550  Mean   :0.729  Mean   : 0.248  Mean   :0.693  Mean   :0.658  
3rd Qu.:0.683  3rd Qu.:0.594  3rd Qu.:0.815  3rd Qu.:0.601  3rd Qu.:0.758  3rd Qu.: 0.319  3rd Qu.:0.732  3rd Qu.:0.695  
Max.   :0.747  Max.   :0.729  Max.   :0.979  Max.   :0.747  Max.   :0.831  Max.   : 0.464  Max.   :0.799  Max.   :0.763  
  tr.0.dysp   tr.1.dysp   ts.0.dysp   ts.1.dysp overfitting.dysp consistency.dysp
Min.   :31  Min.   :16  Min.   :7  Min.   :4  Min.   :0.0431  Min.   :0.23  
1st Qu.:31  1st Qu.:16  1st Qu.:7  1st Qu.:4  1st Qu.:0.2148  1st Qu.:0.94  
Median :31  Median :16  Median :7  Median :4  Median :0.2593  Median :0.96  
Mean   :31  Mean   :16  Mean   :7  Mean   :4  Mean   :0.2545  Mean   :0.94  
3rd Qu.:31  3rd Qu.:16  3rd Qu.:7  3rd Qu.:4  3rd Qu.:0.2982  3rd Qu.:0.97  
Max.   :31  Max.   :16  Max.   :7  Max.   :4  Max.   :0.4844  Max.   :0.99  
NA's   :225  
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Table 2.11 Best model performance 
Overview of parameters and performance metrics for the selected model. The first row 
summarizes parameters used by the best model. The second and third rows show performance of 
the best model on train and test set, respectively. ACC=accuracy, SENS=sensitivity, 
SPEC=specificity, PPV=positive predictive value, NPV=negative predictive value, 
MCC=Mathew’s Correlation Coefficient, AUC=Area Under the (ROC) Curve, 
MAQC2=performance metric derived in MicroArray Quality Control Study (Table 2.1).The 
fourth row shows the best model overfitting and consistency. 
 
 
  
sample_filter data_type gene_filter feature_selection number_features prediction_mode balanced phenotype.dysp
imbal cpm 0.15 lmgb 200 wv FALSE dysplasia_status
ACC.tr.dysp SENS.tr.dysp SPEC.tr.dysp PPV.tr.dysp NPV.tr.dysp MCC.tr.dysp AUC.tr.dysp MAQC2.tr.dysp
0.8135 0.8792 0.7795 0.6754 0.9263 0.6296 0.8862 0.8505
ACC.ts.dysp SENS.ts.dysp SPEC.ts.dysp PPV.ts.dysp NPV.ts.dysp MCC.ts.dysp AUC.ts.dysp MAQC2.ts.dysp
0.6913 0.705 0.6834 0.576 0.8205 0.3914 0.777 0.7364
tr.0.dysp tr.1.dysp ts.0.dysp ts.1.dysp index.dysp overfitting.dysp consistency.dysp
31 16 7 4 2.2.1.3.4.3.20.1 0.1092 0.9814
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Figure 2.2 Biomarker performance in cross validation. 
(1-7 row-wise) Boxplots summarizing AUC on test set across 7700 models stratified by model 
parameter. (8-14 row-wise) Boxplots summarizing degree of overfitting across 7700 models 
stratified by model parameters.   
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Figure 2.3  Biomarker performance on positive and negative controls. 
Summaries of performance of 7700 models predicting PML presence, sex, and smoking status, as 
well as shuffled equivalents (negative controls).Summary of AUC in test samples (first row), 
AUC in training samples (second row), and overfitting (third row) stratified by balancing. 
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Figure 2.4 Summary of biomarker performance measures used to select the best model. 
7,700 models for PML presence prediction were tested on true and shuffled dysplasia labels and 
their performance was summarized across 500 cross-validations using the area under the curve 
(AUC). Model consistency was defined as model’s ability to select the same genes in all 500 
cross-validations. Model overfitting was defined as the difference between train set AUC and test 
set AUC. The final model was chosen as one having the highest possible test set AUC among 
highly consistent and least overfitting models, and is highlighted in red. 
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Figure 2.5 Biomarker performance in validation set (n=17). 
To evaluate biomarker’s performance predicting PML presence, the biomarker was trained on discovery set 
samples (n=58) and tested in validation set samples (n=17) left out of the discovery process. (TOP LEFT) 
ROC curve summarizing performance in the validation set (red) and in a negative control set constructed 
by shuffling the dysplasia labels in the validation samples 100 times (black with grey confidence interval 
area). (TOP RIGHT) Heatmap showing 200 biomarker genes (rows) and 17 validation samples (columns). 
Horizontal color bars correspond to dysplasia / normal phenotype: top bar shows biomarker prediction, and 
middle and bottom bars show actual dysplasia grade and status. Vertical color bar corresponds to the 
directionality of genes in 58 discovery samples. (BOTTOM LEFT) Boxplot showing biomarker score 
stratified by dysplasia status. (BOTTOM MIDDLE) Boxplot showing biomarker score stratified by 
dysplasia grade. (BOTTOM RIGHT) Density plot of biomarker scores stratified by dysplasia status.  
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Figure 2.6 Biomarker performance in an overlapping microarray set (n=36). 
To evaluate biomarker’s performance predicting PML presence, the biomarker was trained on discovery set 
samples (n=58) and tested in overlapping microarray validation samples (n=36). (TOP LEFT) ROC curve 
summarizing performance in the validation set. (TOP RIGHT) Heatmap showing 200 biomarker genes 
(rows) and 36 validation samples (columns). Horizontal color bars correspond to dysplasia / normal 
phenotype: top bar shows biomarker prediction, and middle and bottom bars show actual dysplasia grade 
and status. Vertical color bar corresponds to the directionality of genes in 58 discovery samples. 
(BOTTOM LEFT) Boxplot showing biomarker score stratified by dysplasia status. (BOTTOM 
MIDDLE) Boxplot showing biomarker score stratified by dysplasia grade. (BOTTOM RIGHT) Density 
plot of biomarker scores stratified by dysplasia status. 
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Figure 2.7 Biomarker performance in an independent microarray set (n=158). 
To evaluate biomarker’s performance predicting PML presence, the biomarker was trained on discovery set 
samples (n=58) and tested in independent microarray validation samples (n=158). (TOP LEFT) ROC 
curve summarizing performance in the validation set. (TOP RIGHT) Heatmap showing 200 biomarker 
genes (rows) and 158 validation samples (columns). Horizontal color bars correspond to dysplasia / normal 
phenotype: top bar shows biomarker prediction, and middle and bottom bars show actual dysplasia grade 
and status. Vertical color bar corresponds to the directionality of genes in 58 discovery samples. 
(BOTTOM LEFT) Boxplot showing biomarker score stratified by dysplasia status. (BOTTOM 
MIDDLE) Boxplot showing biomarker score stratified by dysplasia grade. (BOTTOM RIGHT) Density 
plot of biomarker scores stratified by dysplasia status.  
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Figure 2.8 Biomarker performance in a longitudinal RNA-Seq dataset (n=51). 
To evaluate biomarker’s performance predicting PML presence, the biomarker was trained on 
discovery set samples (n=58) and tested in longitudinally collected RNA-Seq validation samples 
(n=51). (TOP LEFT) ROC curve summarizing performance in the validation set. (TOP RIGHT) 
Heatmap showing 200 biomarker genes (rows) and 51 validation samples (columns). Horizontal 
color bars correspond to dysplasia / normal phenotype: top bar shows biomarker prediction, and 
middle and bottom bars show actual dysplasia grade and status. Vertical color bar corresponds to 
the directionality of genes in 58 discovery samples. (BOTTOM LEFT) Boxplot showing 
biomarker score stratified by dysplasia status. (BOTTOM MIDDLE) Boxplot showing 
biomarker score stratified by dysplasia grade. (BOTTOM RIGHT) Density plot of biomarker 
scores stratified by dysplasia status. 
  
  
 
64 
 
Figure 2.9 Performance of biomarker score differences predicting progressing and 
stable/regressing PMLs (n=28 pairs). 
To evaluate biomarker’s performance predicting PML progression, biomarker scores were first 
calculated independently for each sample (Figure 2.8). Consecutively collected samples were 
then paired, and the difference between post and pre biomarker scores was calculated. In addition, 
progression and regression were calculated as the difference in dysplasia grade between post and 
pre time points. (LEFT) ROC curve summarizing performance of biomarker score difference 
predicting PML progression. (MIDDLE) Boxplot showing biomarker score differences stratified 
by PML progression. (BOTTOM RIGHT) Density plot of biomarker score differences stratified 
by PML progression. 
 
  
Biomarker performance (n=28 pairs) 
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Figure 2.10 Biomarker performance in a microarray lung cancer set 1 (n=164). 
To evaluate biomarker’s performance predicting lung cancer presence, the biomarker was trained 
on discovery set samples (n=58) and tested in microarray validation samples (n=164). (TOP 
LEFT) ROC curve summarizing performance in the validation set. (TOP RIGHT) Heatmap 
showing 200 biomarker genes (rows) and 164 validation samples (columns). Horizontal color 
bars correspond to cancer / normal phenotype: top bar shows biomarker prediction, and bottom 
bar shows actual lung cancer status. Vertical color bar corresponds to the directionality of genes 
in 58 discovery samples. (BOTTOM LEFT) Boxplot showing biomarker score stratified by 
cancer status. (BOTTOM RIGHT) Density plot of biomarker scores stratified by cancer status. 
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Figure 2.11 Biomarker performance in a microarray lung cancer set 2 (n=299). 
To evaluate biomarker’s performance predicting lung cancer presence, the biomarker was trained 
on discovery set samples (n=58) and tested in microarray validation samples (n=299). (TOP 
LEFT) ROC curve summarizing performance in the validation set. (TOP RIGHT) Heatmap 
showing 200 biomarker genes (rows) and 299 validation samples (columns). Horizontal color 
bars correspond to cancer / normal phenotype: top bar shows biomarker prediction, and bottom 
bar shows actual lung cancer status. Vertical color bar corresponds to the directionality of genes 
in 58 discovery samples. (BOTTOM LEFT) Boxplot showing biomarker score stratified by 
cancer status. (BOTTOM RIGHT) Density plot of biomarker scores stratified by cancer status. 
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Figure 2.12 Biomarker performance in an RNA-Seq lung SCC tumor biopsy dataset 
(n=553). 
To evaluate biomarker’s performance predicting tumor vs. normal samples in subjects with lung 
cancer, the biomarker was trained on discovery set samples (n=58) and tested in RNA-Seq tumor 
and adjacent normal biopsy validation samples (n=553). (TOP LEFT) ROC curve summarizing 
performance in the validation set. (TOP RIGHT) Heatmap showing 200 biomarker genes (rows) 
and 553 validation samples (columns). Horizontal color bars correspond to cancer (tumor) / 
normal phenotype: top bar shows biomarker prediction, and bottom bar shows actual tissue type. 
Vertical color bar corresponds to the directionality of genes in 58 discovery samples. (BOTTOM 
LEFT) Boxplot showing biomarker score stratified by tissue type. (BOTTOM RIGHT) Density 
plot of biomarker scores stratified by tissue type. 
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Table 2.12 Functional enrichment of 200 biomarker genes. 
Functional enrichment analysis conducted using Enrichr. Shown are categories with significant 
(q-value < 0.05) enrichment. 
 
  
database category pval qval
Reactome_2016 Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins._Homo sapiens_R-HSA-163200 1.95E-13 8.94E-11
WikiPathways_2016 Electron Transport Chain_Homo sapiens_WP111 1.51E-12 2.14E-10
KEGG_2016 Huntington's disease_Homo sapiens_hsa05016 8.02E-11 4.02E-09
KEGG_2016 Oxidative phosphorylation_Homo sapiens_hsa00190 5.21E-11 4.02E-09
KEGG_2016 Alzheimer's disease_Homo sapiens_hsa05010 1.12E-10 4.02E-09
KEGG_2016 Parkinson's disease_Homo sapiens_hsa05012 1.26E-10 4.02E-09
GO_Biological_Process_2015 respiratory electron transport chain (GO:0022904) 4.90E-12 5.58E-09
GO_Biological_Process_2015 electron transport chain (GO:0022900) 7.07E-12 5.58E-09
Reactome_2016 The citric acid (TCA) cycle and respiratory electron transport_Homo sapiens_R-HSA-1428517 2.93E-11 6.70E-09
Reactome_2016 Respiratory electron transport_Homo sapiens_R-HSA-611105 1.00E-09 1.53E-07
WikiPathways_2016 Electron Transport Chain_Mus musculus_WP295 2.59E-08 1.83E-06
KEGG_2016 Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 2.94E-07 7.48E-06
Reactome_2016 Gene Expression_Homo sapiens_R-HSA-74160 1.20E-06 0.000137621
WikiPathways_2016 mRNA Processing_Homo sapiens_WP411 4.54E-06 0.000213493
Transcription_Factor_PPIs ESR1 1.48E-06 0.000271659
Transcription_Factor_PPIs PPARGC1A 3.02E-06 0.000276418
GO_Biological_Process_2015 generation of precursor metabolites and energy (GO:0006091) 9.58E-07 0.00050391
WikiPathways_2016 mRNA processing_Mus musculus_WP310 4.04E-05 0.001423104
Transcription_Factor_PPIs POU5F1 3.07E-05 0.001870846
GO_Biological_Process_2015 hydrogen transport (GO:0006818) 6.63E-06 0.002092956
GO_Biological_Process_2015 proton transport (GO:0015992) 5.86E-06 0.002092956
GO_Biological_Process_2015 ribonucleoprotein complex assembly (GO:0022618) 8.96E-06 0.002355194
Transcription_Factor_PPIs ESR2 6.73E-05 0.002464967
Transcription_Factor_PPIs RARA 5.90E-05 0.002464967
KEGG_2016 Cardiac muscle contraction_Homo sapiens_hsa04260 0.000117 0.002482852
GO_Biological_Process_2015 hydrogen ion transmembrane transport (GO:1902600) 1.12E-05 0.00253395
GO_Biological_Process_2015 ribonucleoprotein complex subunit organization (GO:0071826) 1.34E-05 0.002634223
Transcription_Factor_PPIs HDAC8 0.000109 0.003329301
Transcription_Factor_PPIs POU4F1 0.000285 0.007445757
Transcription_Factor_PPIs AR 0.000355 0.008122111
WikiPathways_2016 Oxidative phosphorylation_Homo sapiens_WP623 0.000303 0.008544391
Reactome_2016 Complex I biogenesis_Homo sapiens_R-HSA-6799198 0.000115 0.010571823
Transcription_Factor_PPIs HTT 0.000652 0.013250879
Transcription_Factor_PPIs ILF3 0.000724 0.013250879
Transcription_Factor_PPIs NCOR1 0.000856 0.013263767
Transcription_Factor_PPIs CEBPA 0.00087 0.013263767
Reactome_2016 TP53 Regulates Metabolic Genes_Homo sapiens_R-HSA-5628897 0.000177 0.013498347
Transcription_Factor_PPIs YY1 0.001189 0.016731218
KEGG_2016 Metabolic pathways_Homo sapiens_hsa01100 0.0011 0.019965827
Transcription_Factor_PPIs HDAC2 0.001575 0.020585321
Transcription_Factor_PPIs ATF2 0.002401 0.027221765
Transcription_Factor_PPIs POLR2A 0.002529 0.027221765
Transcription_Factor_PPIs FOXP3 0.002456 0.027221765
Transcription_Factor_PPIs UBTF 0.003019 0.030694945
Reactome_2016 Formation of ATP by chemiosmotic coupling_Homo sapiens_R-HSA-163210 0.000472 0.030911323
Reactome_2016 Transcriptional activation of mitochondrial biogenesis_Homo sapiens_R-HSA-21512010. 0062 0.035512591
Transcription_Factor_PPIs NR4A2 0.004073 0.03922943
Transcription_Factor_PPIs AIRE 0.004468 0.040885473
Transcription_Factor_PPIs SREBF1 0.004708 0.041023352
Transcription_Factor_PPIs CBX3 0.005328 0.042391957
Transcription_Factor_PPIs PDX1 0.005217 0.042391957
BioCarta_2016 Pelp1 Modulation of Estrogen Receptor Activity_Homo sapiens_h_pelp1Pathway 0.000937 0.043108539
Transcription_Factor_PPIs SMARCA4 0.005947 0.043988314
Transcription_Factor_PPIs MYC 0.00625 0.043988314
Transcription_Factor_PPIs SP3 0.006076 0.043988314
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2.3.  Discussion 
 Lung cancer is the leading cause of cancer death in the US, claiming over 160,000 
lives annually. Although CT screening has been shown to be efficacious in detecting 
potentially cancerous lung nodules 109, it is not commonly accessible and its low 
specificity leads to overdiagnosis 32,91which in turn increases patient burden and 
healthcare cost. The low survivability and high mortality among diagnosed patients 
underscores the urgent need for early stage diagnostics in lung cancer. One of the features 
that sometimes accompany lung cancer are bronchial premalignant lesions (PMLs), i.e. 
histological abnormalities often preceding the development of SCC. Although PML 
prevalence is fairly low (in a 1999 study, mild, moderate, severe dysplasia and CIS had a 
prevalence of 44%, 13%, 6%, and 1.6%, respectively 67), their presence in the airway 
indicates an increased risk for developing lung cancer 10,127. Currently, PMLs can be 
detected using autofluorescence bronchoscopy, which similarly to CT, is not commonly 
administered, especially in a preventative context. We hypothesized that the airway field 
of injury developed in cancer-free subjects, can act as a surrogate for the changes 
observed in the early stages of carcinogenesis by mirroring the presence of PMLs in the 
airway. To test this hypothesis, we sought to provide a more specific way to detect and 
monitor PMLs over time, utilizing broadly available and minimally-invasive technology 
such as white light bronchoscopy combined with gene expression profiling, at an easily 
accessible site such as the main stem bronchus. Our findings provide novel insights into 
the earliest molecular events associated with lung carcinogenesis and have the potential 
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to impact lung cancer prevention by providing additional opportunities to evaluate high-
risk smokers at stages of the disease early enough for preventative treatment to be 
effective, including biomarkers for risk stratification and the means to monitor the 
efficacy of chemoprevention agents targeted towards the reduction of PML incidence. 
 In this study, using cytologically normal bronchial airway cells obtained via 
autofluorescence bronchoscopy from lung cancer-free current and former smokers, we 
developed a gene expression-based biomarker capable of distinguishing bronchial 
brushing samples from subjects with and without PMLs. Our biomarker discovery 
pipeline allowed us to test thousands of models, and select a final signature with the 
power to detect as well as monitor PMLs over time. Moreover, we identified biological 
pathways that are dysregulated in the airway field of injury (Table 2.12). Electron transfer 
chain, formation of ATP, oxidative phosphorylation and metabolism were strongly 
enriched among genes up-regulated in the airways of subjects with PMLs. Other up-
regulated pathways included p53 signaling, and mitochondrial biogenesis 78. Among 
upregulated transcription factors, we observed the activating transcription factor 2 (ATF2) 
which is typically overexpressed in NSCLC and is associated with poor prognosis in LC 
by mediating cell proliferation 145. Similarly, another implicated transcription factor, the 
estrogen receptor 1 (ESR1), has been shown to have a prognostic value in NSCLC 
metastasis 7. These results suggest that the PML-associated airway field harbors shared 
alterations observed in individuals with lung cancer, which may be interpreted as some of 
the earliest events in the process of carcinogenesis. 
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 The 200-gene biomarker, measured in the normal-appearing airway epithelium, 
achieved high performance detecting the presence of dysplastic lesions in a small test set 
(AUC=0.92). Its high sensitivity suggests that the test could be used in concert with 
bronchoscopy in cases where lesions cannot be easily visualized due to technological 
limitations. This could potentially enhance the diagnostic power of bronchoscopy and 
warrant aggressive follow-up in lung cancer screening programs for high-risk smokers. 
Additionally, the biomarker might be a fitting candidate for adoption as an intermediate 
endpoint of efficacy in broader clinical settings including intervention trials. While we 
were able to verify that the biomarker is capable of discriminating between samples from 
subjects with and without PMLs in an independent dataset, leveraging the cohort’s 
longitudinal design allowed us to demonstrate an extremely important aspect of this study 
— the biomarker’s capacity to predict progression of the disease.  We found that the 
difference in biomarker scores calculated for pairs of consecutively collected samples, 
was indicative of regressive or progressive/stable disease as defined by disparities in 
recorded histology. This result suggests that the PML-associated field of injury changes 
dynamically over time and that capturing the gene expression longitudinally may allow 
for further stratification of high-risk smokers based on their associate progression risk. 
 To further evaluate the biomarker’s major utility as a tool to identify at-risk 
smokers, we examined the behavior of the biomarker genes in overlapping and 
independent microarray samples. The performance of the biomarker in the overlapping 
samples was high (AUC=0.73) despite the fact that, historically, biomarkers developed 
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using RNA-Seq and tested in microarray datasets have, by design, a higher chance of 
discordance 125. Although the good performance in these samples could be partially 
attributed to the fact that the tested samples originated from a subset of subjects used for 
the development of the biomarker, the biomarker performed not much worse on a subset 
of independent samples (AUC = 0.63). It is important to note however, that the lower 
AUC in independent samples may be driven by the low number of severe dysplasias 
(n=3) with relatively high biomarker scores, which seem to disrupt the overall association 
of lower biomarker scores with increasing grades of dysplasia (Figure 2.7), thus 
suggesting that incorporating additional samples represented more equally by each 
dysplasia grade could help refine the biomarker. Overall, these findings showcase the 
biomarker’s cross-platform applicability, supporting the use of the biomarker in a wider 
range of settings, especially at medical institutions where gene expression profiling by 
microarrays is preferred over RNA-Seq for financial or technical reasons.  
 In addition, we tested the behavior of biomarker genes in the setting of lung 
cancer, both within bronchial brushings and tumor biopsies. In a microarray brushing 
dataset 1, as well as TCGA samples, the biomarker predicted the presence of lung cancer 
exceptionally well (AUC=0.69 in brushings from subjects with and without LC, and 
AUC=0.87 in lung tumor and adjacent normal biopsies). However, we observed a near 
random behavior of the biomarker in microarray brushing dataset 2 (AUC=0.52). It is 
unclear exactly why the biomarker did not perform similarly on the two microarray 
brushing sets, especially since dataset 2 contained almost twice as many samples as 
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dataset 1, which eliminates the issue of inadequate sample size to detect differences. 
However, it is feasible that the different Affymetrix platform used to profile each dataset 
(HG-U133A for dataset 1 and Human Gene ST 1.0 Array for dataset 2) played a role, and 
that data preprocessing steps may have to be tailored for the particular array in the future. 
Another potential explanation may be related to the fact that dysplasia status is unknown 
for the lung cancer datasets, and has the potential to improve the biomarker’s 
performance in cases were high-grade dysplasia correlates with positive cancer status, 
and worsen the performance if there is no association. Interestingly, when cancer 
predictions derived from our biomarker score were compared to those made with an 
existing clinico-genomic biomarker for lung cancer (PERCEPTATM) commercialized 
recently by Veracyte 115we observed subsets of cancer and normal samples that were 
predicted correctly only by our biomarker suggesting a potential improvement of overall 
predictability if the biomarkers are combined that should be explored. Furthermore, we 
observed that a subset of biological pathways enriched among the biomarker genes were 
commonly altered in lung cancer, suggesting a similar mechanism of action possibly 
reflecting the earliest transcriptomic changes in the process of carcinogenesis. 
 There are a number of limitations to our study. While the size of the discovery set 
was sufficiently large to warrant statistical power of our classifier, the validation set 
sample size was relatively small, encouraging the reproduction of our findings in an 
additional, much larger sequencing dataset in the future. However, we provide extensive 
evidence for the high degree of validity of the results by testing the biomarker in 
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additional datasets that differed from the discovery and validation sets by the gene-
expression platform used (i.e., RNA-Seq vs. microarray), the condition of interest (i.e., 
bronchial dysplasia vs. lung cancer), or the tissue sampled (bronchial epithelium vs. SCC 
tumor). In addition, the histological grade assigned to each brushing was defined as the 
worst histology observed in multiple biopsies at the same time point within a patient. As 
such, in theory, it provides a surrogate measure of the overall state of patient’s 
premalignant disease. However, it does not take into consideration several plausible 
scenarios, including anecdotal cases in which two patients with at least one severe 
dysplasia lesion have varied composition of the remaining lesions observed (one could 
have 10 other severe lesions, while the other could have 10 normals). Although 
intuitively these patients’ overall airway health should not be considered to be the same, a 
phenotype of “severe dysplasia” is likely to be applied to both by currently employed 
methods, suggesting that further investigation of the effects of the number and severity of 
PMLs on the airway field of injury should be conducted. Moreover, since the amount of 
time between procedures is not standardized among study participants, defining 
progression to best reflect the actual disease evolution, can prove to be a difficult task. 
The rate at which PMLs change on a histological-grade level (as opposed to condition 
level, i.e. dysplasia vs. normal) over time remains incompletely understood. Thus, it is 
unclear if a period of one month between procedures provides enough time to be able to 
observe a sustained (and real) change in histology; similarly, the merits of defining lesion 
progression based on two time points 24 months apart might be uncertain. Finally, when 
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assessing progression, it is important to be aware of the possibility of observing 
“regression to the mean”. In theory, this statistical phenomenon may explain why an 
extreme case such as severe dysplasia is more likely to regress than remain stable (or 
progress), and concordantly, why a hyperplastic lesion is more likely to progress. In fact, 
we observed a significant dependence between histological grade of the baseline lesion 
and progression in the RPCI data (Pearson’s Chi-squared test p-value=0.028). In practice 
however, the confounding may be due to the fact that performing biopsy on an advanced 
lesion may have a therapeutic effect by removing most of the abnormal tissue in the 
process and encouraging wound repair mechanisms and scar formation, which may 
induce the subsequent (though unsustained) regression of the lesion that may not be 
reflected by the airway field of injury. 
 While we were able to demonstrate the utility of the biomarker as a predictor of 
PML presence in a wide range of datasets, further development and testing in a larger 
cohort is needed to confirm the biomarker’s ability to predict future PML progression. 
Longitudinal studies would provide the information needed to assess the rate at which the 
airway field responds to changes in lesion histology and thus help design future studies as 
well as standardize screening procedures. Moreover, the examination of lesion locations 
within the respiratory tract could yield insights into the relationship between airway field 
gene expression and distance to “reporting” lesions. Additionally, alternative methods for 
classifying brushes based on observed lesion histologies should be explored, as well as 
the influence of PML number and severity on the overall assessment of premalignant 
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disease. Finally, important characteristics of many diagnostic procedures, such as 
negative predictive value (NPV) and positive predictive value (PPV), should be 
optimized to maximize the efficacy of the biomarker in specific clinical applications, 
which could potentially change its overall performance. 
2.4.  Conclusions 
 In summary, this work marks one of the first attempts at leveraging gene 
expression harbored by cytologically-normal bronchial epithelial cells to detect and 
monitor PMLs over time. The high performance of the gene expression-based biomarker 
in discriminating samples from subjects with and without PMLs provides evidence for 
the existence of a PML-specific field of injury. In addition, the shared genomic response 
in the field of injury of subjects with lung cancer and subjects with PMLs who are lung-
cancer free, suggests that biological pathways which become activated in diseased 
subjects (e.g. OXPHOS), may reflect some of the first molecular changes in the process 
of lung carcinogenesis. 
 Despite several challenges, we were able to develop a gene expression-based 
biomarker for the presence of PMLs that suggests great clinical utility. Focusing on lung 
cancer prevention as opposed to detection by characterizing the transcriptomic events that 
take place in premalignancy holds great promise and this study represents an important 
milestone in defining a precision medicine approach to targeting the vulnerable parts in 
the molecular machinery playing an important role in lung carcinogenesis..
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CHAPTER THREE: Identifying miRNA/mRNA Regulatory Interactions Associated 
with Severity of Lung Cancer Premalignant Lesions 
3.1. Background  
 PMLs are preinvasive histological abnormalities in the central airway, that can be 
observed and sampled via autofluorescence bronchoscopy, and reproducibly graded by a 
pathologist 86. Although PMLs constitute the presumed precursors of SCC of the lung, it’s 
been shown that their multiplicity and severity positively correlate with an increased risk 
for developing any subtype of LC 10,55. The natural history of PMLs, which follows a 
step-wise progression model whereby normal cells proceed through pathological stages 
from hyperplasia and squamous metaplasia, to mild, moderate and severe dysplasia, to 
carcinoma in-situ63,74 does not explain if and when a lesion may progress to invasive 
SCC. In fact, PMLs are dynamic and their histology might worsen and improve multiple 
times within a patient 22(Figure 3.1). In this chapter, we hypothesize that monitoring 
changes in transcriptional and regulatory landscapes of PMLs could allow us to pinpoint 
the processes involved in the development of premalignant disease and predict PML 
progression with greater certainty. 
 The Pre-Cancer Genome Atlas (PCGA) is a promising, multi-consortium 
initiative, which aims to conduct comprehensive multi-omic longitudinal profiling of 
PMLs using DNA, mRNA and miRNA sequencing of airway brushes and lesion biopsies 
25. Motivated by the same urgent need to develop alternative premalignancy diagnostics 
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described in Chapter 2, the PCGA is an invaluable source of sequential bronchoscopies, 
providing the opportunity to follow the natural history of the PMLs over time in-vivo and 
capture the possibly earliest molecular events that may contribute to the progression of 
PMLs towards LC. 
 In deciphering the processes underlying the progression of lesions, we considered 
the unprecedented role that miRNAs play in gene expression regulation in the context of 
human disease. miRNAs are short non-coding RNA molecules which target genes for 
degradation, and it is believed that they regulate nearly all animal processes, including 
development and pathological processes 45,93. In cancer, miRNAs can function either as 
tumor suppressors or oncomiRs, and as such have the potential to influence disease 
processes by becoming therapeutic targets 93. In this chapter, we test this theory in the 
context of premalignant disease by examining gene co-expression networks and their 
association with miRNAs and the severity and progression of PMLs. 
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Figure 3.1. Example lung map of biopsy locations and corresponding histology grades 
changing over time. 
A real-life example of a patient with a dynamic PML history. (A LEFT) Spatial lung map 
highlighting premalignant lesion locations biopsied at least once for one subject over time. 
Locations are labeled A-H. (A RIGHT) PML histological grade changes across 5 time points. (B) 
Progression definitions and classification of two example lesions (H and E) at selected time 
points (2 and 4).  
  
Defining progression 
>0 ~ progressing lesion 
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B 
C 
D 
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H 
51 2 3 4 
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D
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H
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Timeline 
B H 2 E 4 
Long term previous (current grade – worst past grade) [LT prev] regressing progressing 
Short term previous (current grade – preceding grade) [ST prev] regressing progressing 
Short term next (following grade – current grade) [ST next] stable regressing 
Long term next (worst future grade – current grade) [LT next] progressing regressing 
Last biopsy (grade at most recent time point – current gr.) [last] progressing regressing 
Normal 
Hyperplasia 
Metaplasia 
Mild D. 
Mod. D. 
Sev. D. 
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3.2. Methods 
3.2.1. Sample Collection and Histological Grading 
 Bronchial lesion biopsies were obtained from current and former smokers 
enrolled in the High-Risk Lung Cancer-Screening Program at Roswell Park Cancer 
Institute (RPCI) (Buffalo, NY) between December 2009 and March 2013. Central 
airways were visualized using autofluorescence bronchoscopy, and abnormally 
fluorescing areas were sampled and subsequently graded by a pathologist using the 
following scoring system: 
Histology Dysplasia grade 
[0, 22) Normal 
[22, 23) Hyperplasia 
[23, 24) Metaplasia 
[24, 25) Mild dysplasia 
[25, 26) Moderate dysplasia 
[26+) Severe dysplasia 
  
3.2.2. RNA and miRNA Library Preparation and Sequencing 
 Total RNA and miRNA was extracted from samples using miRNeasy Mini kit 
(Qiagen) according to manufacturer's instructions.  Sequencing libraries were prepared 
for total RNA samples using Illumina® TruSeq® RNA Sample Preparation Kit v2 and for 
miRNA using NEBNext® Multiplex Small RNA Library Prep Set for Illumina 
(NEBioLabs, Inc.) according to manufacturer’s instructions for each kit. Briefly, the total 
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RNA was ligated with sequencing adapters, reverse-transcribed, and PCR-amplified to 
create an individual cDNA library per sample. The libraries were pooled in groups of 6-
10 and then PAGE gel-purified to select the adapter-ligated constructs derived from the 
22-nt and 30-nt small RNA fragments. The size-selected library pools were then finally 
sequenced in the corresponding lanes of a Single Flow Cell on the Illumina® HiSeq 2500 
to generate more than 10 million single-read 36-bp reads per sample.  
3.2.3. Data Generation, Summarization and Quality Control  
 De-multiplexing and generation of FASTQ files was performed using Illumina® 
CASAVA. mRNA-Seq reads were aligned to the human genome (hg19) using STAR 34 
with default parameters. Alignment and quality metrics were calculated using RSeQC 
v2.3.3 140. Gene expression levels were summarized using RSEM 72. R software for 
statistical computing v3.1.1 (http://www.r-project.org) was used to conduct all further 
analyses.  miRNA-Seq reads longer than 15nt were aligned to the hg19 using Bowtie 
v0.12.7 69. miRNA expression levels were quantified using Bedtools v2.9.0 as the number 
of reads aligning to mature microRNA catalogued in miRBase v18 42 as previously 
described in 26  
Sample and Gene Filtering  
 mRNA and miRNA-Seq data were inspected for the presence of duplicates. 
Duplicates of two miRNAs with identical expression pattern and ID, but slightly different 
starting and ending chromosomal positions, were removed from further analysis. Samples 
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were first filtered based on the availability of mRNA and miRNA sequencing, and only 
samples sequenced using both protocols were included. mRNA samples were then 
quality-assessed based on the Transcript Integrity Number (TIN) metric, which measures 
the degree of in vitro RNA degradation 139. Samples with TIN values beyond 2 standard 
deviations from the mean TIN value were tagged as potential outliers. Surrogate Variable 
Analysis was conducted to identify latent sources of variability among miRNA samples 
using the sva R package. We found that the SV with the strongest contribution was highly 
correlated with batch. Raw counts were normalized to counts per million (CPM) and 
log2-transformed using cpm function in edgeR package v3.8.6. Genes unlikely to carry 
information about traits under investigation due to their very low expression (rowSums 
[the sum of log2cpm across all samples] < 0) or variability across samples (IQR [Inter-
Quartile Range] <= 0) were removed. Library sizes for the QC-filtered raw counts were 
calculated using the calcNormFactors function in edgeR with the TMM (weighted 
trimmed mean of M-values) 102 method. Library size-adjusted counts per million (CPM) 
were log2-transformed.  The mean-variance trend of the log2CPM values was then 
modeled on the observation level using the voom function in limma v3.22.7, taking into 
account the experimental design including batch and TIN covariates. Principal 
Component Analysis (PCA) 92 was then conducted on filtered normalized counts, and 
samples for which either PC1 or PC2 value exceeded 2 standard deviations from the 
mean of the respective PC were identified as additional potential outliers. Moreover, 
sample quality was evaluated by clustering samples based on pairwise Pearson’s, and any 
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samples not clustering with the rest were tagged as potential outliers. Samples identified 
as an outlier by at least two of the evaluated QC measures (TIN, PC1, PC2, and 
correlation), were removed from downstream analyses. After filtering, raw counts were 
voom-transformed once again as described above. 
3.2.4. Defining Lesion Progression 
 Lesion progression is typically defined by comparing histology grades assigned to 
a lesion sampled at two time points. However, the decision regarding which procedure 
will be considered the baseline and which the follow-up can depend on several factors, 
including the potential of the PML to “store” information about the past or the future, and 
the time difference between considered procedures. Taking this into account, we evaluate 
multiple definitions of progression (Figure 3.1): 
LT prev - Long Term Previous-based definition of progression - the histology of the 
lesion under evaluation is compared to the worst histology observed at the same location 
in the past: 
 
ST  prev - Short Term Previous - the histology of the lesion under evaluation is compared 
to the histology of the lesion observed at an immediately preceding time point: 
 
ST next - Short Term Next - the histology of the lesion under evaluation is compared to 
the histology of the lesion observed at an immediately following time point: 
∆ℎ#$% = ℎ#$%'( − max'-'( ℎ#$%' 	
∆ℎ#$% = ℎ#$%'( − ℎ#$%'*+ 	
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LT next - Long Term Next - the histology of the lesion under evaluation is compared to 
the worst histology observed at the same location in the future: 
 
Last - the histology of the lesion under evaluation is compared to the last histology 
observed at the same location: 
 
Lesions with a negative histology change were considered regressing, while those for 
which the change in histology was non-negative were considered stable/progressing. 
3.2.5. miRCAT – miRNA Combined Association with Traits 
 To identify miRNAs and genes associated with traits of interest, we developed 
miRCAT - miRNA Combined Association with Traits pipeline detailed in following 
sections. Briefly, miRCAT facilitates the discovery of implicated miRNAs in two ways 
simultaneously: (1) directly, using linear modeling, and (2) indirectly, by leveraging gene 
expression (Figure 3.2). Three entities participate in the process: miRNAs and their 
corresponding expression patterns, gene modules (groups of coexpressed genes 
summarized by the 1st principal component), and traits including histological lesion grade 
and the five definitions of lesion progression mentioned above, as well as control traits, 
such as subtype (molecular subclass derived de novo by Dr. Jennifer Beane) and smoking 
status. In the direct step (3.2.11), miRNAs are associated with traits using a linear mixed 
∆ℎ#$% = ℎ#$%'() − 	ℎ#$%', 	
∆ℎ#$% = max*+*, ℎ#$%* − 	ℎ#$%*, 	
∆ℎ#$% = ℎ#$%'()* − 	ℎ#$%'- 	
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effects model, and all miRNAs with a significant FDR are retained for further analysis. In 
the indirect step, miRNAs are first associated with gene modules that contain a 
significant number of their predicted targets (3.2.10), after which these modules are 
associated with traits through a linear mixed effects model (3.2.7). Since the function of 
miRNAs is often determined by the characteristics of genes they target, the direct and 
indirect steps together allow us to identify not only miRNAs associated with a particular 
trait, but miRNAs whose predicted targets are also associated and behave like targets. 
Figure 3.2 miRNA Combined Association with Traits (miRCAT) 
Schematic outlining the steps in miRCAT analysis. miRNAs are associated with traits first 
directly by a linear mixed effects model and then indirectly by trait-association of gene modules 
containing their targets.  
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3.2.6. Constructing Gene Coexpression Network 
 Voom-transformed mRNA reads and the corresponding weights were used to 
calculate residuals of a linear mixed-effects model using lmer function in lme4 v1.1-8 13 
correcting for fixed quality-related effects such as batch and TIN, and a random patient 
effect. The Restricted Maximum Likelihood Estimation (REML) feature of the lmer 
function was turned off in favor of the log-likelihood estimation method.  The residuals 
were then used as input for WGCNA 147.  
 WGCNA is a systems biology approach which facilitates the identification of 
subsets of genes that are highly similar to each other. Genes are clustered into disjoint 
modules based on their expression profile correlation. Module membership and gene 
connectivity within and between modules can be analyzed to discover novel biological 
functions, pathways, master regulators or uncovered sources of heterogeneity within 
samples. Specifically, within the WCGNA framework, a network is defined as a set of 
nodes (genes) connected by links reflecting the significance of similarity between any 
pair of gene expression profiles, and genes particularly strongly coexpressed are clustered 
into disjoint modules. Briefly, an n x m matrix of n genes and m samples is taken as 
input. First, a simmetrical n x n similarity matrix is filled with values between 0 and 1 
corresponding to the absolute values of the Pearson’s correlation coefficients calculated 
between every pair of gene expression profiles: 
The similarity matrix is then transformed into an adjacency matrix. Typically, in an 
	"#$ = &'((*+,+#, *+,+$)  
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unweighted network, a threshold is chosen to dichotomize true edges (cor > threshold) 
and no edges (cor < threshold). In a weighted network however, the measure describing 
adjacency is continuous, and is obtained by raising the similarity matrix to a soft-
thresholding power beta (estimated using the pickSoftThreshold function in the WGCNA 
v1.46 package), exaggerating the gene-gene relationships (weak relationships become 
weaker and strong become stronger). The beta parameter, or soft threshold, is chosen in a 
way that ensures the network’s scale-free topology (few hubs, many sparsely connected 
genes). Next, a Topological Overlap Matrix (TOM) is calculated based on adjacency 
values, which defines the degree of interconnectedness between any pair of genes (two 
genes are most strongly interconnected if they are each other’s neighbors and if they 
share all of their other neighbors) 144. Finally, using average linkage hierarchical clustering 
algorithm, genes are assigned to disjoint clusters (modules). To make module 
identification and referencing easier, WGCNA assigns unique colors to all modules. 
Customarily, genes insufficiently co-expressed with any other gene (cor <threshold) are 
assigned to the grey module. 
 To ensure the reproducibility of module assignment among genes, WGCNA was 
additionally ran 50 times in cross validation on randomly chosen 80% of samples using 
the same beta value and seed = 20170217 + iteration number. The matchLabels 
function in WGCNA was used to standardize module color labeling among the reference 
and all cross-validation runs. Briefly, overlaps between the reference modules and each of 
the cross-validation assignments were assessed using Fisher’s Exact Test, after which 
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each cross-validation module was labeled with the color of the reference module with 
which it overlapped most significantly. A consensus network was generated by assigning 
each gene to its most frequently assigned in cross-validation module. The conservation of 
modules in the reference network was assessed by module overlaps with the consensus 
network and any module with FET p-value < 0.05 was considered conserved. It is 
important to note that the consensus network was used solely to establish preservation of 
modules in the reference network, and only the unmodified reference network was used 
in further analysis.  
3.2.7. Identifying Genes Associated with PML Grade and Progression 
 Module-specific gene expression was summarized by the 1st principal components 
(referred to as module eigengene or ME hereafter) calculated using the expression 
profiles of module gene members’. MEs facilitate the quantification of co-relationships 
between modules and clinical variables, as well as assessment of essentiality of each gene 
as a module member. Due to high correlation of genes within any given module, the ME-
based summarization allows to draw accurate conclusions about the association between 
traits of interest and individual genes.  
 A linear mixed-effects model was used to assess the association between MEs and 
traits of interest. Since each module was summarized based on the quality-adjusted 
residual expression of its members, the fit was adjusted for random patient effect only: 
 !"##	%&'(#:	*+	~	-./0-	 + 	1|4/-0(5-	
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Module-trait pairs were retained for further analysis, if the FDR-corrected ANOVA p-
value between full and null models did not exceed the threshold of 0.05. 
3.2.8. Defining miRNA Gene Targets 
 Prior biological knowledge about computationally and experimentally validated 
miRNA targets was leveraged in this step of the miRCAT algorithm. The publicly 
available online miRGate database5 (http://mirgate.bioinfo.cnio.es/miRGate/) was queried 
using an Application Program Interface (API). The compiled matrix included a row for 
each miRNA-gene interaction with the corresponding statistical information about the 
strength of prediction depending on algorithm used (Pictar, miRBase, miRanda, 
RNAhybrid, TargetScan). For each miRNA, a target set (a list of predicted targets) was 
then compiled, which included genes identified by at least one of the prediction 
algorithms. 
3.2.9. Defining miRNA “Gene Neighbors” 
 For each miRNA, a gene “neighborhood” was defined as well. Pairwise 
Spearman’s correlation coefficients were calculated for every miRNA-gene pair and 
corrected for multiple comparisons using the Bonferroni method. Genes significantly 
anti-correlated with a miRNA (rho < 0, adj.p < 0.05) were included in its 
“neighborhood”. 
!"##	%&'(#:	*+	~	1|/012(31	
 
  
 
90 
3.2.10. Identifying miRNA Associated with Gene Modules 
An association between miRNA and gene modules was established by assessing 
module member overlaps with target sets (3.2.8) and “neighborhoods” (3.2.9). Fisher’s 
Exact Test (FET) was used to quantify the significance of the overlaps, and miRNA-
module pairs with FDR<0.05 for both tests were retained for further analysis. 
3.2.11. Identifying miRNA Associated with PML Grade and Progression 
 Similar to how association between modules and traits of interest was established 
in (3.2.7), the “direct” association between miRNAs and traits was evaluated by a linear 
mixed effects model, correcting for random patient effect only. 
 
miRNA-trait pairs were retained for further analysis, if the FDR-corrected ANOVA p-
value between the full and null models did not exceed the threshold of 0.05. 
 The “indirect” association between miRNAs and traits of interest was evaluated 
by jointly considering the previously established relationships between miRNAs and gene 
modules (3.2.10), as well as between gene modules and traits (3.2.7). miRNAs were 
associated with traits of interest “indirectly” if the miRNA and trait were significantly 
associated with the same module (Figure 3.3). 
 We focused on miRNAs that associate with certain traits both directly and 
indirectly, in other words “universally”. 
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3.2.12. Functional Enrichment 
 The biology of “universally” associated miRNAs was evaluated by a literature 
search using miRBase database. The functional annotation of the mediating module gene 
members was conducted using Enrichr 28 and GeneOntology (GO) via 
GOenrichmentAnalysis function in WGCNA R package. 
3.3. Results 
3.3.1. Demographic and Clinical Characteristics of Sample Population 
 A total of 161 premalignant lesions from 27 current and former smokers were 
biopsied using autofluorescence bronchoscopy at the RPCI. Each subject underwent the 
procedure between 1 and 7 times (2.7 times on average) and had between 1 and 17 
lesions biopsied (6 lesions on average) across all visits. Subjects were on average 59 
years old with about 50 pack years, predominantly Caucasian, and equally likely to be 
female or male. There were no significant differences in these characteristics between 
normal and dysplastic samples. However, while samples from current smokers were 
equally distributed between the two groups, there were significantly more samples from 
former smokers among normal samples (p=0.001) (we did not observe a significant 
difference in smoking status on a subject level) (Table 3.1). 
3.3.2. Gene, miRNA and Sample filtering 
 57,773 genes and 2,794 miRNAs were included on the sequencing platform. 
Mixed miRNA IDs of the form MI#_MIMAT# were split into the corresponding Stem-
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Loop Sequence ID (MI#) and the Mature miRNA Accession ID (MIMAT#). Among the 
miRNAs, two (MI0003127_MIMAT0002808 and MI0003127_MIMAT0026606) had 
duplicates which were subsequently removed. The remaining 2,792 miRNA Accession 
IDs, mapped to 2,576 miRNA IDs catalogued in miRBase v20. 
 A total of 288 RNA and 258 miRNA samples were extracted from lesion biopsies 
and bronchial brushes. Of those, 251matched mRNA-miRNA samples were retained, and 
subset to 163 biopsies. After filtering out probes with low or non-variable expression, 
16,710 genes and 642 miRNAs remained. Samples were then further filtered based on 4 
quality measures: TIN, PC1, PC2 and expression correlation. TIN was calculated for 
mRNA samples (meanTIN=77.92, sdTIN=2.34), and 6 samples were tagged as potential 
outliers. PC1 and PC2 were calculated for mRNA samples (meanPC1~0, sdPC1=57.5, 
meanPC2~0, sdPC2=52.6 ) and miRNA samples (meanPC1~0, sdPC1=11.5, meanPC2~0, 
sdPC2=9.4 ), and 28 samples were tagged as outliers by at least one of the PCs regardless 
of molecule. No samples were outliers on a dendrogram by expression correlation. 
Overall, only 2 samples were considered outliers by at least 2 methods and subsequently 
discarded, leaving 161 samples used in all further analyses (Table 3.1). Finally, the new 
expression subset was subject to final gene and miRNA variance filtering, which resulted 
in 16,733 genes and 643 miRNA (580 unique miRBase IDs) considered throughout the 
following sections. 
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3.3.3. Genes Associated with PML Grade and Progression 
 Quality-adjusted residuals of gene expression were clustered using WGCNA, and 
14 disjoint modules were identified (excluding the grey module, which included 4 genes 
and will be excluded from further summaries). Median module size was 906, with the 
smallest module containing 82 genes and the largest 3690 genes (Table 3.3). Gene 
expression within modules was collapsed and summarized by the module eigengene 
(ME), i.e. the first principal component of the module members’ gene expression profiles. 
The top panel of 
Figure 3.4 shows a dendrogram showcasing the relationship between MEs, suggesting 
that some modules (e.g. pink and grey60), and thus the genes they contain, are more 
similar to each other than to members of other modules. In addition, an annotated 
heatmap in the bottom panel of the figure shows the strengths of correlations between 
module MEs. 
 One-way ANOVA was conducted to identify gene modules significantly 
associated with traits of interest, including histological grade, histological subtype, and 
multiple definitions of progression, as well as smoking status (control) by comparing a 
full linear mixed effects model (ME ~ trait + 1|patient) to the null model (ME ~ 
1|patient). Because modules were derived using expression residuals corrected for batch 
and TIN, only the patient random effect was added to the models. Ten modules were 
associated with at least one trait (FDR<0.05), and all traits except progression definitions 
based on the past (LT prev, ST prev) and last time points were represented by at least one 
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module, for a total of 25 unique module-trait pairs. Histological grade was associated 
with the black, brown, cyan, darkturquoise, greenyellow and magenta modules. Future-
based short term (ST next) progression was associated with the grey60, pink, and red 
modules. Future-based long term (LT next) progression was associated with the grey60 
and pink modules (Table 3.4). 
 Reproducibility of the gene modules was tested by running WGCNA 50 times in 
cross-validation, using randomly chosen 80% of samples each time, and combining 
resulting gene clusterings into one consensus module assignment. Gene membership was 
compared between the original and consensus module assignments by calculating 
overlaps using FET. All 14 modules achieved a significant overlap, and thus were 
considered conserved (Figure 3.5).  
3.3.4. miRNAs Associated with PML Grade and Progression 
First, one-way ANOVA was conducted to identify miRNA “directly” associated 
with traits by comparing a full linear mixed effects model (miRNA ~ trait + batch + 
1|patient) to the null model (miRNA ~ batch + 1|patient). 47 miRNAs were associated 
“directly” with at least one trait of interest (127 including control traits) (FDR < 0.05), 
and grade, LT next progression, subtype, and smoking were represented by at least one 
module, for a total of 52 unique miRNA-trait pairs (219 including control traits) (Table 
3.5). 
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 Next, to assess the “indirect” associations with trait, miRNAs were first assigned 
to gene modules. The miRGate database was used to identify computationally predicted 
miRNA targets. On average, the 580 queried miRBase IDs had 1,440 targets (sd=932) 
among the 16,733 queried genes. In parallel, for every miRNA, a gene neighborhood was 
defined as a set of genes significantly anticorrelated with a given miRNA (Spearman’s 
correlation; Bonferroni adjusted p-value < 0.05). On average, miRNAs had 212 neighbors 
(sd=286). For every module - miRNA pair, Fisher’s Exact Test (FET) was performed to 
assess the overlap between the module and the miRNA’s target set and its neighborhood. 
481 unique miRNAs were associated with at least one module via targets only (FET FDR 
< 0.05). 422 miRNAs were associated with at least one module via neighbors only (FET 
FDR < 0.05). 164 miRNAs were associated with at least one module via targets and 
neighbors, and thus retained for further analysis (Table 3.6). Finally, gene modules were 
associated with traits via ANOVA. The results had already been discussed in 3.3.3 above 
(Table 3.5).  
 There were 31 miRNAs associated “universally” (“directly” via LME and 
“indirectly” by leveraging gene expression) with traits of interest (111 including control 
traits) (Table 3.5, Figure 3.6). Eight unique modules were involved as association 
mediators. Modules darkturquoise, brown, magenta and black were frequent mediators of 
miRNA association with grade, although only darkturquoise did not associate with any 
other trait (Table 3.7), while the remaining three modules shared their association with 
subtype (Table 3.10). The grey60 and pink modules tended to mediate association with 
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future-based short-term (LT next) progression (Table 3.8). The same two modules, in 
addition to blue and red, were also shared mediators for smoking and subtype (Table 3.9, 
Table 3.10). 
 We also observed that the universal miRNAs clustered into 4 distinct groups 
(Figure 3.6). Clusters 1 and 4 contained miRNAs associated with grade, and were down- 
and up-regulated in high-grade dysplasia, respectively. Cluster 2 contained miRNAs 
upregulated in progressing lesions and low-grade subtypes. Cluster 3 contained miRNAs 
upregulated in high-grade dysplasia as well as subtype. Surprisingly however, despite the 
substantial level of redundancy among the miRNA expression profiles within each 
cluster, we did not observe a significant overlap among the targets of miRNAs that 
belong to one cluster (Figure 3.11). 
3.3.5. Biological Enrichment and Pathway Analysis 
 Biological enrichment analysis was conducted using the web-based functional 
annotation tool Enrichr 28 and GeneOntology (GO) (Table 3.11). Module darkturquoise, 
which only mediated associations with grade, was enriched in genes implicated in cell 
cycle processes, regulation of TP53 activity, epithelial cell differentiation, and Hippo 
signaling pathway. Genes belonging to the progression-associated grey60 and pink 
modules were involved in cell differentiation and development. Module lightgreen was 
dominated by genes altered as part of immune response pathways, however it did not 
significantly associate with any traits (lowest observed FDR=0.49). 
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 Among cluster 1 miRNAs downregulated in high-grade dysplasia, miRNAs 34b 
and 34c were found to be strongly associated with module darkturquoise which was 
primarily cell death and apoptosis related. These miRNAs have previously been found to 
be relevant in these processes in the context of many cancers 85, 49, as they are directly 
targeted by TP53 – a transcription factor encoded by the tumor suppressor gene p53, 
which upon DNA damage or stress response may induce cell cycle arrest. Recently, a 
study showed that overexpression of miR-34b increases cell sensitivity to radiation in 
NSCLC A549 cell line 9. Another cluster 1 member, miRNA-4423 has been shown to be 
downregulated in bronchial epithelium of smokers with lung cancer as a primate-specific 
regulator of epithelial cell differentiation 94. In another study, scientists discovered that 
low expression of miR-92b is indicative of resistance to cisplatin, a common form of 
chemotherapy often administered in lung cancer 148, which could be the result of targeting 
genes responsible for DNA repair. Cluster 4 included miRNAs upregulated in high-grade 
dysplasia. For example, miR-944, whose association was mediated by the ciliogenesis-
related magenta module, is an oncomiR. Up-regulated in NSCLC and a target of ΔNp63, 
it up-regulates p53 expression and is involved in induction of epidermal differentiation 64. 
Recently, a study has demonstrated its potential as an early lung cancer biomarker 98. 
 Cluster 2 associated with progression and subtype, contained miRNAs mediated 
by the grey60, pink and blue modules. These modules contained genes implicated in 
MAPK pathway (responsible for cell differentiation and proliferation in Ras-mutated 
lung cancer), Wnt signaling (related to processes promoting tumor progression 97), 
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epithelial cell proliferation, and lung development. Among cluster 2 miRNAs, miR-423 
was especially interesting because of existing evidence for its capacity to promote tumor 
progression43. In addition, let-7, a well known tumor suppressor, which is frequently lost 
in NSCLC, has been shown to reverse tumor progression in mice 131.  
 Finally, cluster 3 was represented by miRNAs upregulated in high-grade dysplasia 
and subtype, as well as the magenta and brown modules also mediating associations 
among cluster 2 genes. A member of cluster 3, miR-136 was shown to exhibit antiviral 
behavior against Influenza exposed to A549 human lung epithelial cell line 149 and was 
routinely overexpressed in lung cancer, suggesting a role in inhibition of tumor 
suppressors. In breast cancer, miR-655 was shown to halt the cell transition from 
epithelial to mesenchymal phenotype, typical of metastatis. 
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Table 3.1 Demographic characteristics of the RNA-Seq PML biopsy dataset stratified by 
dysplasia status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. Top table 
summarizes data by samples, and bottom table summarizes data by subjects. P-values are for the 
comparison between the Dysplasia and Normal groups, using two sample t-tests for continuous 
variables or Fisher’s exact test for categorical variables. 
 
 
 
  
Factor Overall Dysplasia Normal p-value
No. Samples 161 66 95
Age 57.50 (6.22) 57.66 (6.62) 57.4 (5.97) 0.783
Sex 0.87
female 101 42 59
male 60 24 36
Race 1
Caucasian 156 64 92
Other 5 2 3
Lung Cancer 0 0 0
Smoking 0.001
current 86 45 41
former 73 19 54
NA 2 2 0
Pack Years 48.91 (19.5) 50.14 (16.56) 48.06 (21.36) 0.509
Histological grade < 0.001
Normal 29 29
Hyperplasia 26 26
Metaplasia 40 40
Mild Dysplasia 19 19 	
Moderate Dysplasia 35 35
Severe Dysplasia 12 12
Factor Overall
No. Subjects 27
No. of procedures (mean [range]) 2.7 (1-7 visits)
No. of lesions biopsied in total (mean [range]) 6 (1-17 lesions)
Days between visits (mean [range]) 350 (98-742 days)
Age 59.21 (7.73)
Sex
female 14
male 13
Race
Caucasian 25
African American 2
Lung Cancer 0
Smoking
current 11
former 16
Pack Years 50.44 (22.9)
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Table 3.2 Sample quality control results. 
Samples were quality-evaluated based on transcript integrity number (TIN), the 1st and 2nd 
principal components (PC1 and PC2) and correlation with other samples (cor). Samples were 
excluded if they were considered outliers by at least two quality metrics. 
 
 
Sample ID TIN PC1 PC2 cor excluded
PCGA-01-0001-070-19300-00587BX TRUE FALSE FALSE FALSE FALSE
PCGA-01-0001-074-19762-00901BX TRUE TRUE FALSE FALSE TRUE
PCGA-01-0001-077-19762-00899BX TRUE TRUE FALSE FALSE TRUE
PCGA-01-0007-050-18131-00528BX TRUE FALSE FALSE FALSE FALSE
PCGA-01-0014-089-20660-00744BX TRUE FALSE FALSE FALSE FALSE
PCGA-01-0021-010-19826-00723BX TRUE FALSE FALSE FALSE FALSE
PCGA-01-0001-037-20126-01120BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0002-050-23843-00279BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0002-050-24062-00443BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0004-050-27317-00606BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0007-050-18033-00456BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0008-050-22263-01196BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0023-010-21429-00830BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0031-050-24285-00856BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0008-050-21682-00841BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0015-011-17638-01327BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0023-048-21429-00829BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0026-089-22473-00859BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0031-021-24726-01062BX FALSE TRUE FALSE FALSE FALSE
PCGA-01-0001-074-20126-01116BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0001-074-20343-01315BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0022-089-21996-01170BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0031-050-24061-00666BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0001-050-19762-00903BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0005-050-17489-00728BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0021-050-20449-01092BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0021-070-20449-01089BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0022-093-21996-01171BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0025-074-21689-01105BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0025-094-21689-01107BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0029-048-22678-00815BX FALSE FALSE TRUE FALSE FALSE
PCGA-01-0029-093-22678-00813BX FALSE FALSE TRUE FALSE FALSE
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Figure 3.3 Conceptual representation of miRCAT results.  
The blue bar on top represents an indirect association with traits. The colorful bar underneath it 
represent the WGCNA modules. The red bar on the bottom represents direct association with 
traits. The table visualizes direct (red), indirect (blue) and universal (purple) associations between 
miRNAs (columns) and traits (rows), Lines connecting traits to modules, modules to miRNAs 
and miRNAs to traits represent significant associations. miRNAs are considered to be associated 
universally if they associate both directly and indirectly. miRNA names and module colors are 
arbitrarily chosen to aid in visualization of the concept, and do not correspond to results.  
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Figure 3.4 Summarized module eigengene relationships.  
(TOP) Module eigenegene (ME) dendrogram. ME distances quantified with Spearman’s 
correlation. (BOTTOM) A heatmap showing the absolute value of correlation between MEs. 
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Figure 3.5 Consensus WGCNA. 
To evaluate robustness of biopsy-derived mRNA coexpression modules (Original), WGCNA was 
run 50 times on randomly selected 80% of the samples (p1, p2, …, p50). In each iteration, 
resulting modules were compared to the original assignment and recolored to reflect strongest 
overlap with one original module. Consensus modules were generated by assigning each gene to 
the module most frequently assigned in the 50 iterations.  
 
Table 3.3 WGCNA gene coexpression module sizes 
 
 
  
magentadarkturquoise blue brown red grey60 lightgreen black
3691 2550 2471 1287 993 970 932 880
pink purple greenyellow cyan royalblue darkred grey
832 680 679 579 103 82 4
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Table 3.4 Gene modules significantly associated with traits. 
Modules associated with at least one trait of interest and the corresponding significance levels. 
All listed associations are significant (ANOVA FDR<0.05). The black, brown, cyan, 
darkturquoise, greenyellow and magenta modules were associated with grade. The grey60 and 
pink modules were associated with future-based progression. Additionally, the red module 
specifically associated with short-term future-based progression. 
 
  
module trait value.p value.fdr
black grade 1.20E-03 6.01E-03
black subtype 2.59E-06 7.76E-06
blue smoking 3.49E-03 1.05E-02
blue subtype 6.67E-03 1.25E-02
brown grade 1.95E-03 7.30E-03
brown subtype 9.07E-07 3.40E-06
cyan grade 8.81E-03 2.20E-02
cyan smoking 8.63E-04 3.24E-03
cyan subtype 7.60E-04 1.63E-03
darkturquoise grade 1.17E-05 8.79E-05
greenyellow grade 5.75E-03 1.73E-02
greenyellow smoking 7.99E-03 2.00E-02
grey60 ST next 7.87E-03 4.46E-02
grey60 LT next 5.14E-04 7.71E-03
grey60 smoking 3.68E-04 2.28E-03
grey60 subtype 4.94E-16 3.70E-15
magenta grade 1.47E-06 2.21E-05
magenta subtype 7.32E-04 1.63E-03
pink ST next 4.66E-03 4.46E-02
pink LT next 3.74E-03 2.80E-02
pink smoking 4.56E-04 2.28E-03
pink subtype 5.70E-18 8.54E-17
red ST next 8.93E-03 4.46E-02
red smoking 2.61E-04 2.28E-03
red subtype 2.54E-09 1.27E-08
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Figure 3.6 Expression of miRNAs universally associated with grade or progression 
The unsupervised heatmap clusters miRNAs using Ward.D2 clustering into four groups: clusters 
1 and 4 which tend to associate with grade, cluster 2 which associates with progression and 
subtype, and cluster 3 which associates with grade and subtype. 
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Figure 3.7 Grade-associated miRNAs from cluster 1 
Cluster 1 containing 9 miRNAs with an association with grade mediated by the black and 
darkturquoise modules. 
 
Figure 3.8 Progression and subtype-associated miRNAs from cluster 2 
Cluster 2 containing 8 miRNAs with an association with progression and subtype mediated by the 
blue, pink and grey60 modules.  
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Figure 3.9 Grade and subtype-associated miRNAs from cluster 3 
Cluster 3 containing 7 miRNAs with an association with grade and subtype mediated by the 
magent and brown modules.  
 
Figure 3.10 Grade-associated miRNAs from cluster 4 
Cluster 4 containing 7 miRNAs with an association with grade mediated by the black, magenta 
and brown modules.  
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Figure 3.11 Target overlaps in clusters containing coexpressed miRNAs. 
Despite high coexpression of miRNAs within these clusters, the miRNAs did not share a 
significant number of their targets. Color bar corresponds to significance level of Fisher’s Exact 
Test. 
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Table 3.5 Summary of miRNAs significantly associated with traits of interest.  
Number of miRNAs that significantly associate with traits of interest via one-way ANOVA 
correcting for batch and random patient effect (FDR<0.05). The universal group includes 
miRNAs associated with a given trait both directly (via ANOVA) or indirectly (via association 
with gene modules).  
 
 
 
 
 
 
 
 
Table 3.6 Summary of miRNAs associated with gene modules via target sets and 
“neighborhoods”. 
Number of miRNAs whose target sets and “neighbors” significantly overlap with modules 
(Fisher’s Exact Test Bonferroni-adjusted p-value < 0.05) 
 
  
LT prev ST prev ST next LT next last
direct miRNA 36 0 0 0 16 0 109 58
indirect miRNA 81 0 0 47 45 0 130 87
universal miRNA 24 0 0 0 8 0 97 34
trait grade
progression
subtype smoking
magenta darkturquoise lightgreen grey60 purple red greenyellow
targets 245 299 81 100 22 65 173
neighbors 113 36 89 113 20 58 27
both 42 20 17 25 0 2 2
blue brown black cyan pink royalblue darkred
targets 263 191 85 0 125 0 0
neighbors 112 65 85 22 107 2 0
both 48 17 10 0 26 0 0
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Table 3.7 miRNAs and the mediating modules universally associated with grade. 
 
 
 
 
 
Table 3.8 miRNAs and the mediating modules universally associated with progression. 
LT next is long-term next progression. Some miRNAs are listed multiple times due to the fact that 
their association with progression was mediated by multiple modules. 
 
  
miRbaseID trait module miRbaseID trait module
hsa-let-7c-5p grade darkturquoise hsa-miR-411-3p grade magenta
hsa-miR-1180-3p grade darkturquoise hsa-miR-4423-5p grade darkturquoise
hsa-miR-1295a grade darkturquoise hsa-miR-452-3p grade magenta
hsa-miR-136-5p grade brown hsa-miR-500a-5p grade magenta
hsa-miR-136-5p grade magenta hsa-miR-500a-5p grade black
hsa-miR-2110 grade darkturquoise hsa-miR-642a-5p grade darkturquoise
hsa-miR-339-5p grade brown hsa-miR-655-3p grade magenta
hsa-miR-34b-5p grade darkturquoise hsa-miR-656-3p grade magenta
hsa-miR-34b-5p grade black hsa-miR-708-5p grade magenta
hsa-miR-34c-5p grade darkturquoise hsa-miR-7974 grade brown
hsa-miR-362-5p grade magenta hsa-miR-7974 grade magenta
hsa-miR-374b-3p grade magenta hsa-miR-92b-3p grade black
hsa-miR-376c-3p grade magenta hsa-miR-92b-5p grade darkturquoise
hsa-miR-379-3p grade magenta hsa-miR-944 grade magenta
miRbaseID trait module
hsa-miR-1275 LT next grey60
hsa-miR-1301-3p LT next pink
hsa-miR-1301-3p LT next grey60
hsa-miR-2110 LT next grey60
hsa-miR-2110 LT next pink
hsa-miR-23a-5p LT next grey60
hsa-miR-23b-5p LT next pink
hsa-miR-423-5p LT next grey60
hsa-miR-423-5p LT next pink
hsa-miR-744-5p LT next grey60
hsa-miR-760 LT next grey60
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Table 3.9 miRNAs and mediating modules universally associated with smoking  
Some miRNAs are listed multiple times due to the fact that their association with smoking was 
mediated by multiple modules. 
 
 
 
  
miRbaseID trait module miRbaseID trait module
hsa-let-7c-5p smoking blue hsa-miR-3065-5p smoking pink
hsa-miR-10a-5p smoking blue hsa-miR-30c-2-3p smoking blue
hsa-miR-10b-5p smoking blue hsa-miR-330-5p smoking grey60
hsa-miR-125a-5p smoking blue hsa-miR-378a-3p smoking blue
hsa-miR-125b-1-3p smoking blue hsa-miR-378c smoking grey60
hsa-miR-126-5p smoking red hsa-miR-378g smoking blue
hsa-miR-127-3p smoking blue hsa-miR-378i smoking blue
hsa-miR-1301-3p smoking grey60 hsa-miR-422a smoking blue
hsa-miR-1301-3p smoking pink hsa-miR-5001-3p smoking pink
hsa-miR-147b smoking grey60 hsa-miR-548e-3p smoking pink
hsa-miR-182-5p smoking grey60 hsa-miR-625-5p smoking pink
hsa-miR-183-5p smoking blue hsa-miR-671-5p smoking grey60
hsa-miR-1976 smoking grey60 hsa-miR-675-5p smoking grey60
hsa-miR-1976 smoking pink hsa-miR-760 smoking grey60
hsa-miR-199a-5p smoking blue hsa-miR-7974 smoking pink
hsa-miR-200c-3p smoking pink hsa-miR-93-3p smoking pink
hsa-miR-2277-5p smoking blue hsa-miR-941 smoking blue
hsa-miR-3064-5p smoking blue hsa-miR-96-5p smoking grey60
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Table 3.10 miRNAs and mediating modules universally associated with subtype 
Some miRNAs are listed multiple times due to the fact that their association with subtype was 
mediated by multiple modules. 
 
  
miRbaseID trait module miRbaseID trait module miRbaseID trait module
hsa-let-7f-5p subtype blue hsa-miR-199a-5p subtype magenta hsa-miR-411-3p subtype magenta
hsa-miR-106b-3p subtype pink hsa-miR-199a-5p subtype blue hsa-miR-422a subtype blue
hsa-miR-106b-5p subtype black hsa-miR-199b-5p subtype brown hsa-miR-423-5p subtype pink
hsa-miR-10a-5p subtype brown hsa-miR-199b-5p subtype magenta hsa-miR-423-5p subtype grey60
hsa-miR-10a-5p subtype blue hsa-miR-200b-3p subtype grey60 hsa-miR-429 subtype grey60
hsa-miR-10b-5p subtype brown hsa-miR-200c-3p subtype pink hsa-miR-4446-3p subtype black
hsa-miR-10b-5p subtype blue hsa-miR-2110 subtype pink hsa-miR-4446-3p subtype pink
hsa-miR-125a-5p subtype blue hsa-miR-2110 subtype grey60 hsa-miR-4446-3p subtype grey60
hsa-miR-125a-5p subtype brown hsa-miR-214-5p subtype magenta hsa-miR-455-5p subtype magenta
hsa-miR-125b-1-3p subtype blue hsa-miR-218-5p subtype brown hsa-miR-4685-3p subtype grey60
hsa-miR-126-5p subtype magenta hsa-miR-22-3p subtype brown hsa-miR-493-3p subtype magenta
hsa-miR-126-5p subtype red hsa-miR-2277-5p subtype blue hsa-miR-497-5p subtype magenta
hsa-miR-1262 subtype grey60 hsa-miR-23a-3p subtype magenta hsa-miR-497-5p subtype brown
hsa-miR-127-3p subtype blue hsa-miR-23a-5p subtype grey60 hsa-miR-5001-3p subtype pink
hsa-miR-127-5p subtype magenta hsa-miR-23b-5p subtype blue hsa-miR-504-5p subtype blue
hsa-miR-1271-5p subtype magenta hsa-miR-23b-5p subtype pink hsa-miR-548e-3p subtype pink
hsa-miR-1287-5p subtype blue hsa-miR-301a-5p subtype blue hsa-miR-576-5p subtype black
hsa-miR-1287-5p subtype brown hsa-miR-3064-5p subtype blue hsa-miR-585-3p subtype magenta
hsa-miR-1301-3p subtype pink hsa-miR-3065-5p subtype pink hsa-miR-625-5p subtype pink
hsa-miR-1301-3p subtype grey60 hsa-miR-30c-2-3p subtype blue hsa-miR-629-5p subtype grey60
hsa-miR-1304-3p subtype blue hsa-miR-30c-2-3p subtype black hsa-miR-642a-3p subtype grey60
hsa-miR-1304-5p subtype pink hsa-miR-3158-3p subtype pink hsa-miR-6504-5p subtype magenta
hsa-miR-1306-5p subtype pink hsa-miR-32-3p subtype black hsa-miR-6504-5p subtype brown
hsa-miR-130a-3p subtype red hsa-miR-330-5p subtype grey60 hsa-miR-654-3p subtype magenta
hsa-miR-130b-5p subtype blue hsa-miR-335-3p subtype magenta hsa-miR-655-3p subtype magenta
hsa-miR-136-5p subtype magenta hsa-miR-34b-3p subtype pink hsa-miR-656-3p subtype magenta
hsa-miR-136-5p subtype brown hsa-miR-34b-5p subtype black hsa-miR-671-3p subtype blue
hsa-miR-139-3p subtype magenta hsa-miR-34b-5p subtype grey60 hsa-miR-671-5p subtype grey60
hsa-miR-141-3p subtype grey60 hsa-miR-34c-5p subtype grey60 hsa-miR-675-5p subtype grey60
hsa-miR-147b subtype grey60 hsa-miR-3615 subtype pink hsa-miR-744-5p subtype grey60
hsa-miR-154-5p subtype magenta hsa-miR-374b-3p subtype magenta hsa-miR-760 subtype grey60
hsa-miR-181d-5p subtype magenta hsa-miR-376c-3p subtype magenta hsa-miR-7974 subtype pink
hsa-miR-182-5p subtype grey60 hsa-miR-378a-3p subtype blue hsa-miR-7974 subtype magenta
hsa-miR-183-5p subtype blue hsa-miR-378c subtype grey60 hsa-miR-7974 subtype brown
hsa-miR-185-3p subtype pink hsa-miR-378g subtype magenta hsa-miR-92b-3p subtype pink
hsa-miR-18a-3p subtype pink hsa-miR-378g subtype blue hsa-miR-92b-3p subtype black
hsa-miR-193a-5p subtype brown hsa-miR-379-3p subtype magenta hsa-miR-93-3p subtype pink
hsa-miR-195-3p subtype black hsa-miR-3909 subtype blue hsa-miR-941 subtype blue
hsa-miR-195-5p subtype brown hsa-miR-3909 subtype brown hsa-miR-942-5p subtype pink
hsa-miR-1976 subtype grey60 hsa-miR-3909 subtype pink hsa-miR-96-5p subtype grey60
hsa-miR-1976 subtype pink hsa-miR-3913-5p subtype blue
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Table 3.11 Functional enrichment of 14 coexpression modules discovered in lesion biopsies. 
 
module trait module size
n module 
genes in 
term
Bonf. p-val term ID ontology term name
black grade, subtype 812 81 8.26E-84 GO:0022626 CC cytosolic ribosome
black grade, subtype 812 79 9.42E-80 GO:0006415 BP translational termination
black grade, subtype 812 86 2.04E-76 GO:0006414 BP translational elongation
black grade, subtype 812 81 1.26E-74 GO:0006614 BP SRP-dependent cotranslational protein targeting to membrane
black grade, subtype 812 81 1.86E-73 GO:0006613 BP cotranslational protein targeting to membrane
black grade, subtype 812 81 6.86E-73 GO:0045047 BP protein targeting to ER
black grade, subtype 812 81 6.86E-73 GO:0072599 BP establishment of protein localization to endoplasmic reticulum
black grade, subtype 812 81 1.04E-69 GO:0000184 BP nuclear-transcribed mRNA catabolic process
black grade, subtype 812 93 2.61E-68 GO:0006413 BP translational initiation
black grade, subtype 812 82 4.73E-67 GO:0070972 BP protein localization to endoplasmic reticulum
blue smoking, subtype 1755 521 2.33E-12 GO:0016070 BP RNA metabolic process
blue smoking, subtype 1755 419 1.69E-09 GO:0051252 BP regulation of RNA metabolic process
blue smoking, subtype 1755 463 2.15E-08 GO:0003676 MF nucleic acid binding
blue smoking, subtype 1755 413 2.31E-08 GO:0006351 BP transcription
blue smoking, subtype 1755 399 2.55E-07 GO:2001141 BP regulation of RNA biosynthetic process
blue smoking, subtype 1755 568 2.59E-07 GO:0010467 BP gene expression
blue smoking, subtype 1755 395 2.70E-07 GO:0006355 BP regulation of transcription
blue smoking, subtype 1755 293 2.84E-07 GO:0003677 MF DNA binding
blue smoking, subtype 1755 465 4.51E-07 GO:0010468 BP regulation of gene expression
blue smoking, subtype 1755 77 7.84E-07 GO:0008380 BP RNA splicing
brown grade, subtype 1141 203 0.001436157 GO:0003677 MF DNA binding
brown grade, subtype 1141 490 0.014226622 GO:0005634 CC nucleus
brown grade, subtype 1141 300 0.597424 GO:0003676 MF nucleic acid binding
brown grade, subtype 1141 8 1 GO:0010390 BP histone monoubiquitination
brown grade, subtype 1141 710 1 GO:0043231 CC intracellular membrane-bounded organelle
brown grade, subtype 1141 300 1 GO:0046872 MF metal ion binding
brown grade, subtype 1141 300 1 GO:0043169 MF cation binding
brown grade, subtype 1141 15 1 GO:0055072 BP iron ion homeostasis
brown grade, subtype 1141 40 1 GO:0000785 CC chromatin
brown grade, subtype 1141 71 1 GO:0005694 CC chromosome
darkturquoise grade 2412 289 1.80E-31 GO:0000278 BP mitotic cell cycle
darkturquoise grade 2412 534 1.23E-28 GO:0031981 CC nuclear lumen
darkturquoise grade 2412 394 3.22E-24 GO:0007049 BP cell cycle
darkturquoise grade 2412 311 4.95E-22 GO:0022402 BP cell cycle process
darkturquoise grade 2412 136 1.86E-19 GO:0007067 BP mitotic nuclear division
darkturquoise grade 2412 78 3.21E-17 GO:0007059 BP chromosome segregation
darkturquoise grade 2412 364 5.44E-17 GO:0005654 CC nucleoplasm
darkturquoise grade 2412 301 1.61E-15 GO:0044822 MF poly(A) RNA binding
darkturquoise grade 2412 73 3.02E-14 GO:0000793 CC condensed chromosome
darkturquoise grade 2412 192 2.45E-13 GO:0051301 BP cell division
grey60 progr4, subtype, smoking 924 118 8.78E-59 GO:0031012 CC extracellular matrix
grey60 progr4, subtype, smoking 924 109 6.09E-50 GO:0030198 BP extracellular matrix organization
grey60 progr4, subtype, smoking 924 109 6.09E-50 GO:0043062 BP extracellular structure organization
grey60 progr4, subtype, smoking 924 98 9.68E-50 GO:0005578 CC proteinaceous extracellular matrix
grey60 progr4, subtype, smoking 924 408 1.50E-41 GO:0007275 BP multicellular organismal development
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module trait module size
n module 
genes in 
term
Bonf. p-val termID ontology term name
grey60 progr4, subtype, smoking 924 172 8.80E-41 GO:0007155 BP cell adhesion
grey60 progr4, subtype, smoking 924 446 1.06E-38 GO:0032502 BP developmental process
grey60 progr4, subtype, smoking 924 382 1.20E-38 GO:0071944 CC cell periphery
grey60 progr4, subtype, smoking 924 123 4.53E-38 GO:0001944 BP vasculature development
grey60 progr4, subtype, smoking 924 373 1.25E-37 GO:0005886 CC plasma membrane
lightgreen 875 372 8.69E-114 GO:0002376 BP immune system process
lightgreen 875 270 2.74E-99 GO:0006955 BP immune response
lightgreen 875 210 2.84E-88 GO:0001775 BP cell activation
lightgreen 875 178 2.95E-83 GO:0045321 BP leukocyte activation
lightgreen 875 224 2.03E-75 GO:0002682 BP regulation of immune system process
lightgreen 875 241 3.08E-71 GO:0006952 BP defense response
lightgreen 875 152 1.20E-69 GO:0046649 BP lymphocyte activation
lightgreen 875 411 8.83E-64 GO:0071944 CC cell periphery
lightgreen 875 404 1.84E-63 GO:0005886 CC plasma membrane
lightgreen 875 170 6.23E-63 GO:0050776 BP regulation of immune response
magenta grade, subtype 3142 186 7.48E-56 GO:0005929 CC cilium
magenta grade, subtype 3142 107 1.55E-43 GO:0044782 BP cilium organization
magenta grade, subtype 3142 114 2.52E-43 GO:0060271 BP cilium morphogenesis
magenta grade, subtype 3142 96 2.00E-38 GO:0042384 BP cilium assembly
magenta grade, subtype 3142 50 6.13E-18 GO:0036064 CC ciliary basal body
magenta grade, subtype 3142 29 2.53E-17 GO:0030990 CC intraciliary transport particle
magenta grade, subtype 3142 44 6.97E-17 GO:0005930 CC axoneme
magenta grade, subtype 3142 46 4.58E-16 GO:0031514 CC motile cilium
magenta grade, subtype 3142 341 2.45E-15 GO:0042995 CC cell projection
magenta grade, subtype 3142 32 4.60E-15 GO:0003341 BP cilium movement
pink progr4, smoking, subtype 739 114 1.32E-13 GO:0048699 BP generation of neurons
pink progr4, smoking, subtype 739 107 2.54E-13 GO:0030182 BP neuron differentiation
pink progr4, smoking, subtype 739 117 9.08E-13 GO:0022008 BP neurogenesis
pink progr4, smoking, subtype 739 150 2.03E-12 GO:0007399 BP nervous system development
pink progr4, smoking, subtype 739 139 1.23E-10 GO:0048468 BP cell development
pink progr4, smoking, subtype 739 165 2.23E-09 GO:0009653 BP anatomical structure morphogenesis
pink progr4, smoking, subtype 739 257 4.30E-09 GO:0007275 BP multicellular organismal development
pink progr4, smoking, subtype 739 204 6.64E-09 GO:0030154 BP cell differentiation
pink progr4, smoking, subtype 739 78 1.40E-08 GO:0000904 BP cell morphogenesis involved in differentiation
pink progr4, smoking, subtype 739 78 1.79E-08 GO:0031175 BP neuron projection development
red smoking, subtype 943 158 4.01E-07 GO:0005739 CC mitochondrion
red smoking, subtype 943 86 1.75E-06 GO:0032446 BP protein modification by small protein conjugation
red smoking, subtype 943 81 4.03E-06 GO:0016567 BP protein ubiquitination
red smoking, subtype 943 20 6.32E-05 GO:0070469 CC respiratory chain
red smoking, subtype 943 7 8.76E-05 GO:0046977 MF TAP binding
red smoking, subtype 943 220 0.000159011 GO:0031090 CC organelle membrane
red smoking, subtype 943 60 0.000307633 GO:0019941 BP modification-dependent protein catabolic process
red smoking, subtype 943 636 0.000466202 GO:0043231 CC intracellular membrane-bounded organelle
red smoking, subtype 943 64 0.000552028 GO:0044257 BP cellular protein catabolic process
red smoking, subtype 943 7 0.000659805 GO:0019885 BP antigen processing and presentation of endogenous peptide antigen via MHC class I
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3.4. Discussion 
 PMLs are preinvasive histological abnormalities in the airway epithelium that can 
be reproducibly graded by a pathologist. Because many patients with lung cancer will 
also experience numerous severe PMLs, PMLs have been regarded as risk markers for 
any subtype of LC and the presumed precursors of SCC. Although the natural history of 
PMLs has been well documented, the proposed linear nature of lesion progression from 
hyperplasia to invasive carcinoma, does not reflect the often erratic behavior of lesions 
over time, as PMLs are dynamic and their histology may worsen and improve multiple 
times within a patient. Little is known about the molecular mechanisms behind PML 
progression. In fact, although we may be able to observe PMLs over time, it is currently 
not possible to predict if and when a lesion will progress to invasive carcinoma, relying 
solely on visual clues and patient’s lesion history (histological grade, number and follow 
up status). In this chapter, we provide novel insights into transcriptional and regulatory 
processes likely governing PML progression by examining relevant expression changes 
demonstrated by genes and miRNAs in lesion biopsy samples over time.  
 We identified 31 miRNAs associated with PML histological grade or progression. 
Among those, we discovered four classes characterized by the co-association with traits 
of interest and control traits. While miRNAs contained in clusters 1, 3 and 4 associated 
with dysplasia grade, the biology of these miRNAs and mediating modules involved a 
wide array of mechanisms, including processes involved in cell proliferation, 
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differentiation, development and death– confirming that cancer may arise as a result of 
many disruptive cellular processes. In addition, miRNAs associated with multiple traits 
via multiple mediating modules could be of particular interest, although it is important to 
note that some of the associations may be driven by high correlation of genes belonging 
to multiple modules. Nonetheless, further exploration of miRNAs possibly governing 
multiple downstream biological processes, could yield additional insights into lesion 
progression. 
 Because a golden standard for defining lesion progression has not been 
established to date, we tested five definitions of progression, which reflect the potential 
capacity of the PMLs to store information about the past and the future, and the unknown 
rates at which gene and miRNA expression may respond to histological changes in PMLs 
over time. We observed gene and miRNA associations with the long-term future-based 
progression only. Since the LT next progression assumes comparison with the worst 
observed histology in the future, this is an encouraging result, as it suggests that the 
expression of genes and miRNAs observed in lesion biopsies might harbor information 
about PMLs being “preprogrammed” or destined to progress or regress. Although, all 
used samples represented a spectrum of premalignant disease and excluded invasive 
carcinoma, this fact would be especially useful in cases where extremely high or low 
expression of a progression-associated miRNA could be used to determine elevated risk 
for progressing into invasive carcinoma. Similarly, it may not be surprising to observe no 
associations with short-term progression, as the difference in time between consecutive 
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time points was not standardized and in many instances may be too short to be reflected 
on a molecular level (although, ST next was represented by “indirect” associations, but 
no miRNAs associated with it “directly” and thus there was no evidence for regulatory 
mechanisms implicated in this kind of progression). In addition, although it may be 
feasible for PMLs to harbor information about their worst histology observed in the past 
(much like crumpled paper that can never be brought back to the initial state, due to 
irreversible physical changes), past-based progression was not associated by any 
miRNAs and genes. 
 There are several limitations of our study. First, the relationship between a 
worsening histological state of individual PMLs and the overall health of the patient, and 
thus their LC risk, remains sparsely understood. Although we can define progression by 
comparing histology at consecutive time points, it is unclear if a single PML predicted to 
progress five grades (and potentially to invasive carcinoma), poses an equivalently 
elevated risk as multiple PMLs progressing in a milder manner (by three grades only for 
example). This means that while we could predict that a lesion will progress to carcinoma 
and direct a patient to a chemoprevention trial or administer a therapeutic, patients with 
multiple lesions progressing less aggressively might be at the same risk - we just don’t 
know the cumulative effect of PMLs on the overall health of the patient. 
What is more, although we have observed significant associations with progression in our 
data, there may be other (perhaps better) definitions of progression we should consider, 
which may incorporate the number and severity of all PMLs present at a time. An 
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example would be progression defined based on a regression line fitted to the numerical 
histology data spaced proportionally according to time difference between time points 
(Figure 3.1. Example lung map of biopsy locations and corresponding histology grades 
changing over time.Figure 3.1). In theory, such regression line could provide a better 
overview of the total changes within a PML over time. However, we found that this 
measure was biased against subjects with large number of biopsies, for whom the slope 
of the regression line became closer to 0 with each additional time point (regression to 
the mean), and thus excluded this definition from consideration. Nonetheless, this proves 
that there are many different angles and perspectives for solving the problem of defining 
progression. 
In addition, time difference between time points is not standardized, nor corrected for in 
this analysis. As discussed in Chapter 2, the individual follow-up histology of PMLs in 
the context of LT next progression may benefit from alternative definitions as well. Here, 
we consider the worst histology observed at later time points. However, one may argue 
that an average is more appropriate. There is a problem with both ideas - with enough 
time points, we might be able to observe severe dysplasia as worst histology, as well as 
metaplasia (the true transitional state) as the average in any PML. 
 Although we were able to identify miRNAs and genes whose expression patterns 
reflect progression in lesions, additional studies should be conducted to examine if any of 
these alterations are present in lesions that eventually progress into invasive carcinoma. 
However, these studies are difficult to conduct, as they require substantially long follow-
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up time. For example, in a 2008 study by Salaun et al 104, 37 patients were monitored 
over the course of 12 years, which was sufficient to observe that 94% of lesions that 
progressed into invasive carcinoma were carcinomas in situ at baseline, and 79% of 
lesions that spontaneously regressed were severe dysplasias. After a similar follow up, a 
study by van Boerdonk et al. demonstrated that 55/164 patients with premalignant lesions 
developed lung cancer within that time frame (median time to event was 16.5 months) 136. 
 What is more, although a consensus coexpression network was built solely for the 
purpose of evaluating the reproducibility of the biopsy-derived modules, it will be 
important to explore the possibility of using the consensus network (instead of the 
reference network) for all analysis. Finally, additional evaluation of the results will be 
necessary in order to narrow down the list of grade - and progression-associated genes 
and miRNAs for experimental validation. This may include analyzing additional datasets 
and examining preservation of regulatory patterns, or selecting candidates confirmed 
individually in subjects with a high number of lesions to reduce the patient effect. 
3.5. Conclusions 
This chapter features a new paradigm for evaluating the role of miRNAs in 
biological processes involved in the progression of bronchial premalignant lesions. 
Leveraging the expression of genes likely targeted by miRNAs in our data, our results 
suggest that gene and miRNA expression extracted from bronchial premalignant lesion 
biopsies can be successfully used to determine PML severity and their capacity to 
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progress. The grade- and progression-associated genes were enriched in pathways often 
dysregulated in many cancers including that of the lung. In addition, many of the 
miRNAs associated with grade and progression play a significant role in inducing 
resistance to chemotherapy, promoting metastasis or tumor progression. This suggests 
that perturbation of these pathways in a precancerous environment may constitute a 
catalyst for future malignant changes, and that the commonalities between the regulatory 
processes involved in premalignancy and tumorigenesis may be the earliest events 
required for tumor development. In a clinical context, the presented methodology may 
provide a source of miRNA biomarkers that would facilitate identification of 
asymptomatic patients at high risk of developing lung cancer.  
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CHAPTER FOUR: Identifying Shared Genomic and Regulatory Alterations 
Associated with Lung Carcinogenesis in the Field, the Lesion and the Tumor 
4.1. Background  
Lung squamous cell premalignant lesions have been previously shown to be risk 
markers for developing lung cancer, as many patients with invasive carcinoma present 
with this histological abnormality of the airway 10,54. However, despite the fact that the 
PMLs are the presumed precursors for SCC, their monitoring has not been widely 
adopted as part of lung cancer screening programs. In Chapter 2, we presented a gene 
expression-based biomarker derived from bronchial brushing samples that could be used 
to detect PML presence in high-risk individuals. In addition, in Chapter 3, we 
demonstrated that gene and miRNA expression extracted from lesion biopsies could be 
used to select a subset of subjects at highest risk for developing lung cancer due to the 
propensity of their lesions to progress, possibly to invasive carcinoma. Since the natural 
history of PMLs rarely follows the well-documented linear progression model and cannot 
be currently predicted by visual inspection and lesion history alone, the possibility of 
monitoring PMLs using gene and miRNA-expression opens the doors to new screening 
paradigms. However, due to the substantial invasiveness of procedures involving biopsy, 
in this chapter we sought to examine if bronchial brushings could be leveraged not only 
to detect PMLs but also to track the pathological changes associated with lesion 
progression over time. To address this challenge, we examined the preservation of 
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regulatory patterns characteristic of PML severity and progression we previously 
observed in lesion biopsies, in the context of airway field of injury. 
4.2. Methods 
4.2.1. Sample Collection: Bronchial Brushes from the PCGA 
 Bronchial airway brushes were obtained longitudinally from current and former 
smokers undergoing autofluorescence bronchoscopy at RPCI between December 2009 
and March 2013 (For a detailed description of the RPCI cohort refer to Chapter 2). In 
addition, abnormally fluorescing areas (apparent and suspected PMLs) were sampled 
using endobronchial biopsy and subsequently graded by a pathologist. The worst 
observed PML histology was recorded and assigned to the bronchial brushing collected at 
the same time point. 
4.2.2. Sample Collection: Tumor Biopsies from the TCGA 
 The TCGA cohort has previously been described in Chapter 2. 
4.2.3. Redefining Lesion Grade and Progression 
 The definition of a lesion grade can no longer be directly applied to bronchial 
brushing samples, as they include only normal-appearing epithelial cells, while their 
pathologist-assigned histological grade reflects the worst histology observed among 
biopsied lesions. However, it seems reasonable to treat the brushing grade as equivalent 
to PML grade in all comparisons made in this Chapter. 
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 Since no golden standard currently exists for defining PML progression, in 
Chapter 3 we propose 5 plausible definitions that account for PML’s future and past 
histology modifications, as well as the varied time between procedures. Although the 
concept of progression is not as intuitive in the context of bronchial brushes, we classify 
brushing samples by applying the same definitions keeping in mind their more 
appropriate interpretation as progression of disease as opposed to progression of an 
individual lesion.  
4.2.4. Identifying genes and miRNAs Associated with Grade and Progression in 
Bronchial Brushings 
 We applied miRCAT to bronchial brushing samples to identify genes and 
miRNAs whose expression was associated with grade or progression. We first built a 
brush-specific gene co-expression network using WGCNA and the same preprocessing 
steps and parameters as outlined for biopsies in Chapter 3. To facilitate a direct 
comparison between module assignments in biopsies and brushes, resulting modules 
were then tested for gene overlaps with the biopsy-derived modules, and those with 
significant overlaps were relabeled with an equivalent module color. The remaining steps 
of the miRCAT pipeline were then carried out without modification. 
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4.2.5. Testing Preservation of Biopsy-Derived Gene Modules Associated with PML 
Grade and Progression in Bronchial Brushes 
Biopsy-derived co-expression module preservation in brushes 
 To evaluate if any of the grade- and progression-associated genes identified in 
lesion biopsies behaved similarly among the brushing samples, we employed the 
modulePreservation function in the WGCNA package. The brush-specific adjacency 
matrix as well as the biopsy-derived gene-module assignment were used as the test and 
reference networks respectively to calculate preservation statistics as described in 68. 
Briefly, network attributes such as network density (average connection strength for all 
pairs of genes), and network-wide or intramodular node connectivity (or degree, the sum 
of connection strengths between a gene and all other genes in the network, or genes 
belonging to the same module, respectively), were calculated and combined into two 
composite preservation measures: (1) Zsummary statistic, which sums the median values of 
multiple connectivity and density-based measures (making sure they are weighed 
equally) and classifies a module as strongly preserved if Zsummary > 10, weakly to 
moderately preserved if 2 < Zsummary < 10, and not preserved if Zsummary < 2; as well as (2) 
a medianRank, which similarly allows for a direct comparison of multiple individual 
conservation statistics in multiple modules at once, but is less sensitive to module size 
due to its reliance on relative preservation among modules (as opposed to absolute 
measures).  
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Gene Set Enrichment Analysis 
 In addition, Gene Set Enrichment Analysis (GSEA) 126 was conducted to examine 
the enrichment of biopsy-derived grade and progression associated genes and miRNAs 
among brush-specific samples. Gene sets consisting of biopsy-derived module members 
were generated according to a t-value calculated for a linear mixed effects model 
correcting for batch and a random patient effect, modeling either dysplasia grade (treated 
as a numeric variable with values 1-6 corresponding to Normal – Severe dysplasia) or 
progression, by splitting them into submodules up- (t>0) and down-regulated (t<0) in the 
traits of interest. These gene sets were labeled with module color, trait and direction (e.g. 
magenta.grade.UP). Similar approach was applied to generate four miRNA sets, which 
involved grouping miRNAs by their associated trait and the directionality of that 
association. These gene sets were labeled with trait and direction of association (e.g. 
miRNA.progression.DOWN) In addition, target-specific gene sets were generated and 
included only neighboring target genes of each miRNA associated with a given trait in a 
given direction. These gene sets were labeled with the name of the miRNA, the trait and 
the direction (e.g. miR34b.grade.DOWN) 
 Ranked gene lists were generated in the brush data by ranking genes and miRNAs 
according to an LME t-value reflecting the strength and directionality of association with 
either grade or progression.  
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4.2.6. Testing Preservation of Biopsy-Derived miRNAs Associated with PML Grade and 
Progression in Lung SCC Tumors 
 GSEA was also conducted to examine the enrichment of biopsy-derived grade- 
and progression-associated genes and miRNAs among the TCGA lung SCC samples. The 
same gene sets were used as in the case of bronchial brushings. Ranked lists were 
generated in the TCGA data by ranking genes and miRNAs according to a Student’s t 
statistic reflecting the strength and directionality of association with tissue type (tumor 
vs. adjacent normal). 
4.3. Results 
4.3.1. Sample Population: The PCGA brushes 
 86 brushing samples were collected longitudinally from high-risk current and 
former smokers 57 years of age on average, the majority of whom were Caucasian (93%) 
and female (57%). 54 brushings categorized as Dysplasia originated from subjects whose 
worst histological grade observed at that timepoint was mild dysplasia or worse. 
Conversely, 32 brushings categorized as Normal originated from subjects with the worst 
histology of Metaplasia or better (Table 4.1)  
4.3.2. Sample Population: The TCGA 
 Sample population for the TCGA cohort has been previously described in Chapter 
2. 
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4.3.3. Genes and miRNAs Associated with Traits of Interest in Bronchial Brushings 
 miRCAT pipeline was applied to 86 bronchial brushings to discover genes and 
miRNAs associated with grade, progression, or control traits such as smoking and 
subtype. We discovered 31 co-expression modules containing on average 485 genes, 
ranging in size between 42 and 2166 genes. Although we did not observe any universal 
relationships with any of the traits, 13 miRNAs exhibited direct association with 
smoking, and 6 miRNAs (3 overlapping) were associated indirectly with short term 
previous progression via the blue module (Table 4.2). let-7c-5p was the only progression-
associated miRNA we also observed in biopsies. 
4.3.4. Shared Gene and miRNA Alterations Present in the Field, the Lesion and the 
Tumor 
 Biopsy-derived gene co-expression modules were tested for preservation in the 
brushing data using network connectivity and density attributes. We found strong 
preservation of all modules (Zsummary > 10), with the exception of the progression-
associated module grey60, which was moderately preserved (Zsummary = 8.6) (Figure 4.1). 
 In addition, we examined the enrichment of biopsy-derived genes and miRNAs 
associated with traits of interest in brushing samples. Four biopsy-derived modules 
mediating grade association (Table 3.7) were split into up- and downregulated 
submodules and utilized as gene sets in GSEA. The darkurquoiseUP, brownUP, and 
magentaDOWN were significantly enriched among the brushing data and tumor samples 
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in the corresponding direction (FDR q-val<0.05). The blackUP module was enriched 
specifically in tumors, while the blackDOWN and brownDOWN modules were only 
enriched among brushes. Interestingly, the black module was enriched oppositely in 
tumors as compared to brushes (Figure 4.2). 
 Two biopsy-derived modules mediating progression association (Table 3.8) were 
split into up- and down-regulated submodules and utilized as gene sets in GSEA. We did 
not find a significant (FDR q-val < 0.05) enrichment of the grey60 and pink submodules 
among the brushing data in either direction (Figure 4.2) 
 In addition to evaluating if the genes associated with grade and progression in 
biopsies behave similarly in brushes, we examined the preservation of expression patterns 
of miRNAs and their targets. Biopsy-derived miRNAs associated with grade and 
progression were split by trait into up- and down-regulated submodules and utilized as 
gene sets in GSEA. We found that only miRNAs up-regulated with progression were 
significantly enriched among upregulated brush miRNAs (FDR q=0.011) (Figure 4.3). 
All biopsy-derived miRNAs associated with progression were upregulated, thus we did 
not consider a gene set containing down-regulated miRNAs. When evaluating the 
preservation of miRNA targets however, we observed that 14 miRNA target sets 
associated with grade were enriched in brushes associated with dysplasia (FDR < 0.05; 
additional 6 were enriched with FDR<0.25). Two miRNA target sets upregulated in 
progression were enriched in brushes in the same direction (FDR<0.25). Finally, 16 
miRNA target sets associated with grade were enriched in the corresponding direction 
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among tumor biopsies (FDR < 0.05; additional 4 were enriched with FDR<0.25) (Figure 
4.4).  
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Table 4.1 Demographic characteristics of the RNA-Seq PML bronchial brushing dataset 
stratified by dysplasia status. 
Data are means (SD) for continuous variables and counts for dichotomous variables. Top table 
summarizes data by samples, and bottom table summarizes data by subjects. P-values are for the 
comparison between the Dysplasia and Normal groups, using two sample t-tests for continuous 
variables or Fisher’s exact test for categorical variables. 
 
 
 
  
Factor Overall Dysplasia Normal p-value
No. Samples 86 54 32
Age 57.89 (6.7) 57.95 (7.03) 57.79 (6.18) 0.91
Sex 0.26
female 49 28 21
male 37 26 11
Race 1
Caucasian 80 50 30
Other 4 3 1
Unknown 2 1 1
Lung Cancer 0 0 0
Smoking 0.008
current 40 31 9
former 35 16 19
NA 11 7 4
Pack Years 49.35 (21.6) 48 (20.38) 51.62 (23.6) 0.46
Histological grade < 0.001
Normal 6 6
Hyperplasia 11 11
Metaplasia 15 15
Mild Dysplasia 8 8 	
Moderate Dysplasia 9 9
Severe Dysplasia 17 17
Factor Overall
No. Subjects 30
No. of procedures (mean [range]) 2.9 (1-9 visits)
Days between visits (mean [range]) 362 (84-1176 days)
Age 59.26 (7.45)
Sex
female 15
male 15
Race
Caucasian 27
African American 2
NA 1
Lung Cancer 0
Smoking
current 12
former 12
NA 6
Pack Years 49.80 (22.11)
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Table 4.2 Direct and indirect miRNA association with traits in brushes 
miRNA association with traits including grade, progression, smoking and subtype, was evaluated 
using miRCAT pipeline. 13 miRNAs were associated directly via LME with smoking status. 6 
miRNAs (3 overlapping) were associated indirectly with short-term previous progression via the 
blue module.  
 
  
miRbaseID trait miRbaseID trait module
hsa-let-7c-5p smoking hsa-miR-30e-3p progr2 blue
hsa-miR-125a-5p smoking hsa-miR-3182 progr2 blue
hsa-miR-125b-2-3p smoking hsa-miR-3607-3p progr2 blue
hsa-miR-1295a smoking hsa-let-7f-5p progr2 blue
hsa-miR-190b smoking hsa-let-7c-5p progr2 blue
hsa-miR-2110 smoking hsa-miR-125b-2-3p progr2 blue
hsa-miR-30c-2-3p smoking
hsa-miR-34c-3p smoking
hsa-miR-34c-5p smoking
hsa-miR-3607-3p smoking
hsa-miR-642a-3p smoking
hsa-miR-642a-5p smoking
hsa-miR-99b-5p smoking
Direct association Indirect association
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Figure 4.1 Biopsy-derived module preservation in brushing data. 
Modules are considered strongly preserved if Zsummary>10, weakly preserved if 
2<Zsummary<10, and not preserved if Zsummary<2. All modules are preserved strongly, with the 
exception of the gray60 module which was preserved weakly. 
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Figure 4.2 Biopsy-derived modules are enriched in brushes and tumor biopsies. 
Gene sets with a significant enrichment score (FDR q-val < 0.05) are marked with (*). Grade-
associated modules darkturquoiseUP, brownUP and magentaDOWN were significantly enriched 
in brushes and tumors.  None of the progression-associated modules were enriched among 
brushing samples. 
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Figure 4.3 Trait associated miRNAs are enriched in brushes and tumor biopsies. 
Gene sets with a significant enrichment score (FDR q-val < 0.05) are marked with (*). 
Only miRNAs positively associated with progression were enriched among up-regulated 
brushing samples. 
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Figure 4.4 Targets of trait associated miRNAs are enriched in brushes and tumor biopsies. 
Gene sets with a significant enrichment score (FDR q-val < 0.05) are marked with (*). 
Only gene sets with FDR < 0.25 are presented. No targets of progression-associated 
miRNAs were significantly enriched among brushing samples  
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4.4. Discussion 
 PMLs have been previously shown to be risk markers for developing lung cancer. 
Although they are precursors for SCC, their monitoring has not been incorporated into 
lung cancer screening programs. In Chapter 2, we showed that we can leverage 
histologically normal brushing samples obtained non-invasively to detect the presence of 
PMLs. In Chapter 3, we demonstrated that gene and miRNA expression extracted from 
lesion biopsies facilitates the identification of regulatory patterns associated with lesion 
severity and progression. Since the natural history of PMLs tends to deviate from the 
well-established linear progression model and cannot be predicted by visual inspection, in 
this chapter we sought to examine if regulatory patterns similar to what we observed in 
biopsies existed in bronchial brushes. The presented findings suggest that gene and 
miRNA expression extracted from bronchial brushes could be used as a surrogate for the 
severity and potential for malignancy of precancerous lesions, and should be explored 
more extensively as a procedure facilitating PML monitoring without the necessity for 
invasive biopsy. 
 We first investigated if PML grade and progression signal could be extracted 
independently from bronchial brushings. Most likely due to the choice of parameters used 
in co-expression network construction that yielded approximately twice as many modules 
as in biopsies as well as a smaller sample size (in comparison to biopsies) that could 
affect correlation significance, we did not observe any universal associations between 
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miRNAs and traits of interest. However, several miRNAs were associated with short 
term previous progression indirectly. For example, miR-30e along with let-7e which were 
upregulated in progressing lesions, have been previously associated with decreased 
survival and dedifferentiation in NSCLC 12,152 – a process characteristic of cancer 
progression in which a differentiated cell might revert back to a less advanced type. miR-
3182 has been shown to be upregulated in EGFR exon 19 deletion adenocarcinomas 58. 
And the loss of miR-125b was reported to accompany melanoma onset and progression 
59. In addition, the association between these miRNAs and progression was mediated by a 
module implicated in transcription and regulation of RNA metabolic process, which has 
been described as one of the hallmarks of cancer 47. These results suggest a potential for 
bronchial brushes to provide insights into PML development. 
 Moreover, we tested this hypothesis indirectly, by evaluating the preservation of 
biopsy-derived modules and miRNAs in brushes. We observed that independently of trait, 
all but one module were conserved between the two datasets. This gave us confidence 
that the relationships between genes in brushes has a high degree of similarity to the 
highly coexpressed gene modules we observed in biopsies. Next, we sought to evaluate 
enrichments of modules, miRNAs and their targets among brushes differentiated by PML 
grade or progression, as well as among lung tumor and adjacent normal samples. We 
found that three modules implicated in cell cycle (UP), ciliogenesis (DOWN) and nucleic 
acid binding (UP) pathways were enriched in the corresponding directions among 
brushes associated with grade as well as TCGA tumor vs. normal samples. The cilia (UP) 
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and nucleic acid binding (UP) submodules were also dysregulated in the same direction 
in brushes, but not in tumor. This might suggest processes specific to bronchial epithelial 
cells that are not as prominent in solid tumor tissues. On the other hand, a module 
implicated in translational elongation and termination (UP) was exclusively enriched 
among tumor samples. In the context of progression, no module gene sets were enriched 
among the progression-associated brushes. The lack of concordance between the gene 
sets is likely due to the fact that progression in biopsies describes a process that is lesion-
specific, while grade changes in brushes over time reflect the changes in the worst 
observed histology in the biopsies. This was also confirmed by the finding that 
independently, miRNAs in brushes were associated (indirectly) with a different (past-
based) definition of progression than biopsies. Surprisingly, when miRNAs were grouped 
by their association with grade and progression, the only enrichment we observed was of 
the upregulated progression-associated miRNAs in brushes upregulated with progression. 
However, the significance of enrichment could have been biased by the small size of the 
miRNA-set. 
 Finally, we evaluated the enrichment of biopsy-derived miRNAs in brushes and 
tumor biopsies on a miRNA target level. We observed concordant enrichment of targets 
of miRNAs associated with grade (UP and DOWN) in brushes as well as tumor biopsies 
(in the concordant direction), including let-7c, miR-34b/c, and miR-944. 
 There are several limitations to our study. As mentioned earlier, the lack of 
universal associations between miRNAs and grade and progression among bronchial 
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brushes is likely due to used parameters that were not tailored towards brush data in 
hopes of reducing the potential for technical biases that could influence the interpretation 
and comparison of biopsy and brush results. An additional experiment should be 
conducted in which module number is decreased. In addition, classifying brushing 
samples by the worst observed histology in biopsies is just one possible way of defining 
dysplasia grade and progression per patient/time point, and other definitions might be 
more appropriate. Finally, although module gene sets were split by the directionality of 
the association between member genes and traits of interest, it will be important to 
construct coexpression modules represented by genes either up- or down-regulated, but 
not both. This step would ensure that the up and down regulated module gene sets 
contained genes deemed coexpressed by the same approach instead of two (first, 
Pearson’s correlation and average linkage hierarchical clustering to build modules, and 
then a linear mixed effects model to split the module into up and downregulated 
submodules). There is a risk that the resulting network will contain more, smaller 
modules, which had posed a bias in the brushing samples. However, the issue may 
become alleviated if we ensure singular-directionality of genes within. In addition, it may 
be interesting to explore the gene sets with bimodal enrichment score plots. For example, 
the brown.grade.DOWN module member-based gene set was significantly enriched in the 
up direction among high-grade brushing samples. However, it seems that a subset of gene 
set members occupying the non-leading edge switch directionality in the brushing dataset 
tested against. Also, among miRNA target-based gene sets, miR-1180 seems to be 
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oppositly enriched among the brushes (FDR < 0.25), but concordantly enriched among 
tumor biopsies (FDR < 0.05). Another kind of gene set could also be considered, which 
would allow for testing only unique miRNA-module-trait triplets that result from the 
indirect and direct association analysis. These new gene sets would include strongly 
correlated miRNA targets that belong to specific grade- or progression-associated 
modules, and would differ from the current target-based gene sets, by specifying separate 
gene sets for every mediating module. Specifically, since a miRNA can be associated 
with a trait via more than one module, currently, one target-based gene set is constructed 
to contain targets that belong to all mediating modules, while a separate new gene set 
would be constructed for each mediating module. This would ensure that biological 
processes that might not overlap between even highly correlated modules, are considered 
and interpreted separately. In the context of module preservation, tumor data could 
benefit from additional analyses, similar to what was done in brushes. Calculating Z-
summary in the TCGA data would allow us to compare preservation between brushes and 
tumors. 
4.5. Conclusions 
In summary, the findings in this chapter lay the groundwork for leveraging 
cytologically-normal airway epithelial cell brushings to glean insights into the lung 
cancer premalignancy. While we did not observe independent brush-specific regulatory 
mechanisms associated with PMLs, we were able to demonstrate that a vast array of 
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miRNAs and their targets found to be associated with PML grade and progression in 
biopsy samples, behaved concordantly among bronchial brushings. Future studies will be 
necessary to reevaluate these commonalities, by either modifying existing methods or 
developing new ones. In addition, identifying a more appropriate definition for lesion 
grade and progression in the context of bronchial brushings that would capture the overall 
state of premalignancy in a patient (e.g. by incorporating multiplicity and precise 
locations of PMLs), will be crucial for proper interpretation of findings. As the link 
between PMLs and lung carcinogenesis becomes better understood, it will become 
important to consider PML monitoring as part of standard of care to aid in the 
identification of high-risk subjects. The possibility of capturing the changes in 
transcriptomic profiles from bronchial brushes, promises to decrease patient burden and 
provide wider accessibility by supplying a minimally invasive way to observe PMLs over 
time. 
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CHAPTER FIVE: General Conclusions and Future Directions 
 The studies featured in this dissertation collectively leverage the transcriptomic 
profiles extracted from bronchial brushes collected in the presence of premalignant 
lesions, and biopsies of the lesion itself to identify biological processes associated with 
PML presence, grade and progression. Importantly, the results from these chapters 
contend that: 
• Cytologically-normal airway epithelial cells obtained via brushings of the main 
stem bronchus harbor biological information about the presence of PMLs within 
the central airway, and can be leveraged as a gene-expression based biomarker 
that can be administered using widely-available white-light bronchoscopy and 
bronchial brushing that is less invasive than biopsy. Ultimately, the biomarker 
could achieve the greatest clinical utility if the sampling was moved to a non-
invasive location, such as the nasal epithelium, where high-risk subjects could be 
identified more readily even if they didn’t meet the enrollment criteria for existing 
screening programs.  
• PMLs, which are the presumed precursors of lung squamous cell carcinoma, are 
risk markers for developing lung cancer. Although PMLs are thought to follow a 
linear progression model, changes in their histology over time are rarely 
predictable by inspection of visual clues or lesion’s history. However, the severity 
and progression of PMLs is reflected in the gene and miRNA expression profiles 
extracted from bronchial premalignant lesion biopsies, monitoring of which could 
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(a) aid in the identification of asymptomatic patients with high-grade lesions 
likely to progress who need a more aggressive follow-up and (b) help facilitate 
disease interception. In addition, the miRCAT approach, which constitutes a new 
paradigm for evaluating the role of miRNAs in biological processes involved in 
the progression of bronchial premalignant lesions, promises great utility in the 
identification of biomarkers of progression and response to therapy, as well as the 
selection of appropriate therapeutic targets  
• The airway field of injury recapitulates a subset of grade and progression-
associated alterations observed in lesions. Although PMLs are typically detected 
using autofluorescence bronchoscopy, the procedure’s scarcity makes it 
unrealistic to be widely used in screening programs. Building on our findings that 
demonstrate that bronchial brushes obtained via white-light bronchoscopy can 
successfully identify individuals with PMLs, and that lesion biopsies carry 
information that can be harnessed to identify subjects with lesions likely to 
progress, we proposed an alternative to biopsy’s invasiveness: Capturing the 
changes in transcriptomic profiles from bronchial brushes, promises to provide 
wider accessibility and decrease patient burden by supplying a minimally invasive 
way to observe PMLs over time.   
 
 
  
 
144 
BIBLIOGRAPHY 
1. Allen TC. Pulmonary Neoplasia. October 2009. doi:10.1043/1543-
2165(2008)132[1053:PN]2.0.CO;2. 
2. Anders S, Huber W. Differential expression analysis for sequence count 
data. Genome biology. 2010;11(10):1. doi:10.1186/gb-2010-11-10-r106. 
3. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with 
high-throughput sequencing data. Bioinformatics (Oxford, England). 
2015;31(2):166-169. doi:10.1093/bioinformatics/btu638. 
4. Anders S, Pyl PT, Huber W. HTSeq–A Python framework to work with 
high-throughput sequencing data. bioRxiv. 2014. doi:10.1101/002824. 
5. Andrés-León E, Peña DG, Gómez-López G, Pisano DG. miRGate: a curated 
database of human, mouse and rat miRNA–mRNA targets. Database. 
2015;2015(0):bav035-bav035. doi:10.1093/database/bav035. 
6. Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 
CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 
2009;9(1):3975. doi:10.1186/1471-2407-9-187. 
7. Atmaca A, Al-Batran S-E, Wirtz RM, et al. The validation of estrogen 
receptor 1 mRNA expression as a predictor of outcome in patients with 
metastatic non-small cell lung cancer. - PubMed - NCBI. International  
Journal of Cancer. 2013;134(10):2314-2321. doi:10.1002/ijc.28571. 
8. AUERBACH O, FORMAN JB, GERE JB, et al. Changes in the bronchial 
epithelium in relation to smoking and cancer of the lung; a report of 
progress. New England Journal of Medicine. 1957;256(3):97-104. 
doi:10.1056/NEJM195701172560301. 
9. BALÇA-SILVA J, NEVES SS, GONÇALVES AC, et al. Effect of miR-34b 
Overexpression on the Radiosensitivity of Non-small Cell Lung Cancer Cell 
Lines. Anticancer Research. 2012;32(5):1603-1609. 
doi:10.1016/j.molcel.2007.05.017. 
10. Banerjee AK. Preinvasive lesions of the bronchus. Journal of Thoracic 
Oncology. 2009;4(4):545-551. doi:10.1097/JTO.0b013e31819667bd. 
11. Barabási A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based 
approach to human disease. Nature Reviews. Genetics. 2011;12(1):56-68. 
  
 
145 
doi:10.1038/nrg2918. 
12. Barh D, Malhotra R, Ravi B, Sindhurani P. MicroRNA let-7: an emerging 
next-generation cancer therapeutic. Current Oncology. 2010;17(1):70-80. 
13. Bates D, Mächler M, Ben Bolker, Walker S. Fitting Linear Mixed-Effects 
Models Using lme4. Journal of Statistical Software. 2015;67(1):1-48. 
doi:10.18637/jss.v067.i01. 
14. Beane J, Beane J, Sebastiani P, et al. A Prediction Model for Lung Cancer 
Diagnosis that Integrates Genomic and Clinical Features. Cancer Prevention 
Research. 2008;1(1):56-64. doi:10.1158/1940-6207.CAPR-08-0011. 
15. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible 
and permanent effects of tobacco smoke exposure on airway epithelial gene 
expression. Genome Biology. 2007;8(9):R201. doi:10.1186/gb-2007-8-9-
r201. 
16. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible 
and permanent effects of tobacco smoke exposure on airway epithelial gene 
expression. Genome Biology. 2007;8(9):R201. doi:10.1186/gb-2007-8-9-
r201. 
17. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of 
p16(INK4a) is an early event in lung cancer and a potential biomarker for 
early diagnosis. Proceedings of the National Academy of Sciences of the 
United States of America. 1998;95(20):11891-11896. 
18. Bin Zhang, Gaiteri C, Bodea L-G, et al. Integrated Systems Approach 
Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease. 
Cell. 2013;153(3):707-720. doi:10.1016/j.cell.2013.03.030. 
19. Blomquist T, Crawford EL, Mullins D, et al. Pattern of antioxidant and DNA 
repair gene expression in normal airway epithelium associated with lung 
cancer diagnosis. Cancer Research. 2009;69(22):8629-8635. 
doi:10.1158/0008-5472.CAN-09-1568. 
20. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death 
& Disease. 2014;5(2):e1065. doi:10.1038/cddis.2014.38. 
21. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and 
plasma predict development and prognosis of computed tomography 
detected lung cancer. Proceedings of the National Academy of Sciences. 
  
 
146 
2011;108(9):3713-3718. doi:10.1073/pnas.1100048108. 
22. Breuer RH, Pasic A, Smit EF, et al. The Natural Course of Preneoplastic 
Lesions in Bronchial Epithelium. Clinical Cancer Research. 2005;11(2):537- 
543. doi:10.1183/09031936.01.00275301. 
23. Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A. Bridging 
the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the 
early detection of lung cancer in the post-National Lung Screening Trial era. 
BMC Medicine 2013 11:1. 2013;11(1):168. doi:10.1186/1741-7015-11-168. 
24. Buja A, Eyuboglu N. Remarks on Parallel Analysis. Multivariate Behavioral 
Research. 1992;27(4):509-540. doi:10.1207/s15327906mbr2704_2. 
25. Campbell JD, Campbell JD, Mazzilli SA, et al. The Case for a Pre-Cancer 
Genome Atlas (PCGA). Cancer Prevention Research. 2016;9(2):119-124. 
doi:10.1158/1940-6207.CAPR-16-0024. 
26. Campbell JD, Liu G, Luo L, et al. Assessment of microRNA differential 
expression and detection in multiplexed small RNA sequencing data. RNA. 
2015;21(2):164-171. doi:10.1261/rna.046060.114. 
27. Carter AJ, Nguyen CN. A comparison of cancer burden and research 
spending reveals discrepancies in the distribution of research funding. BMC 
Public Health. 2012;12(1):277. doi:10.1186/1471-2458-12-526. 
28. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative 
HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 
2013;14:128-128. doi:10.1186/1471-2105-14-128. 
29. Chimal JB. Hsp72 is an early and sensitive biomarker to detect acute kidney 
injury. Nat Rev Nephrol. 2010;6(2):71-73. doi:10.1038/nrneph.2009.225. 
30. Cortes C, Vapnik V. Support-vector networks. Machine Learning. 1995;
20(3):273-297. doi:10.1007/BF00994018. 
31. Cortese DA, Pairolero PC, Bergstralh EJ, et al. Roentgenographically occult 
lung cancer. A ten-year experience. Journal of Thoracic and Cardiovascular 
Surgery. 1983;86(3):373-380. 
32. Detterbeck FC. Overdiagnosis during lung cancer screening: is it an 
overemphasised, underappreciated, or tangential issue? Thorax. 
2014;69(5):407-408. doi:10.1136/thoraxjnl-2014-205140. 
  
 
147 
33. Diaz LA, Bardelli A. Liquid Biopsies: Genotyping Circulating Tumor DNA: 
Journal of Clinical Oncology: Vol 32, No 6. Journal of Clinical Oncology. 
2014. 
34. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq 
aligner. Bioinformatics. 2012;29(1):bts635–21. 
doi:10.1093/bioinformatics/bts635. 
35. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, 
Herman JG. Detection of aberrant promoter hypermethylation of tumor 
suppressor genes in serum DNA from non-small cell lung cancer patients. 
Cancer research. 1999;59(1):67-70. 
36. Feng J, Wang Y, Qing, Qi. Comparison of autofluorescence imaging 
bronchoscopy and white light bronchoscopy for detection of lung cancers 
and precancerous lesions. PPA. 2013;7:621-631. doi:10.2147/PPA.S46749. 
37. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive Identification and 
Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma 
DNA. Science translational medicine. 2012;4(136):136ra68-136ra68. 
doi:10.1126/scitranslmed.3003726. 
38. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized 
Linear Models via Coordinate Descent. Journal of Statistical Software. 
2010;33(1):1-968. doi:10.1109/TPAMI.2005.127. 
39. Gentleman R, Carey V, Huber W, Hahne F. Genefilter: Methods for 
Filtering Genes From High-Throughput Experiments. R package version; 
2015. 
40. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: 
class discovery and class prediction by gene expression monitoring. Science. 
1999;286(5439):531-537. 
41. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery 
and validation. Translational Cancer Research. 2015;4(3):256-269. 
doi:10.3978/j.issn.2218-676X.2015.06.04. 
42. Griffiths Jones S. The microRNA Registry. Nucleic Acids Research. 
2004;32(suppl_1):D109-D111. doi:10.1093/nar/gkh023. 
43. Guan G, Zhang D, Zheng Y, et al. microRNA-423-3p promotes tumor 
progression via modulation of AdipoR2 in laryngeal carcinoma. International 
  
 
148 
Journal of Clinical and Experimental Pathology. 2014;7(9):5683-5691. 
44. Gustafson AM, Soldi R, Anderlind C, et al. Airway PI3K pathway activation 
is an early and reversible event in lung cancer development. Science 
Translational Medicine. 2010;2(26):26ra25-26ra25. 
doi:10.1126/scitranslmed.3000251. 
45. Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Reviews. 
Molecular Cell Biology. 2014;15(8):509-524. doi:10.1038/nrm3838. 
46. Hackett NR, Heguy A, Harvey B-G, et al. Variability of Antioxidant-Related 
Gene Expression in the Airway Epithelium of Cigarette Smokers. Am J 
Respir Cell Mol Biol. 2003;29(3):331-343. doi:10.1165/rcmb.2002-0321OC. 
47. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 
2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013. 
48. Häussinger K, Becker H, Stanzel F, et al. Autofluorescence bronchoscopy 
with white light bronchoscopy compared with white light bronchoscopy 
alone for the detection of precancerous lesions: a European randomised 
controlled multicentre trial. Thorax. 2005;60(6):496-503. 
doi:10.1136/thx.2005.041475. 
49. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death & 
Differentiation. 2010;17(2):193-199. doi:10.1038/cdd.2009.56. 
50. Hoffmann D, Hoffmann I. The less harmful cigarette: a controversial issue. 
A tribute to Ernst L. Wynder. Chemical Research in Toxicology. 2001??????? 
?????????doi:10.1021/tx000260u. 
51. Howlader N, AM N, M K, et al. SEER Cancer Statistics Review, 1975-2013. 
http://seer.cancer.gov/csr/1975_2013/. http://seer.cancer.gov/csr/1975_2013/. 
Published 2016. Accessed March 25, 2017. 
52. Hubers AJ, Heideman DAM, Burgers SA, et al. DNA hypermethylation 
analysis in sputum for the diagnosis of lung cancer: training validation set 
approach. Brit J Cancer. 2015;112(6):1105-1113. doi:10.1038/bjc.2014.636. 
53. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and 
summaries of high density oligonucleotide array probe level data. 
Biostatistics (Oxford, England). 2003;4(2):249-264. 
doi:10.1093/biostatistics/4.2.249. 
  
 
149 
54. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history 
of bronchial preinvasive lesions. Cancer Metastasis Reviews. 2010;29(1):5-14. 
doi:10.1007/s10555-010-9214-7. 
55. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S. Natural history 
of bronchial preinvasive lesions. Cancer Metastasis Rev. 2010;29(1):5-14. 
doi:10.1007/s10555-010-9214-7. 
56. Jordan JD, Landau EM, Iyengar R. Signaling networks: the origins of 
cellular multitasking. Cell. 2000;103(2):193-200. doi:10.1016/S0092-
8674(00)00112-4. 
57. Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. 
Oncogene. 2006;25(46):6176-6187. doi:10.1038/sj.onc.1209912. 
58. Ju L, Han M, Zhao C, Li X. Genome-wide analysis of microRNA signature 
in lung adenocarcinoma with EGFR exon 19 deletion. bioRxiv. 2016. 
doi:10.1101/032367. 
59. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff A-K. 
MicroRNA miR-125b controls melanoma progression by direct regulation of 
c-Jun protein expression. Oncogene. 2013;32(24):2984-2991. 
doi:10.1038/onc.2012.307. 
60. Karlebach G, Shamir R. Modelling and analysis of gene regulatory networks. 
Nature Reviews. Molecular Cell Biology. 2008;9(10):770-780. 
doi:10.1038/nrm2503. 
61. Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA 
sequencing experiments for identifying isoform regulation. Nature Methods. 
2010;7(12):1009-1015. doi:10.1038/nmeth.1528. 
62. Keith RL, Blatchford PJ, Kittelson J, et al. Oral Iloprost Improves 
Endobronchial Dysplasia in Former Smokers. Cancer Prevention Research. 
2011;4(6):793-802. doi:10.1158/1940-6207.CAPR-11-0057. 
63. Keith RL, Miller YE. Lung cancer chemoprevention: current status and 
future prospects. Nature Reviews. Clinical Oncology. 2013;10(6):334-343. 
doi:10.1038/nrclinonc.2013.64. 
64. Kim K-H, Cho E-G, Yu SJ, et al. ΔNp63 intronic miR-944 is implicated in 
the ΔNp63-mediated induction of epidermal differentiation. Nucleic Acids 
Research. 2015;43(15):7462-7479. doi:10.1093/nar/gkv735. 
  
 
150 
65. Kneip C, Schmidt B, Seegebarth A, et al. SHOX2 DNA Methylation Is a 
Biomarker for the Diagnosis of Lung Cancer in Plasma. Journal of Thoracic 
Oncology. 2011;6(10):1632-38. doi:10.1097/JTO.0b013e318220ef9a. 
66. Kukurba KR, Montgomery SB. RNA Sequencing and Analysis. Cold Spring 
Harbor Protoc. 2015;2015(11):pdb.top084970. doi:10.1101/pdb.top084970. 
67. Lam S, LeRiche JC, Zheng Y, et al. Sex-related differences in bronchial 
epithelial changes associated with tobacco smoking. Journal of the National 
Cancer Institute. 1999;91(8):691-696. 
68. Langfelder P, Luo R, Oldham MC, Horvath S. Is my network module 
preserved and reproducible? PLoS Computational Biology. 
2011;7(1):e1001057. doi:10.1371/journal.pcbi.1001057. 
69. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome 
Biology. 2009;10(3):R25. doi:10.1186/gb-2009-10-3-r25. 
70. Law CW, Chen Y, Shi W, Smyth GK. Voom: precision weights unlock 
linear model analysis tools for RNA-seq read counts. Genome Biol???. 2014. 
71. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for 
removing batch effects and other unwanted variation in high-throughput 
experiments. Bioinformatics (Oxford, England). 2012;28(6):882-883. 
doi:10.1093/bioinformatics/bts034. 
72. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq 
data with or without a reference genome. BMC Bioinformatics. 
2011;12(1):323. doi:10.1186/1471-2105-12-323. 
73. Liaw A, Wiener M. Classification and regression by randomForest. R news. 
2002. 
74. Lockwood WW, Wilson IM, Coe BP, et al. Divergent Genomic and 
Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection 
of Different Oncogenic Pathways during Tumor Development. Navarro A, 
ed. PloS one. 2012;7(5):e37775. doi:10.1371/journal.pone.0037775. 
75. MacFarlane L-A, R Murphy P. MicroRNA: Biogenesis, Function and Role 
in Cancer. CG. 2010;11(7):537-561. doi:10.2174/138920210793175895. 
76. Mapstone M, Cheema AK, Fiandaca MS, et al. Plasma phospholipids 
  
 
151 
identify antecedent memory impairment in older adults. Nature Medicine. 
2014;20(4):415-418. doi:10.1038/nm.3466. 
77. Marchetti A, Palma JF, Felicioni L, et al. Early Prediction of Response to 
Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma 
of NSCLC Patients. Journal of Thoracic Oncology. 2015;10(10):1437-1443. 
doi:10.1097/JTO.0000000000000643. 
78. Martinez-Outschoorn UE, Pavlides S, Sotgia F, Lisanti MP. Mitochondrial 
Biogenesis Drives Tumor Cell Proliferation. The American Journal of 
Pathology. 2011;178(5):1949-1952. doi:10.1016/j.ajpath.2011.03.002. 
79. Mascaux C, Laes JF, Anthoine G, et al. Evolution of microRNA expression 
during human bronchial squamous carcinogenesis. European Respiratory 
Journal. 2008;33(2):352-359. doi:10.1183/09031936.00084108. 
80. McClish DK. Analyzing a portion of the ROC curve. Medical Decision 
Making. 1989;9(3):190-195. 
81. McGhee D, Royle PL, Thompson PA. A systematic review of biomarkers for 
disease progression in Parkinson's disease. BMC Neurology. 2013??????. 
82. McGhee DJM, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell 
CE. A Systematic Review of Biomarkers for Disease Progression in 
Alzheimer's Disease. PloS One. 2014;9(2):e88854. 
doi:10.1371/journal.pone.0088854. 
83. Merrick DT, Gao D, Miller YE, et al. Persistence of Bronchial Dysplasia Is 
Associated with Development of Invasive Squamous Cell Carcinoma. 
Cancer Prevention Research. 2016;9(1):96-104. doi:10.1158/1940-6207.
????????0305. 
84. Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F. E1071: Misc 
Functions of the Department of Statistics, Probability Theory Group 
(Formerly: E1071), TU Wien [R Package E1071 Version 1.6-7]. 1st ed. 
Comprehensive R Archive Network (CRAN); 2015. http://CRAN.R-
project.org/package=e1071. 
85. Navarro F, Lieberman J. miR-34 and p53: New Insights into a Complex 
Functional Relationship. Martelli F, ed. PloS One. 2015;10(7):e0132767. 
doi:10.1371/journal.pone.0132767. 
86. Nicholson AG, Perry LJ, Cury PM, et al. Reproducibility of the 
  
 
152 
WHO/IASLC grading system for pre-invasive squamous lesions of the 
bronchus: a study of inter-observer and intra-observer variation. 
Histopathology. 2001;38(3):202-208. 
87. Nygaard AD, Garm Spindler K-L, Pallisgaard N, Andersen RF, Jakobsen A. 
The prognostic value of KRAS mutated plasma DNA in advanced non-small 
cell lung cancer. Lung Cancer. 2013;79(3):312-317. 
doi:10.1016/j.lungcan.2012.11.016. 
88. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are 
there? Nat Reviews. Drug Discov. 2006;5(12):993-96. doi:10.1038/nrd2199. 
89. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive Detection of 
Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative 
Next-Generation Genotyping of Cell-Free Plasma DNA. Clinical Cancer 
Research. 2014;20(6):1698-1705. doi:10.1158/1078-0432.CCR-13-2482. 
90. Paris C, Benichou J, Bota S, et al. Occupational and nonoccupational factors 
associated with high grade bronchial pre-invasive lesions. European 
Respiratory Journal. 2003;21(2):332-341. 
91. Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed 
tomography screening for lung cancer. JAMA Internal Medicine. 2014?
???????????274. doi:10.1001/jamainternmed.2013.12738. 
92. Pearson K. LIII. On lines and planes of closest fit to systems of points in 
space. Philosophical Magazine Series 6. 1901;2(11):559-572. 
doi:10.1080/14786440109462720. 
93. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal 
Transduction and Targeted Therapy. 2016;1:15004. 
doi:10.1038/sigtrans.2015.4. 
94. Perdomo C, Campbell JD, Gerrein J, et al. MicroRNA 4423 is a primate-
specific regulator of airway epithelial cell differentiation and lung 
carcinogenesis. Proceedings of the National Academy of Sciences U S A. 
2013;110(47):18946-18951. doi:10.1073/pnas.1220319110. 
95. Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A 
single-sample microarray normalization method to facilitate personalized-
medicine workflows. Genomics. 2012;100(6):337-344. 
doi:10.1016/j.ygeno.2012.08.003. 
  
 
153 
96. Pierotti MA, Sozzi G, Croce CM. Mechanisms of oncogene activation. 2003. 
https://www.ncbi.nlm.nih.gov/books/NBK12538/. 
97. Polakis P. Wnt Signaling in Cancer. Cold Spring Harbor Perspectives in 
Biology. 2012;4(5):a008052-a008052. doi:10.1101/cshperspect.a008052. 
98. Powrózek T, Krawczyk P, Kowalski DM, Winiarczyk K, Olszyna-Serementa 
M, Milanowski J. Plasma circulating microRNA-944 and microRNA-3662 
as potential histologic type-specific early lung cancer biomarkers. Transla- 
tional Research. 2015;166(4):315-323. doi:10.1016/j.trsl.2015.05.009. 
99. Ritchie ME, Phipson B, Di Wu, et al. limma powers differential expression 
analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 
2015;43(7):gkv007–e47. doi:10.1093/nar/gkv007. 
100. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R 
and S+ to analyze and compare ROC curves. BMC Bioinformatics. 
2011;12(1):77. doi:10.1186/1471-2105-12-77. 
101. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package 
for differential expression analysis of digital gene expression data.  
Bioinformatics. 2010;26(1):139-140. doi:10.1093/bioinformatics/btp616. 
102. Robinson MD, Oshlack A. A scaling normalization method for differential 
expression analysis of RNA-seq data. Genome Biology. 2010;11(3):R25. 
doi:10.1186/gb-2010-11-3-r25. 
103. Saccomanno G. Carcinoma in-situ of the lung: Its development, detection, 
and treatment. Seminars in respiratory medicine. 1982. doi:10.1055/s-2007-
1012480.pdf. 
104. Salaün M, Sesboüé R, Moreno-Swirc S, et al. Molecular Predictive Factors 
for Progression of High-Grade Preinvasive Bronchial Lesions. Am J Respir 
Crit Care Med. 2008;177(8):880-886. doi:10.1164/rccm.200704-598OC. 
105. Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of 
smoking-induced gene expression changes in human airway epithelium. 
Proceedings of the National Academy of Sciences. 2009;106(7):2319-2324. 
doi:10.1073/pnas.0806383106. 
106. Schmidt B, Liebenberg V, Dietrich D, et al. SHOX2 DNA Methylation is a 
Biomarker for the diagnosis of lung cancer based on bronchial aspirates. 
BMC Cancer. 2010;10(1):71. doi:10.1186/1471-2407-10-600. 
  
 
154 
107. Segrè D, DeLuna A, Church GM, Kishony R. Modular epistasis in yeast 
metabolism. - PubMed - NCBI. Nature Genetics. 2004;49(1):703-783. 
doi:10.1038/ng1489. 
108. Seguro AC, ed. Hsp72 Is a Novel Biomarker to Predict Acute Kidney Injury 
in Critically Ill Patients. PloS One. 2014;9(10):e109407. 
doi:10.1371/journal.pone.0109407. 
109. Sestini P. Reduced lung-cancer mortality with CT screening. N Engl J Med. 
2011;365(21):2037–authorreply2037–8. doi:10.1056/NEJMc1110293#SA5. 
110. Sestini S, Boeri M, Marchiano A, et al. Circulating microRNA signature as 
liquid-biopsy to monitor lung cancer in low-dose computed tomography 
screening. Oncotarget. 2015;6(32):32868-32877. 
doi:10.18632/oncotarget.5210. 
111. Shah V, Sridhar S, Beane J, Brody JS, Spira A. SIEGE: Smoking Induced 
Epithelial Gene Expression Database. Nucleic Acids Research. 2005;33 
(Database issue):D573-D579. doi:10.1093/nar/gki035. 
112. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with 
solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 
2011;11(1):71. doi:10.1186/1471-2407-11-374. 
113. Showe MK, Vachani A, Kossenkov AV, et al. Gene Expression Profiles in 
Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non-
Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease. 
Cancer Research. 2009;69(24):9202-9210. doi:10.1158/0008-5472.CAN-09-
1378. 
114. Silvestri GA, Vachani A, Whitney D, et al. A Bronchial Genomic Classifier 
for the Diagnostic Evaluation of Lung Cancer. New England Journal of 
Medicine. 2015;373(3):243-251. doi:10.1056/NEJMoa1504601. 
115. Silvestri GA, Vachani A, Whitney D, et al. A Bronchial Genomic Classifier 
for the Diagnostic Evaluation of Lung Cancer. New England Journal of 
Medicine. 2015;373(3):243-251. doi:10.1056/NEJMoa1504601. 
116. Song L, Langfelder P, Horvath S. Comparison of co-expression measures: 
mutual information, correlation, and model based indices. BMC 
Bioinformatics. 2012;13(1):328. doi:10.1186/1471-2105-13-328. 
117. Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor 
  
 
155 
receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the 
plasma DNA of patients with advanced non–small cell lung cancer during 
treatment with erlotinib. Cancer. 2014;120(24):3896-3901. 
doi:10.1002/cncr.28964. 
118. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA 
signature classifier within computed tomography lung cancer screening: a 
correlative MILD trial study. Journal of Clinical Oncology. 2014;32(8):768- 
773. doi:10.1200/JCO.2013.50.4357. 
119. Spira A, Beane J, Shah V, et al. Effects of cigarette smoke on the human 
airway epithelial cell transcriptome. Proceedings of the National Academy of 
Sciences of the United States of America. 2004;101(27):10143-10148. 
doi:10.1073/pnas.0401422101. 
120. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the 
diagnostic evaluation of smokers with suspect lung cancer. Nature Medicine. 
2007;13(3):361-366. doi:10.1038/nm1556. 
121. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical 
carcinogenesis by vitamin A and its synthetic analogs (retinoids). Federation 
Proceedings. 1976;35(6):1332-1338. 
122. Steiling K, van den Berge M, Hijazi K, et al. A dynamic bronchial airway 
gene expression signature of chronic obstructive pulmonary disease and lung 
function impairment. Am J Respir Crit Care Med. 2013;187(9):933-942. 
123. Steiling K, van den Berge M, Sebastiani P, et al. Airway Gene Expression as 
a Molecular Phenotype of COPD. December 2012. doi:10.1513/pats.8.2.208. 
124. Strimbu K, Tavel JA. What are biomarkers? Current Opinion in HIV and 
AIDS. 2010;5(6):463-466. doi:10.1097/COH.0b013e32833ed177. 
125. Su Z, Fang H, Hong H, et al. An investigation of biomarkers derived from 
legacy microarray data for their utility in the RNA-seq era. Genome Biology. 
2014;15(12):523. doi:10.1186/s13059-014-0523-y. 
126. Subramanian A, Subramanian A, Tamayo P, et al. Gene set enrichment 
analysis: A knowledge-based approach for interpreting genome-wide 
expression profiles. Proceedings of the National Academy of Sciences of the 
United States of America. 2005;102(43):15545-15550. 
doi:10.1073/pnas.0506580102. 
  
 
156 
127. Szabo E. Altered histology provides a positive clinical signal in the bronchial 
epithelium. 2011;4(6):775-778. doi:10.1158/1940-6207.CAPR-11-0214. 
128. Szpechcinski A, Rudzinski P, Kupis W, Langfort R, Orlowski T, 
Chorostowska-Wynimko J. Plasma cell-free DNA levels and integrity in 
patients with chest radiological findings: NSCLC versus benign lung 
nodules. Cancer Letters. 2016;374(2):202-207. 
doi:10.1016/j.canlet.2016.02.002. 
129. Takano T, Fukui T, Ohe Y, et al. EGFRMutations Predict Survival Benefit 
From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A 
Historical Comparison of Patients Treated Before and After Gefitinib 
Approval in Japan. Journal of Clinical Oncology. 2008;26(34):5589-5595. 
doi:10.1200/JCO.2008.16.7254. 
130. Tammemagi MC, Tammemagi MC, Lam SC, et al. Incremental Value of 
Pulmonary Function and Sputum DNA Image Cytometry in Lung Cancer 
Risk Prediction. Cancer Prevention Research. 2011;4(4):552-561. 
doi:10.1158/1940-6207.CAPR-10-0183. 
131. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by 
the let-7 microRNA. Oncogene. 2009;29(11):1580-1587. 
doi:10.1038/onc.2009.445. 
132. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions 
with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111. 
doi:10.1093/bioinformatics/btp120. 
133. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript 
expression analysis of RNA-seq experiments with TopHat and Cufflinks. 
Nature Protocols. 2012;7(3):562-578. doi:10.1038/nprot.2012.016. 
134. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and 
quantification by RNA-Seq reveals unannotated transcripts and isoform 
switching during cell differentiation. Nature Biotechnology. 2010;28(5):511-
515. doi:10.1038/nbt.1621. 
135. Udyavar AR, Hoeksema MD, Clark JE, et al. Co-expression network 
analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic 
driver in a subset of small-cell lung cancer. BMC Systems Biology. 2013;7 
Suppl 5:S1-S1. doi:10.1186/1752-0509-7-S5-S1. 
136. van Boerdonk RAA, Smesseim I, Heideman DAM, et al. Close Surveillance 
  
 
157 
with Long-Term Follow-up of Subjects with Preinvasive Endobronchial 
Lesions. American Journal of Respiratory and Critical Care Medicine. 
2015;192(12):1483-1489. doi:10.1164/rccm.201504-0822OC. 
137. Voet D, Jing R, Cibulskis K, et al. Comprehensive genomic characterization 
of squamous cell lung cancers. Nature. 2012;489(7417):519-525. 
doi:10.1038/nature11404. 
138. Wang G, Wang R, Strulovici-Barel Y, et al. Persistence of Smoking-Induced 
Dysregulation of MiRNA Expression in the Small Airway Epithelium 
Despite Smoking Cessation. Yildirim AÖ, ed. PLoS One. 
2015;10(4):e0120824. doi:10.1371/journal.pone.0120824. 
139. Wang L, Nie J, Sicotte H, et al. Measure transcript integrity using RNA-seq 
data. BMC Bioinformatics. 2016;17(1):e1261. doi:10.1186/s12859-016-
0922-z. 
140. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. 
Bioinformatics (Oxford, England). 2012;28(16):2184-2185. 
doi:10.1093/bioinformatics/bts356. 
141. Whitney DH, Elashoff MR, Porta Smith K, et al. Derivation of a bronchial 
genomic classifier for lung cancer in a prospective study of patients 
undergoing diagnostic bronchoscopy. BMC Medical Genomics. 2015; 
8(1):18. doi:10.1186/s12920-015-0091-3. 
142. Xing L, Su J, Guarnera MA, et al. Sputum microRNA Biomarkers for 
Identifying Lung Cancer in Indeterminate Solitary Pulmonary Nodules. Clin 
Cancer Res. 2015;21(2):484-489. doi:10.1158/1078-0432.CCR-14-1873. 
143. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell 
lung cancer in sputum by a panel of microRNA markers. Modern Pathology. 
2010;23(8):1157-1164. doi:10.1038/modpathol.2010.111. 
144. Yip AM, Horvath S. The Generalized Topological Overlap Matrix for 
Detecting Modules in Gene Networks. BIOCOMP. 2006. 
145. YOU Z, ZHOU Y, GUO Y, CHEN W, CHEN S, WANG X. Activating 
transcription factor 2 expression mediates cell proliferation and is associated 
with poor prognosis in human non-small cell lung carcinoma. Oncology 
Letters. 2016;11(1):760-766. doi:10.3892/ol.2015.3922. 
146. Zander T, Hofmann A, Staratschek-Jox A, et al. Blood-Based Gene 
  
 
158 
Expression Signatures in Non-Small Cell Lung Cancer. Clinical Cancer 
Research. 2011;17(10):3360-3367. doi:10.1158/1078-0432.CCR-10-0533. 
147. Zhang B, Horvath S. A general framework for weighted gene co-expression 
network analysis. Statistical Applications in Genetics and Molecular Biology. 
2005;4(1):Article17. doi:10.2202/1544-6115.1128. 
148. Zhao J, Fu W, Liao H, et al. The regulatory and predictive functions of miR-
17 and miR-92 families on cisplatin resistance of non-small cell lung cancer. 
BMC Cancer. 2015;15(1):114. doi:10.1186/s12885-015-1713-z. 
149. Zhao L, Zhu J, Zhou H, et al. Identification of cellular microRNA-136 as a 
dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 
IAV replication in A549 cells. Scientific Reports. 2015;5:14991. 
doi:10.1038/srep14991. 
150. Zhou T, Zhang W, Sweiss NJ, et al. Peripheral Blood Gene Expression as a 
Novel Genomic Biomarker in Complicated Sarcoidosis. Morty RE, ed. PLoS 
One. 2012;7(9):e44818. doi:10.1371/journal.pone.0044818. 
151. Zhu K, Ding H, Wang W, et al. Tumor-suppressive miR-218-5p inhibits 
cancer cell proliferation and migration via EGFR in non-small cell lung 
cancer. Oncotarget. 2016;7(19):28075-28085. 
doi:10.18632/oncotarget.8576. 
152. Zhu W-Y, Luo B, An J-Y, et al. Differential expression of miR-125a-5p and 
let-7e predicts the progression and prognosis of non-small cell lung cancer. 
Cancer Invest. 2014;32(8):394-401. doi:10.3109/07357907.2014.922569. 
 
 
  
159 
CURRICULUM VITAE 
  
160 
 161 
  
162 
